nct_id
string
updated_at
timestamp[us]
brief_title
string
official_title
string
acronym
string
study_type
string
overall_status
string
study_first_submit_date
timestamp[ms]
start_date
timestamp[ms]
primary_completion_date
timestamp[ms]
completion_date
timestamp[ms]
phases
list
enrollment_count
float64
minimum_age
float64
maximum_age
float64
sex
string
healthy_volunteers
bool
brief_summary
string
detailed_description
string
eligibility_criteria
string
lead_sponsor_name
string
lead_sponsor_class
string
org_study_id_info
dict
why_stopped
string
expanded_access_info
dict
last_update_submit_qc_date
timestamp[ms]
last_update_post_date_struct
dict
study_first_post_date_struct
dict
std_ages
list
study_population
string
sampling_method
string
oversight_has_dmc
bool
design_info
dict
conditions
list
keywords
string
interventions
null
locations
list
collaborators
list
arm_groups
null
outcomes
dict
overall_officials
list
study_references
string
misc_info_module
string
condition_browse_module
dict
intervention_browse_module
dict
mesh_terms
dict
NCT01273766
null
Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies
Impact of Intervention With Deferasirox on the Immune Function of Patients With Hematologic Diseases and Transfusion-Related Iron Overload
None
INTERVENTIONAL
COMPLETED
2011-01-07T00:00:00
null
null
null
[ "PHASE2" ]
16
18
null
ALL
false
RATIONALE: Deferasirox may remove excess iron from the body caused by blood transfusions. PURPOSE: This clinical trial studies deferasirox in treating iron overload caused by blood transfusions in patients with hematologic malignancies.
PRIMARY OBJECTIVES: I. To determine the effects of the iron-chelating agent deferasirox on changes in: neutrophil function; macrophage function; lymphocyte function. SECONDARY OBJECTIVES: I. To determine the effect of chelation on the incidence of bacterial, viral and fungal infections documented by clinical, microbio...
Inclusion Criteria: * Patients must have a pathology confirmed diagnosis of one of the following: myelodysplastic syndrome (MDS); acute leukemia; multiple myeloma; myelofibrosis; lymphoma; chronic anemia; sickle cell anemia * Iron score \>= 2 * Absolute Neutrophil Count (ANC) \>= 1,000 * Platelets \>= 50,000 * Albumin...
Wake Forest University Health Sciences
OTHER
{ "id": "IRB00015287", "link": null, "type": null }
Unknown
{ "hasExpandedAccess": false, "nctId": null, "statusForNctId": null }
2011-01-07T00:00:00
{ "date": "2018-09-07", "type": "ACTUAL" }
{ "date": "2011-01-10", "type": "ESTIMATED" }
[ "ADULT", "OLDER_ADULT" ]
null
null
true
{ "allocation": "NON_RANDOMIZED", "interventionModel": "SINGLE_GROUP", "interventionModelDescription": null, "maskingInfo": { "masking": "NONE", "maskingDescription": null, "whoMasked": null }, "observationalModel": null, "primaryPurpose": "SUPPORTIVE_CARE", "timePerspective": null }
[ "Acute Undifferentiated Leukemia", "Adult Acute Lymphoblastic Leukemia in Remission", "Adult Acute Myeloid Leukemia in Remission", "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities", "Adult Acute Myeloid Leukemia With Del(5q)", "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)", "Adult Acut...
null
null
[ { "city": "Winston-Salem", "country": "United States", "facility": "Comprehensive Cancer Center of Wake Forest University", "geoPoint": { "lat": 36.09986, "lon": -80.24422 }, "state": "North Carolina" } ]
[ { "class": "NIH", "name": "National Cancer Institute (NCI)" } ]
null
{ "other": null, "primary": [ { "description": null, "measure": "Changes in Mean Neutrophil Values (as Measured by Lab) for Arm 1 (Other Arms Were Used for Calibration Only)", "timeFrame": "Baseline, up to 6 months" } ], "secondary": [ { "description": null, "measure": ...
[ { "affiliation": "Wake Forest University Health Sciences", "name": "Mary Ann Knovich, MD", "role": "PRINCIPAL_INVESTIGATOR" } ]
null
{"versionHolder": "2025-06-18"}
{ "ancestors": [ { "id": "D004194", "term": "Disease" }, { "id": "D010335", "term": "Pathologic Processes" }, { "id": "D009370", "term": "Neoplasms by Histologic Type" }, { "id": "D009369", "term": "Neoplasms" }, { "id": "D00823...
{ "ancestors": [ { "id": "D007502", "term": "Iron Chelating Agents" }, { "id": "D002614", "term": "Chelating Agents" }, { "id": "D064449", "term": "Sequestering Agents" }, { "id": "D045504", "term": "Molecular Mechanisms of Pharmacological Ac...
{ "conditions": [ { "id": "D002051", "term": "Burkitt Lymphoma" }, { "id": "D009181", "term": "Mycoses" }, { "id": "D008223", "term": "Lymphoma" }, { "id": "D007938", "term": "Leukemia" }, { "id": "D007951", "term": "Leuke...
NCT00787566
null
Phase 2 Study of Efficacy, Tolerability, and Safety of Intranasal Granisetron for Chemo-Induced Nausea and Vomiting
A Randomized, Single Administration, Double-blind, Parallel-group Phase 2 Dose Finding Study to Assess the Efficacy, Tolerability, and Safety of TRG (Intranasal Granisetron) in Patients With Chemotherapy-induced Nausea and Vomiting (CINV) Associated With the Administration of Highly Emetogenic Chemotherapy
None
INTERVENTIONAL
COMPLETED
2008-11-05T00:00:00
null
null
null
[ "PHASE2" ]
68
18
null
ALL
false
Brief Summary: A randomized, single administration, double-blind, parallel- group Phase 2 dose finding study to assess the efficacy, tolerability, and safety of TRG in patients with chemotherapy-induced nausea and vomiting (CINV) associated with the administration of highly emetogenic chemotherapy. Primary Objective: ...
null
Inclusion Criteria: * Patients with histologically and/or cytologically confirmed cancer * ECOG performance status of 0, 1, or 2 * Patients with life expectancy of at least 3 months * Patients who are chemotherapy naïve * Patients who will be receiving the first cycle of a highly emetogenic regimen according to the MA...
Shin Nippon Biomedical Laboratories, Ltd.
INDUSTRY
{ "id": "TRG-002", "link": null, "type": null }
Unknown
{ "hasExpandedAccess": false, "nctId": null, "statusForNctId": null }
2008-11-06T00:00:00
{ "date": "2011-07-12", "type": "ESTIMATED" }
{ "date": "2008-11-07", "type": "ESTIMATED" }
[ "ADULT", "OLDER_ADULT" ]
null
null
null
{ "allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "interventionModelDescription": null, "maskingInfo": { "masking": "TRIPLE", "maskingDescription": null, "whoMasked": [ "PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR" ] }, "observationalModel": null, "primaryPu...
[ "Chemotherapy-Induced Nausea and Vomiting" ]
["Highly emetogenic chemotherapy induced nausea and vomiting"]
null
[ { "city": "The study is managed by Kendle International, in Wilmington", "country": "United States", "facility": "The study is conducted at 14 Centers, in 14 cities accross the United States", "geoPoint": null, "state": "North Carolina" } ]
null
null
{ "other": null, "primary": [ { "description": null, "measure": "Percentage of Patients With Complete Control", "timeFrame": "24 hours" } ], "secondary": [ { "description": null, "measure": "Percentage of Patients With Complete Response", "timeFrame": "24 hours" ...
null
null
{"versionHolder": "2025-06-18"}
{ "ancestors": [ { "id": "D012817", "term": "Signs and Symptoms, Digestive" } ], "browseBranches": [ { "abbrev": "BC23", "name": "Symptoms and General Pathology" }, { "abbrev": "All", "name": "All Conditions" } ], "browseLeaves": [ { "asFou...
{ "ancestors": [ { "id": "D000932", "term": "Antiemetics" }, { "id": "D001337", "term": "Autonomic Agents" }, { "id": "D018373", "term": "Peripheral Nervous System Agents" }, { "id": "D045505", "term": "Physiological Effects of Drugs" }, ...
{ "conditions": [ { "id": "D009325", "term": "Nausea" }, { "id": "D014839", "term": "Vomiting" } ], "interventions": [ { "id": "D017829", "term": "Granisetron" } ] }
NCT00497666
null
Association Between Rosiglitazone Use and Clinical Course of Diabetic Nephropathy: Population-Based Study
Retrospective Study Evaluating the Association Between Rosiglitazone Use and Clinical Course of Diabetic Nephropathy: Population-Based Study
None
OBSERVATIONAL
UNKNOWN
2007-07-06T00:00:00
null
null
null
null
null
18
90
ALL
null
Recent data show that Rosiglitazone treatment can reduce proteinuria in diabetic patients. However, currently there are no trials that examine the effects of Rosiglitazone on kidney disease progression, that is, doubling of serum creatinine or time to onset of end-stage renal disease, in patients with diabetic nephropa...
Background Type 2 diabetes mellitus is a public health concern, and projections of its future effect are alarming. According to the World Health Organization, diabetes affects more than 170 million people worldwide, and this number will rise to 370 million by 2030 \[1\]. About one third of those affected will eventuall...
Inclusion Criteria: 1. Diagnosis of Diabetes Mellitus Type II 2. Treatment With Oral hypoglycemics 3. Availability of Baseline and follow up clinical data Exclusion Criteria: 1. Insulin Therapy at baseline 2. Malignancy
Assaf-Harofeh Medical Center
OTHER_GOV
{ "id": "346147Rosi", "link": null, "type": null }
Unknown
{ "hasExpandedAccess": false, "nctId": null, "statusForNctId": null }
2007-07-06T00:00:00
{ "date": "2007-07-09", "type": "ESTIMATED" }
{ "date": "2007-07-09", "type": "ESTIMATED" }
[ "ADULT", "OLDER_ADULT" ]
null
null
false
{ "allocation": null, "interventionModel": null, "interventionModelDescription": null, "maskingInfo": null, "observationalModel": "CASE_CONTROL", "primaryPurpose": null, "timePerspective": "OTHER" }
[ "Diabetes", "Diabetic Nephropathy", "Renal Protection" ]
["Diabetes", "Diabetic nephropathy", "renal protection"]
null
[ { "city": "Zerifin,", "country": "Israel", "facility": "Clalit Health Cervices, Central District", "geoPoint": { "lat": 31.95857, "lon": 4.83723 }, "state": null } ]
null
null
null
[ { "affiliation": "Nephrology Division, Assaf Harofeh Medical Center, Zerifin,", "name": "Leonid S Feldman", "role": "PRINCIPAL_INVESTIGATOR" }, { "affiliation": "Assaf-Harofeh Medical Center", "name": "Leonid S Feldman", "role": "PRINCIPAL_INVESTIGATOR" } ]
null
{"versionHolder": "2025-06-18"}
{ "ancestors": [ { "id": "D014570", "term": "Urologic Diseases" }, { "id": "D052776", "term": "Female Urogenital Diseases" }, { "id": "D005261", "term": "Female Urogenital Diseases and Pregnancy Complications" }, { "id": "D000091642", "term":...
{ "ancestors": null, "browseBranches": [ { "abbrev": "Hypo", "name": "Hypoglycemic Agents" }, { "abbrev": "All", "name": "All Drugs and Chemicals" } ], "browseLeaves": [ { "asFound": null, "id": "M1677", "name": "Rosiglitazone", "relevance": "L...
{ "conditions": [ { "id": "D007674", "term": "Kidney Diseases" }, { "id": "D003928", "term": "Diabetic Nephropathies" }, { "id": "D018450", "term": "Disease Progression" } ], "interventions": [] }
NCT01978366
null
Open Label Extension Study of HT-100 in Patients With DMD
An Open Label Extension Study of HT-100 in Patients With Duchenne Muscular Dystrophy Who Have Completed Protocol HALO-DMD-01
None
INTERVENTIONAL
TERMINATED
2013-10-31T00:00:00
null
2016-04-30T00:00:00
2016-04-30T00:00:00
[ "PHASE2" ]
17
6
20
MALE
false
This study is designed to provide 6-months continuous dosing with the study medication, called HT-100, on participants who successfully completed the predecessor study (HALO-DMD-01). The main purpose of this study is to assess chronic safety, tolerability, pharmacodynamic activity (testing the drug's effect on DMD) and...
null
Inclusion Criteria: * Completed both the single ascending dose (SAD) and multiple ascending dose (MAD) phases of predecessor study HALO-DMD-01 * Maintained the same corticosteroid therapy from the predecessor study HALO-DMD-01 * Ability to provide written informed consent * Ambulatory or non-ambulatory Exclusion Crit...
Processa Pharmaceuticals
INDUSTRY
{ "id": "HALO-DMD-02", "link": null, "type": null }
Dosing stopped
{ "hasExpandedAccess": false, "nctId": null, "statusForNctId": null }
2013-10-31T00:00:00
{ "date": "2020-09-03", "type": "ACTUAL" }
{ "date": "2013-11-07", "type": "ESTIMATED" }
[ "CHILD", "ADULT" ]
null
null
true
{ "allocation": "NON_RANDOMIZED", "interventionModel": "PARALLEL", "interventionModelDescription": null, "maskingInfo": { "masking": "NONE", "maskingDescription": null, "whoMasked": null }, "observationalModel": null, "primaryPurpose": "TREATMENT", "timePerspective": null }
[ "Duchenne Muscular Dystrophy" ]
["Duchenne muscular dystrophy", "halofuginone hydrobromide", "anti-fibrotic", "anti-inflammatory", "muscle regeneration", "protein synthesis inhibitor"]
null
[ { "city": "Sacramento", "country": "United States", "facility": "University of California, Davis Medical Center", "geoPoint": { "lat": 38.58157, "lon": -121.4944 }, "state": "California" }, { "city": "Baltimore", "country": "United States", "facility": "Kennedy Kr...
null
null
{ "other": null, "primary": [ { "description": null, "measure": "Safety and tolerability of administration of 6 months of chronic, oral, multiple doses of HT-100 to boys with DMD.", "timeFrame": "Months 2, 4, 6, 7" } ], "secondary": [ { "description": null, "measure": "...
[ { "affiliation": "AkashiTherapeutics", "name": "Diana M Escolar, MD", "role": "STUDY_DIRECTOR" } ]
null
{"versionHolder": "2025-06-18"}
{ "ancestors": [ { "id": "D020966", "term": "Muscular Disorders, Atrophic" }, { "id": "D009135", "term": "Muscular Diseases" }, { "id": "D009140", "term": "Musculoskeletal Diseases" }, { "id": "D009468", "term": "Neuromuscular Diseases" }...
{ "ancestors": [ { "id": "D000970", "term": "Antineoplastic Agents" }, { "id": "D003049", "term": "Coccidiostats" }, { "id": "D000981", "term": "Antiprotozoal Agents" }, { "id": "D000977", "term": "Antiparasitic Agents" }, { "id...
{ "conditions": [ { "id": "D009136", "term": "Muscular Dystrophies" }, { "id": "D020388", "term": "Muscular Dystrophy, Duchenne" } ], "interventions": [ { "id": "C010176", "term": "Halofuginone" } ] }
NCT01971866
null
Camera Based System to Monitor Patient Movement During Radiation Treatment
Improving Safety and Accuracy of Proton Therapy by Use of Camera-Based Patient Localization System
DS02
OBSERVATIONAL
TERMINATED
2013-10-17T00:00:00
null
null
null
null
1
18
null
ALL
false
This study aims to investigate the advantages of using AlignRT, a commercially available, FDA approved camera-based imaging system for proton therapy patients prior to and during their radiation treatment delivery.
null
Inclusion Criteria: Patients with tumors of the brain, head and neck, thorax, upper abdomen, posterior spine/sacrum and extremities
University of Florida
OTHER
{ "id": "UFPTI 1215-DS02", "link": null, "type": null }
Slow enrollment, feasibility issues
{ "hasExpandedAccess": false, "nctId": null, "statusForNctId": null }
2013-10-23T00:00:00
{ "date": "2016-01-27", "type": "ESTIMATED" }
{ "date": "2013-10-29", "type": "ESTIMATED" }
[ "ADULT", "OLDER_ADULT" ]
Patients who are undergoing proton radiation therapy at UFPTI
NON_PROBABILITY_SAMPLE
true
{ "allocation": null, "interventionModel": null, "interventionModelDescription": null, "maskingInfo": null, "observationalModel": "CASE_ONLY", "primaryPurpose": null, "timePerspective": "PROSPECTIVE" }
[ "Set up and Monitoring of Patients Receiving Proton Radiation" ]
["Proton radiation", "AlignRT"]
null
[ { "city": "Jacksonville", "country": "United States", "facility": "University of Florida Proton Therapy Institute", "geoPoint": { "lat": 30.33218, "lon": -81.65565 }, "state": "Florida" } ]
null
null
{ "other": null, "primary": [ { "description": null, "measure": "Paired difference between image accuracy plan data from the AlignRT system compared to the current x-ray based imaging system.", "timeFrame": "3 months" } ], "secondary": null }
[ { "affiliation": "University of Florida Proton Therapy Institute", "name": "Maria Mamalui-Hunter, PhD", "role": "PRINCIPAL_INVESTIGATOR" } ]
null
{"versionHolder": "2025-06-18"}
null
null
null
NCT04912466
null
IBI322 Monotherapy or Combination Therapy in Subjects With Advanced Malignant Tumors.
A Phase 1a/1b Study Evaluating the Safety, Tolerability and Preliminary Efficacy of IBI322 Monotherapy or Combination Therapy in Subjects With Advanced Malignant Tumors.
None
INTERVENTIONAL
COMPLETED
2021-05-28T00:00:00
null
2022-12-03T00:00:00
2023-08-25T00:00:00
[ "PHASE1" ]
61
18
75
ALL
false
The Phase Ia study was designed to evaluate the tolerability, safety, PK, PD, immunogenicity and primary resistance of single therapy tumor activity in subjects with advanced or metastatic solid tumors who have failed standard treatment. Phase Ib study was designed to evaluate the safety and initial efficacy of IBI322 ...
null
Inclusion Criteria: 1. Histologically/cytologically confirmed, locally advanced unresectable or metastatic tumors. 2. Per RECIST1, at least one evaluable or measurable lesion. 3. Male or female subject above 18 years old, no more than 75 years old. 4. Eastern Cooperative Oncology Group Performance Status (ECOG PS) per...
Innovent Biologics (Suzhou) Co. Ltd.
INDUSTRY
{ "id": "CIBI322A105", "link": null, "type": null }
Unknown
{ "hasExpandedAccess": false, "nctId": null, "statusForNctId": null }
2021-05-28T00:00:00
{ "date": "2023-09-06", "type": "ACTUAL" }
{ "date": "2021-06-03", "type": "ACTUAL" }
[ "ADULT", "OLDER_ADULT" ]
null
null
false
{ "allocation": "NA", "interventionModel": "SINGLE_GROUP", "interventionModelDescription": null, "maskingInfo": { "masking": "NONE", "maskingDescription": null, "whoMasked": null }, "observationalModel": null, "primaryPurpose": "TREATMENT", "timePerspective": null }
[ "Advanced Solid Tumor" ]
null
null
[ { "city": "Jinan", "country": "China", "facility": "Shandong Province Cancer Hospital", "geoPoint": { "lat": 36.66833, "lon": 116.99722 }, "state": "Shandong" } ]
null
null
{ "other": null, "primary": [ { "description": null, "measure": "Number of DLT", "timeFrame": "21 Days" }, { "description": null, "measure": "Number of treatment related AEs", "timeFrame": "up to 90 days post last dose" }, { "description": null, "m...
[ { "affiliation": "No.440, Jiyan Road, Jinang City, Shandong Province, China", "name": "Jinming Yu, M.D.", "role": "PRINCIPAL_INVESTIGATOR" } ]
null
{"versionHolder": "2025-06-18"}
{ "ancestors": null, "browseBranches": null, "browseLeaves": null, "meshes": [ { "id": "D009369", "term": "Neoplasms" } ] }
{ "ancestors": null, "browseBranches": [ { "abbrev": "All", "name": "All Drugs and Chemicals" } ], "browseLeaves": [ { "asFound": null, "id": "M10184", "name": "Immunoglobulins", "relevance": "LOW" }, { "asFound": null, "id": "M4225", "na...
{ "conditions": [ { "id": "D009369", "term": "Neoplasms" } ], "interventions": [] }
NCT03409666
null
Randomized Controlled RSA Study Comparing the Taperloc Complete Versus the Taperloc Complete Microplasty.
Randomized Controlled Study Comparing the Taperloc Complete Versus the Taperloc Complete Microplasty.
None
INTERVENTIONAL
COMPLETED
2018-01-08T00:00:00
null
2020-11-06T00:00:00
2020-11-06T00:00:00
[ "NA" ]
50
18
70
ALL
false
This is a single center, prospective, randomized controlled study. The primary objective of this study is to measure migration over two years with RSA. Patients will be randomized in two arms, receiving a Taperloc Complete Reduced Distal or a Taperloc Complete Microplasty hip stem.
A total of 50 patients will be enrolled into the study, randomized 1:1. All patients will receive a G7 limited hole acetabular cup with E1 liner. All potential study subjects will be required to participate in the Informed Consent process.
Inclusion Criteria: * Non-inflammatory degenerative joint disease including osteoarthritis, avascular necrosis and rheumatoid arthritis. * Correction of functional deformity. * Male or female -≥ 18 and ≤ 70 years of age * Subjects willing to return for follow-up evaluations. * Subjects able to read and understand D...
Zimmer Biomet
INDUSTRY
{ "id": "ORTHO.CR.GH60", "link": null, "type": null }
Unknown
{ "hasExpandedAccess": false, "nctId": null, "statusForNctId": null }
2018-01-17T00:00:00
{ "date": "2022-07-14", "type": "ACTUAL" }
{ "date": "2018-01-24", "type": "ACTUAL" }
[ "ADULT", "OLDER_ADULT" ]
null
null
false
{ "allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "interventionModelDescription": "1:1 assignment of treatment", "maskingInfo": { "masking": "NONE", "maskingDescription": null, "whoMasked": null }, "observationalModel": null, "primaryPurpose": "TREATMENT", "timePerspective": nul...
[ "Hip Osteoarthritis", "Noninflammatory Degenerative Joint Disease", "Avascular Necrosis", "Correction of Functional Deformity", "Rheumatoid Arthritis" ]
["Total Hip Arthroplasty", "Medical Device", "Performance", "Safety", "Hip prosthesis", "Roentgen Stereophotogrammetric Analysis"]
null
[ { "city": "Roosendaal", "country": "Netherlands", "facility": "Bravis", "geoPoint": { "lat": 51.53083, "lon": 4.46528 }, "state": null } ]
null
null
{ "other": null, "primary": [ { "description": null, "measure": "Stability Over a Period of Two Year Measured by Migration With Röntgen Stereophotogrammetric Analysis (RSA)", "timeFrame": "2 years postoperatively" } ], "secondary": [ { "description": null, "measure": "D...
[ { "affiliation": "Zimmer Biomet", "name": "Paola Vivoda, BSc", "role": "STUDY_DIRECTOR" } ]
null
{"versionHolder": "2025-06-18"}
{ "ancestors": [ { "id": "D001168", "term": "Arthritis" }, { "id": "D009140", "term": "Musculoskeletal Diseases" }, { "id": "D012216", "term": "Rheumatic Diseases" }, { "id": "D010335", "term": "Pathologic Processes" } ], "browseBranc...
null
{ "conditions": [ { "id": "D010003", "term": "Osteoarthritis" }, { "id": "D007592", "term": "Joint Diseases" }, { "id": "D015207", "term": "Osteoarthritis, Hip" }, { "id": "D009336", "term": "Necrosis" } ], "interventions": null }
NCT00622466
null
Sorafenib and Paclitaxel in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Sorafenib and Paclitaxel for Measurable Metastatic HER2-Negative Breast Cancer
None
INTERVENTIONAL
TERMINATED
2008-02-22T00:00:00
null
null
null
[ "PHASE2" ]
20
18
null
ALL
false
RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing....
OBJECTIVES: Primary * To evaluate the efficacy of sorafenib tosylate and paclitaxel by measuring tumor response, as defined by RECIST criteria, in patients with metastatic, HER2-negative breast cancer. Secondary * To evaluate time to disease progression in patients treated with this regimen. * To evaluate six-month...
DISEASE CHARACTERISTICS: Inclusion criteria: * Histologically\* confirmed breast cancer * Stage IV (metastatic) disease * Radiographic evidence of metastases NOTE: \*Histological confirmation of the actual metastasis is not required. * Measurable disease by RECIST criteria defined as ≥ 1 unidimensionally meas...
University of Texas Southwestern Medical Center
OTHER
{ "id": "STU 082010-161", "link": null, "type": null }
Study sponsor requested that the study be permanently closed by letter.
{ "hasExpandedAccess": false, "nctId": null, "statusForNctId": null }
2008-02-22T00:00:00
{ "date": "2020-10-19", "type": "ACTUAL" }
{ "date": "2008-02-25", "type": "ESTIMATED" }
[ "ADULT", "OLDER_ADULT" ]
null
null
true
{ "allocation": "NA", "interventionModel": "SINGLE_GROUP", "interventionModelDescription": null, "maskingInfo": { "masking": "NONE", "maskingDescription": null, "whoMasked": null }, "observationalModel": null, "primaryPurpose": "TREATMENT", "timePerspective": null }
[ "Breast Cancer" ]
["stage IV breast cancer", "male breast cancer", "recurrent breast cancer", "HER2-negative breast cancer"]
null
[ { "city": "Dallas", "country": "United States", "facility": "University of Texas Southwestern Medical Center", "geoPoint": { "lat": 32.78306, "lon": -96.80667 }, "state": "Texas" } ]
null
null
{ "other": null, "primary": [ { "description": null, "measure": "Time to Tumor Progression", "timeFrame": "Time from first treatment to disease progression or death (up to 36 months)" } ], "secondary": [ { "description": null, "measure": "Tumor Response Rate", "ti...
[ { "affiliation": "Simmons Cancer Center", "name": "Barbara B. Haley, MD", "role": "PRINCIPAL_INVESTIGATOR" } ]
null
{"versionHolder": "2025-06-18"}
{ "ancestors": [ { "id": "D009371", "term": "Neoplasms by Site" }, { "id": "D009369", "term": "Neoplasms" }, { "id": "D001941", "term": "Breast Diseases" }, { "id": "D012871", "term": "Skin Diseases" } ], "browseBranches": [ { ...
{ "ancestors": [ { "id": "D000972", "term": "Antineoplastic Agents, Phytogenic" }, { "id": "D000970", "term": "Antineoplastic Agents" }, { "id": "D050257", "term": "Tubulin Modulators" }, { "id": "D050256", "term": "Antimitotic Agents" },...
{ "conditions": [ { "id": "D001943", "term": "Breast Neoplasms" } ], "interventions": [ { "id": "D017239", "term": "Paclitaxel" }, { "id": "D000077157", "term": "Sorafenib" } ] }
NCT03807466
null
Feedback to Improve Rational Strategies of Antibiotic Initiation and Duration in Long Term Care
Feedback to Improve Rational Strategies of Antibiotic Initiation and Duration in Long Term
FIRST AID-LTC
INTERVENTIONAL
COMPLETED
2019-01-15T00:00:00
null
2020-04-30T00:00:00
2021-03-31T00:00:00
[ "NA" ]
356
null
null
ALL
false
There is a high rate of inappropriate antibiotic use in long-term care (LTC) facilities, with both unnecessary initiation and prolongation of treatments. Although there are challenges to rational antibiotic use in LTC, the variability in antibiotic initiation and use of prolonged treatment durations is driven by prescr...
Overarching Goals The overarching goals of FIRST AID - LTC are two-fold: 1. Improve rational antibiotic prescribing by physicians to minimize harms among LTC residents. 2. Advance the science of audit-and-feedback to improve physician prescribing practices. Specific Aims To improve rational antibiotic prescribing i...
To Identify an LTC Resident Inclusion Criteria: An individual having a minimum of 2 records on separate days within the quarter meeting any combination of the following criteria: * a record for a non-emergency long-term care inpatient services OR * an Ontario Drug Benefits record administered in long-term care Inde...
Institute for Clinical Evaluative Sciences
OTHER
{ "id": "441-2017", "link": null, "type": null }
Unknown
{ "hasExpandedAccess": false, "nctId": null, "statusForNctId": null }
2019-01-15T00:00:00
{ "date": "2021-08-25", "type": "ACTUAL" }
{ "date": "2019-01-17", "type": "ACTUAL" }
[ "CHILD", "ADULT", "OLDER_ADULT" ]
null
null
true
{ "allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "interventionModelDescription": "Assess two interventional parallel study models consisting of two intervention arms each", "maskingInfo": { "masking": "TRIPLE", "maskingDescription": "The team at Health Quality Ontario will be aware of the ...
[ "Antibiotic Initiation", "Antibiotic Duration" ]
null
null
[ { "city": "Toronto", "country": "Canada", "facility": "ICES", "geoPoint": { "lat": 43.70011, "lon": -79.4163 }, "state": "Ontario" } ]
[ { "class": "OTHER_GOV", "name": "Canadian Institutes of Health Research (CIHR)" }, { "class": "OTHER_GOV", "name": "Ontario Agency for Health Protection and Promotion" }, { "class": "OTHER", "name": "Health Quality Ontario" } ]
null
{ "other": null, "primary": [ { "description": null, "measure": "Antibiotic initiation", "timeFrame": "3 months" }, { "description": null, "measure": "Antibiotic duration", "timeFrame": "3 months" } ], "secondary": [ { "description": null, "mea...
[ { "affiliation": "ICES", "name": "Nick Daneman, MD", "role": "PRINCIPAL_INVESTIGATOR" } ]
[{"pmid": "33754632", "type": "DERIVED", "citation": "Daneman N, Lee SM, Bai H, Bell CM, Bronskill SE, Campitelli MA, Dobell G, Fu L, Garber G, Ivers N, Lam JMC, Langford BJ, Laur C, Morris A, Mulhall C, Pinto R, Saxena FE, Schwartz KL, Brown KA. Population-Wide Peer Comparison Audit and Feedback to Reduce Antibiotic I...
{"versionHolder": "2025-06-18"}
null
{ "ancestors": null, "browseBranches": [ { "abbrev": "Infe", "name": "Anti-Infective Agents" }, { "abbrev": "All", "name": "All Drugs and Chemicals" } ], "browseLeaves": [ { "asFound": null, "id": "M4222", "name": "Anti-Bacterial Agents", "rele...
{ "conditions": null, "interventions": [] }
NCT04868266
null
End Tidal Carbon Dioxide in Minimal Sedation
A Randomized Controlled Trial of the Effect of Capnography for Preventing Hypoxia in Minimally Sedated Pediatric Patients
ETCO2
INTERVENTIONAL
ACTIVE_NOT_RECRUITING
2021-04-25T00:00:00
null
2024-04-30T00:00:00
2024-12-30T00:00:00
[ "NA" ]
214
null
18
ALL
false
This randomized controlled study investigated the effect of end-tidal carbon dioxide monitoring in pediatric patients undergoing minimal sedation.
null
Inclusion Criteria: * pediatric patients undergoing minimal sedation for procedure. Exclusion Criteria: * none
Seoul National University Hospital
OTHER
{ "id": "D-2103-187-1208", "link": null, "type": null }
Unknown
{ "hasExpandedAccess": false, "nctId": null, "statusForNctId": null }
2021-04-27T00:00:00
{ "date": "2024-05-31", "type": "ACTUAL" }
{ "date": "2021-04-30", "type": "ACTUAL" }
[ "CHILD", "ADULT" ]
null
null
null
{ "allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "interventionModelDescription": null, "maskingInfo": { "masking": "NONE", "maskingDescription": null, "whoMasked": null }, "observationalModel": null, "primaryPurpose": "PREVENTION", "timePerspective": null }
[ "Complication of Anesthesia" ]
null
null
[ { "city": "Seoul", "country": "Korea, Republic of", "facility": "Jin-Tae Kim", "geoPoint": { "lat": 37.566, "lon": 126.9784 }, "state": null } ]
null
null
{ "other": null, "primary": [ { "description": null, "measure": "Incidence of oxygen desaturation", "timeFrame": "from immediately after sedation to end of procedure, up to 2 hours" } ], "secondary": [ { "description": null, "measure": "number of Staff intervetions", ...
null
null
{"versionHolder": "2025-06-18"}
{ "ancestors": null, "browseBranches": [ { "abbrev": "BC23", "name": "Symptoms and General Pathology" }, { "abbrev": "All", "name": "All Conditions" } ], "browseLeaves": [ { "asFound": null, "id": "M4185", "name": "Hypoxia", "relevance": "LOW" ...
null
{ "conditions": [], "interventions": null }
NCT06147466
null
Time Spent In Target Glucose Range in Women With T2D Diabetes in Pregnancy
Time Spent In the Target Glucose Range and MatErnaL and Neonatal Effects in Women With tYpe 2 Diabetes in Pregnancy (TIMELY)
Timely
OBSERVATIONAL
RECRUITING
2023-04-03T00:00:00
null
2026-03-01T00:00:00
2026-06-01T00:00:00
null
50
18
null
FEMALE
true
Prospective cohort study to determine to what extent women with type 2 diabetes are achieving the time in the target range outlined for women with type 1 diabetes (70-140 mg/dl or 3.5-7.8 mmol/l), overall and by trimester, by standard CGM measures and functional data analysis
null
Inclusion Criteria: 1. Women with type 2 diabetes diagnosed prior to pregnancy or prior to 20 weeks gestation with either a HbA1c of \>6.5%, fasting glucose ≥7.0, or 2 hr glucose ≥11.1 on a 75g OGTT. To make the diagnosis in pregnancy one needs 2 values equal to or greater than the values above. 2. ≤14 weeks gestation...
Mount Sinai Hospital, Canada
OTHER
{ "id": "21-0065-E", "link": null, "type": null }
Unknown
{ "hasExpandedAccess": false, "nctId": null, "statusForNctId": null }
2023-11-21T00:00:00
{ "date": "2024-03-20", "type": "ACTUAL" }
{ "date": "2023-11-27", "type": "ACTUAL" }
[ "ADULT", "OLDER_ADULT" ]
Pregnant Women with Type 2 diabetes with either a HbA1c of \>6.5%, fasting glucose ≥7.0, or 2 hr glucose ≥11.1 on a 75g OGTT
NON_PROBABILITY_SAMPLE
false
{ "allocation": null, "interventionModel": null, "interventionModelDescription": null, "maskingInfo": null, "observationalModel": "COHORT", "primaryPurpose": null, "timePerspective": "PROSPECTIVE" }
[ "Diabete Type 2", "Pregnancy in Diabetic" ]
["glucose range", "neonatal outcomes", "glycemic control", "hypoglycemia", "insulin resistance", "preganant", "pregnancy", "CGM", "Continuous Glucose Monitoring", "Dexcom", "maternal outcomes", "Pregnancy in Diabetes"]
null
[ { "city": "Toronto", "country": "Canada", "facility": "Mount Sinai Hospital", "geoPoint": { "lat": 43.70011, "lon": -79.4163 }, "state": "Ontario" } ]
[ { "class": "OTHER", "name": "University of Manitoba" }, { "class": "OTHER", "name": "Women's College Hospital" } ]
null
{ "other": null, "primary": [ { "description": null, "measure": "Time in target range", "timeFrame": "7-9 months" } ], "secondary": [ { "description": null, "measure": "Delivery outcome", "timeFrame": "7-9 months" }, { "description": null, "mea...
[ { "affiliation": "Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital", "name": "Denice Feig", "role": "PRINCIPAL_INVESTIGATOR" } ]
null
{"versionHolder": "2025-06-18"}
{ "ancestors": [ { "id": "D003920", "term": "Diabetes Mellitus" }, { "id": "D044882", "term": "Glucose Metabolism Disorders" }, { "id": "D008659", "term": "Metabolic Diseases" }, { "id": "D004700", "term": "Endocrine System Diseases" }, ...
{ "ancestors": null, "browseBranches": [ { "abbrev": "Hypo", "name": "Hypoglycemic Agents" }, { "abbrev": "All", "name": "All Drugs and Chemicals" } ], "browseLeaves": [ { "asFound": null, "id": "M10365", "name": "Insulin", "relevance": "LOW" ...
{ "conditions": [ { "id": "D011254", "term": "Pregnancy in Diabetics" }, { "id": "D016640", "term": "Diabetes, Gestational" }, { "id": "D003924", "term": "Diabetes Mellitus, Type 2" } ], "interventions": [] }
NCT05279066
null
Validation of Ejection Fraction and Cardiac Output Using Biostrap Wristband
A Clinical Validation Study for Measuring Cardiac Output and Ejection Fraction Using a Wrist-worn Device.
None
OBSERVATIONAL
UNKNOWN
2022-01-27T00:00:00
null
2022-07-15T00:00:00
2022-07-15T00:00:00
null
100
18
null
ALL
true
In this study, the investigators will compare the accuracy of the Biostrap wristband, a wearable device with a clinical-grade Photoplethysmography (PPG) sensor, to measure ejection fraction and cardiac output in patients undergoing a cardiac ultrasound and pulmonary arterial catheterization, respectively.
This in an introductory clinical study with both cardiac patients undergoing elective cardiac ultrasound and cardiac ICU patients with pulmonary arterial catheters featuring Biostrap wristband. This is a single site, non-blinded, non-randomized study. The wristband is a wearable device that contains a clinical-grade Ph...
Inclusion Criteria: 1. ≥ 18 years of age. 2. Subjects who are undergoing elective cardiac ultrasound as an outpatient for group 1 or are scheduled for/completed a pilmonary arterial catheterization for group 2. 3. Written informed consent obtained from subject and ability for subject to comply with the requirements of...
University of California, Los Angeles
OTHER
{ "id": "21-001030", "link": null, "type": null }
Unknown
{ "hasExpandedAccess": false, "nctId": null, "statusForNctId": null }
2022-03-03T00:00:00
{ "date": "2022-03-15", "type": "ACTUAL" }
{ "date": "2022-03-15", "type": "ACTUAL" }
[ "ADULT", "OLDER_ADULT" ]
Men and woman over the age of 18 years old.
NON_PROBABILITY_SAMPLE
false
{ "allocation": null, "interventionModel": null, "interventionModelDescription": null, "maskingInfo": null, "observationalModel": "COHORT", "primaryPurpose": null, "timePerspective": "CROSS_SECTIONAL" }
[ "Heart Failure" ]
["ejection fraction", "cardiac output"]
null
[ { "city": "Los Angeles", "country": "United States", "facility": "Ronald Reagan UCLA Medical Center", "geoPoint": { "lat": 34.05223, "lon": -118.24368 }, "state": "California" } ]
null
null
{ "other": null, "primary": [ { "description": null, "measure": "Association between obtained PPG waveforms and recorded ejection (EF) fractions", "timeFrame": "6 months" }, { "description": null, "measure": "Association between obtained PPG waveforms and recorded cardiac o...
null
null
{"versionHolder": "2025-06-18"}
{ "ancestors": [ { "id": "D006331", "term": "Heart Diseases" }, { "id": "D002318", "term": "Cardiovascular Diseases" } ], "browseBranches": [ { "abbrev": "BC14", "name": "Heart and Blood Diseases" }, { "abbrev": "All", "name": "All Condit...
{ "ancestors": null, "browseBranches": [ { "abbrev": "Infe", "name": "Anti-Infective Agents" }, { "abbrev": "All", "name": "All Drugs and Chemicals" } ], "browseLeaves": [ { "asFound": null, "id": "M11767", "name": "Metronidazole", "relevance":...
{ "conditions": [ { "id": "D006333", "term": "Heart Failure" } ], "interventions": [] }
NCT06874166
null
Social Cognition in Dystrophinopathies and Neurodevelopmental Disorders
Social Cognition in Dystrophinopathies and Neurodevelopmental Disorders. Behavioural and Psychophisiological Measures
None
OBSERVATIONAL
NOT_YET_RECRUITING
2025-02-17T00:00:00
null
null
null
null
45
4
null
MALE
true
The primary aim of this observational study is to investigate specific aspects of social cognition in dystrophinopathies. Body awareness, interpersonal distance and emotional processing will be measured in a sample of patients affected by Becker (BMD) and Duchenne (DMD) muscular dystrophy, compared with a sample of pat...
Study procedure includes: 1. Eligibility assessment according to inclusion and exclusion criteria. 2. Administration of questionnaires and scales for the characterization of cognitive and psychological features related with BMD/DMD and OI : Wechsler Intelligence Scale for Children 4th Edition (WISC-IV), Raven's Progres...
Inclusion Criteria: * Patients diagnosed with Duchenne and Becker muscular dystrophy (genetic and histological diagnosis and clinical diagnosis) (ambulant and non-ambulant). * Patients diagnosed with osteogenesis imperfecta. * Control group: participants without any neurological or psychiatric disorder Exclusion Crit...
IRCCS Eugenio Medea
OTHER
{ "id": "L2-227", "link": null, "type": null }
Unknown
{ "hasExpandedAccess": false, "nctId": null, "statusForNctId": null }
2025-03-11T00:00:00
{ "date": "2025-03-13", "type": "ACTUAL" }
{ "date": "2025-03-13", "type": "ACTUAL" }
[ "CHILD", "ADULT", "OLDER_ADULT" ]
For the statistical power analysis the size of the effect reported in Candini et al., 2017 (η2p = 0.28) has been considered, about the effect of diagnostic features on the peripersonal space, and the effect reported by Garcia et al., 2023 (η2p = 0.20) about the differences between DMD/BMD patients and neurotypicals in ...
NON_PROBABILITY_SAMPLE
false
{ "allocation": null, "interventionModel": null, "interventionModelDescription": null, "maskingInfo": null, "observationalModel": "CASE_CONTROL", "primaryPurpose": null, "timePerspective": "CROSS_SECTIONAL" }
[ "Duchenne / Becker Muscular Dystrophy", "Osteogenesis Imperfecta (OI)", "Social Cognition" ]
["Social Cognition", "Duchenne / Becker muscular dystrophy", "Osteogenesis Imperfecta (OI)", "EEG", "Interpersonal distance", "Interoception"]
null
null
null
null
{ "other": null, "primary": [ { "description": null, "measure": "Interoception", "timeFrame": "Day 1" }, { "description": null, "measure": "Interpersonal distance", "timeFrame": "Day 1" }, { "description": null, "measure": "Emotional processing", ...
null
null
{"versionHolder": "2025-06-18"}
{ "ancestors": [ { "id": "D020966", "term": "Muscular Disorders, Atrophic" }, { "id": "D009135", "term": "Muscular Diseases" }, { "id": "D009140", "term": "Musculoskeletal Diseases" }, { "id": "D009468", "term": "Neuromuscular Diseases" }...
null
{ "conditions": [ { "id": "D009136", "term": "Muscular Dystrophies" }, { "id": "D020388", "term": "Muscular Dystrophy, Duchenne" }, { "id": "D010013", "term": "Osteogenesis Imperfecta" }, { "id": "D065886", "term": "Neurodevelopmental Disorde...
NCT06580366
null
Comparing Sennosid A+B and Sodium Picosulfate/Magnesium Oxide/Citric Acid for Bowel Preparation
Sennosid A+B Versus Sodium Picosulfate/Magnesium Oxide/Citric Acid for Bowel Preparation; A Prospective Randomized Observer-Blinded Study
None
INTERVENTIONAL
NOT_YET_RECRUITING
2024-08-27T00:00:00
null
2024-12-22T00:00:00
2025-03-22T00:00:00
[ "PHASE4" ]
600
18
80
ALL
false
Colonoscopy Preparation: Comparing Sennoside A+B and PM/Ca Colonoscopy is a test used to examine the inside of the bowel. Proper bowel preparation is crucial because it helps doctors get a clear view during the procedure. What is Sennoside A+B? Sennoside A+B is a type of laxative made from the senna plant. It works b...
Colonoscopy is an endoscopic imaging method used to examine the lumen and mucosa of the bowel. It is the gold standard method used for colorectal cancer screening and the detection of most colorectal pathologies. Successful bowel preparation is one of the key factors for a successful colonoscopic examination. Sennosid...
Inclusion Criteria: * Adults aged 18-80 years scheduled for elective outpatient colonoscopy. * Ability to provide informed consent. Exclusion Criteria: * History of intra-abdominal surgery. * Chronic kidney failure. * Congestive heart failure. * Chronic liver failure. * Inflammatory bowel disease. * Electrolyte imba...
Hitit University
OTHER
{ "id": "HititUniversity-2024-43", "link": null, "type": null }
Unknown
{ "hasExpandedAccess": false, "nctId": null, "statusForNctId": null }
2024-08-28T00:00:00
{ "date": "2024-08-30", "type": "ACTUAL" }
{ "date": "2024-08-30", "type": "ACTUAL" }
[ "ADULT", "OLDER_ADULT" ]
null
null
false
{ "allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "interventionModelDescription": null, "maskingInfo": { "masking": "SINGLE", "maskingDescription": null, "whoMasked": [ "INVESTIGATOR" ] }, "observationalModel": null, "primaryPurpose": "SCREENING", "timePerspective": nu...
[ "Bowel Preparation" ]
["Bowel preparation", "Colonoscopy", "sennosid A+B", "Sodium Picosulfate"]
null
[ { "city": "Çorum", "country": "Turkey", "facility": "Hitit University Erol Olcok Training and Research Hospital", "geoPoint": { "lat": 40.54889, "lon": 34.95333 }, "state": null } ]
null
null
{ "other": null, "primary": [ { "description": null, "measure": "Sennosid A+B versus Sodium Picosulfate/Magnesium Oxide/Citric Acid for Bowel Preparation: A Prospective Randomized Observer-Blinded Study", "timeFrame": "4 months" } ], "secondary": null }
[ { "affiliation": "Hitit University", "name": "İbrahim Durak", "role": "STUDY_CHAIR" } ]
[{"pmid": "24659864", "type": "BACKGROUND", "citation": "Park S, Lim YJ. Adjuncts to colonic cleansing before colonoscopy. World J Gastroenterol. 2014 Mar 21;20(11):2735-40. doi: 10.3748/wjg.v20.i11.2735."}, {"pmid": "32424868", "type": "BACKGROUND", "citation": "Coskun Y, Yuksel I. Polyethylene glycol versus split hig...
{"versionHolder": "2025-06-18"}
null
{ "ancestors": [ { "id": "D000863", "term": "Antacids" }, { "id": "D045504", "term": "Molecular Mechanisms of Pharmacological Action" }, { "id": "D005765", "term": "Gastrointestinal Agents" }, { "id": "D000925", "term": "Anticoagulants" }...
{ "conditions": null, "interventions": [ { "id": "D008277", "term": "Magnesium Oxide" }, { "id": "C005701", "term": "Picosulfate sodium" }, { "id": "D019343", "term": "Citric Acid" }, { "id": "D000077559", "term": "Sodium Citrate" } ]...
NCT05371366
null
The Puncturable Atrial Septal Defect Occluder Trial (the PASSER Trial)
A Multicenter, Randomized, Parallel-controlled Clinical Trial to Evaluate the Efficacy and Safety of a New Atrial Septal Defect Occluder, ReAces®, and Delivery System for the Treatment of Atrial Septal Defect Occlusion
None
INTERVENTIONAL
UNKNOWN
2022-05-04T00:00:00
null
2023-04-22T00:00:00
2023-04-22T00:00:00
[ "NA" ]
128
18
70
ALL
false
A multicenter, randomized, parallel-controlled clinical trial to evaluate the efficacy and safety of a new atrial septal defect occluder, ReAces®, and delivery system for the treatment of atrial septal defect occlusion. Compared with the traditional atrial septal occluder, this new atrial septal occluder supports re-pu...
null
Inclusion Criteria: 1. aged 18-70 years; 2. with congenital secundum atrial septal defect; 3. the maximal ASD diameter was ≤38 mm; 4. with atrial-level left-to-right shunt, with Qp/Qs shunt ratio ≥1.5:1, or TTE or clinical manifestations indicated the existence of defect that inducing overfilling of right atrium; 5. t...
Shanghai Zhongshan Hospital
OTHER
{ "id": "HYYL2022-06ZC-01", "link": null, "type": null }
Unknown
{ "hasExpandedAccess": false, "nctId": null, "statusForNctId": null }
2022-05-07T00:00:00
{ "date": "2022-05-24", "type": "ACTUAL" }
{ "date": "2022-05-12", "type": "ACTUAL" }
[ "ADULT", "OLDER_ADULT" ]
null
null
null
{ "allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "interventionModelDescription": null, "maskingInfo": { "masking": "NONE", "maskingDescription": null, "whoMasked": null }, "observationalModel": null, "primaryPurpose": "TREATMENT", "timePerspective": null }
[ "Atrial Septal Defect" ]
null
null
[ { "city": "Shanghai", "country": "China", "facility": "180 Fenglin Road", "geoPoint": { "lat": 31.22222, "lon": 121.45806 }, "state": "Shanghai" } ]
null
null
{ "other": null, "primary": [ { "description": null, "measure": "Successful rate of complete closure of atrial septal defect", "timeFrame": "0-360 days" } ], "secondary": [ { "description": null, "measure": "Adverse events", "timeFrame": "0-360 days" } ] }
null
null
{"versionHolder": "2025-06-18"}
{ "ancestors": [ { "id": "D006330", "term": "Heart Defects, Congenital" }, { "id": "D018376", "term": "Cardiovascular Abnormalities" }, { "id": "D002318", "term": "Cardiovascular Diseases" }, { "id": "D006331", "term": "Heart Diseases" },...
null
{ "conditions": [ { "id": "D006343", "term": "Heart Septal Defects" }, { "id": "D006344", "term": "Heart Septal Defects, Atrial" } ], "interventions": null }
NCT00992966
null
Vibration Response Imaging (VRI) in Children With Acute Respiratory Symptoms
Vibration Response Imaging (VRI) in Children With Acute Respiratory Symptoms.
None
OBSERVATIONAL
SUSPENDED
2009-10-08T00:00:00
null
null
null
null
80
3
18
ALL
false
The VRI device may provide a complementary diagnostic tool for lung examination and aid the physician in determining whether a chest x-ray should be performed.
This study is a prospective, single center study to determine the value of VRI images as an aid in determining whether a chest x ray is necessary to evaluate children presenting with acute respiratory complaints. Study participants will be children, selected from the Emergency Department (ED), who were designated to u...
Inclusion Criteria: 1. Subject's parent or legal guardian, is able and willing to read the Informed Consent, understands the Informed Consent, and provides written Informed Consent for the subject; if the minor child is in fact able to give consent, the minor's consent must be obtained in addition to the consent of th...
Deep Breeze
INDUSTRY
{ "id": "DB048", "link": null, "type": null }
Study initiation has been delayed due to Sponsor decision
{ "hasExpandedAccess": false, "nctId": null, "statusForNctId": null }
2009-10-08T00:00:00
{ "date": "2010-08-20", "type": "ESTIMATED" }
{ "date": "2009-10-09", "type": "ESTIMATED" }
[ "CHILD", "ADULT" ]
A total number of 80 patients in the age range of 3-18 and consisting of both boys and girls, preferably in an equal distribution
PROBABILITY_SAMPLE
true
{ "allocation": null, "interventionModel": null, "interventionModelDescription": null, "maskingInfo": null, "observationalModel": "COHORT", "primaryPurpose": null, "timePerspective": "PROSPECTIVE" }
[ "Pneumonia" ]
["to acquire database of pneumonia cases in children"]
null
null
null
null
null
[ { "affiliation": "Shnider medical center", "name": "Liora Kornreich, M.D", "role": "PRINCIPAL_INVESTIGATOR" }, { "affiliation": "Shnider medical center", "name": "Liora Kornreich, Professor", "role": "PRINCIPAL_INVESTIGATOR" } ]
null
{"versionHolder": "2025-06-18"}
{ "ancestors": [ { "id": "D012141", "term": "Respiratory Tract Infections" }, { "id": "D007239", "term": "Infections" }, { "id": "D008171", "term": "Lung Diseases" }, { "id": "D012140", "term": "Respiratory Tract Diseases" } ], "brows...
null
{ "conditions": [ { "id": "D011014", "term": "Pneumonia" }, { "id": "D012818", "term": "Signs and Symptoms, Respiratory" } ], "interventions": null }
NCT03829566
null
Autologous Transplant To End NMO Spectrum Disorder
Autologous Hematopoietic Stem Cell Transplant for Neuromyelitis Optica Spectrum Disorder (NMOSD)
ATTEND
INTERVENTIONAL
WITHDRAWN
2019-02-01T00:00:00
null
null
2025-11-28T00:00:00
[ "PHASE2", "PHASE3" ]
0
18
65
ALL
false
This study is designed to treat your disease with an autologous stem cell transplant using a regimen of immune suppressant drugs and chemotherapy to reset your immune system and to determine if your disease will go into long-term remission.
The autologous stem cell transplant used in this research study is an investigational procedure that uses cyclophosphamide (chemotherapy), rabbit antithymocyte globulin (rATG) (a protein that kills the immune cells that are thought to be causing your disease), rituximab (a biologic drug that targets B cells of your imm...
Inclusion Criteria: 1. Age 18 - 65 years old at the time of pre-transplant evaluation 2. An established diagnosis of NMOSD (with or without aquaporin 4 (AQP4)-IgG antibody) Exclusion Criteria: 1. Under age of 18 or over age of 65 2. Prisoners 3. Psychiatric illness or mental deficiency making compliance with treatme...
Northwestern University
OTHER
{ "id": "DIAD.ATTEND.2018", "link": null, "type": null }
Discontinued by Investigator
{ "hasExpandedAccess": false, "nctId": null, "statusForNctId": null }
2019-02-01T00:00:00
{ "date": "2019-11-20", "type": "ACTUAL" }
{ "date": "2019-02-04", "type": "ACTUAL" }
[ "ADULT", "OLDER_ADULT" ]
null
null
true
{ "allocation": "NA", "interventionModel": "SINGLE_GROUP", "interventionModelDescription": null, "maskingInfo": { "masking": "NONE", "maskingDescription": null, "whoMasked": null }, "observationalModel": null, "primaryPurpose": "TREATMENT", "timePerspective": null }
[ "Neuromyelitis Optica", "Devic's Disease", "NMO Spectrum Disorder" ]
["Autologous Stem Cell Transplantation", "Hematopoietic Stem Cell Transplant"]
null
[ { "city": "Chicago", "country": "United States", "facility": "Northwestern University, Feinberg School of Medicine", "geoPoint": { "lat": 41.85003, "lon": -87.65005 }, "state": "Illinois" }, { "city": "Chicago", "country": "United States", "facility": "Northwester...
null
null
{ "other": null, "primary": [ { "description": null, "measure": "Progression-Free Survival", "timeFrame": "5 years" } ], "secondary": [ { "description": null, "measure": "Relapse-Free Survival", "timeFrame": "5 years" }, { "description": null, ...
[ { "affiliation": "Northwestern University", "name": "Richard Burt, MD", "role": "PRINCIPAL_INVESTIGATOR" } ]
null
{"versionHolder": "2025-06-18"}
{ "ancestors": [ { "id": "D009188", "term": "Myelitis, Transverse" }, { "id": "D020278", "term": "Demyelinating Autoimmune Diseases, CNS" }, { "id": "D020274", "term": "Autoimmune Diseases of the Nervous System" }, { "id": "D009422", "term": ...
{ "ancestors": [ { "id": "D007166", "term": "Immunosuppressive Agents" }, { "id": "D007155", "term": "Immunologic Factors" }, { "id": "D045505", "term": "Physiological Effects of Drugs" }, { "id": "D018501", "term": "Antirheumatic Agents" ...
{ "conditions": [ { "id": "D009471", "term": "Neuromyelitis Optica" } ], "interventions": [ { "id": "D008775", "term": "Methylprednisolone" }, { "id": "D000077555", "term": "Methylprednisolone Acetate" }, { "id": "D008776", "term": "Methy...
NCT05046366
null
Development of an Artificial Intelligence System for Intelligent Pathological Diagnosis and Therapeutic Effect Prediction Based on Multimodal Data Fusion of Common Tumors and Major Infectious Diseases in the Respiratory System Using Deep Learning Technology.
Research and Development of an Artificial Intelligence Technology System for Digital Pathological Diagnosis and Therapeutic Effect Prediction Based on Multimodal Data Fusion of Common Tumors and Major Infectious Diseases in the Respiratory System Using Deep Learning Technology.
None
OBSERVATIONAL
UNKNOWN
2021-06-27T00:00:00
null
null
null
null
1,000
18
90
ALL
true
To improve accurate diagnosis and treatment of common malignant tumors and major infectious diseases in the respiratory system, we aim to establish a large medical database that includes standardized and structured clinical diagnosis and treatment information such as electronic medical records, image features, patholog...
The main aims are as follows: 1. To establish a medical big data platform for multi-modal information fusion of common tumors and major infectious diseases (lung cancer/pulmonary nodules, tuberculosis, and COVID-19) based on the existing pathological image features and clinical multi-omics information database: The me...
Inclusion Criteria: 1. Participants with the clinical diagnosis of lung cancer, pulmonary tuberculosis, and COVID-19. 2. Participants that have signed informed consent. 3. Participants \>= 18 years old and \< 90 years old. 4. Participants with detailed electronic medical records, image records, pathological records, m...
Wuhan Union Hospital, China
OTHER
{ "id": "[2021]IEC(491)", "link": null, "type": null }
Unknown
{ "hasExpandedAccess": false, "nctId": null, "statusForNctId": null }
2021-09-15T00:00:00
{ "date": "2021-11-16", "type": "ACTUAL" }
{ "date": "2021-09-16", "type": "ACTUAL" }
[ "ADULT", "OLDER_ADULT" ]
Common malignant tumors and major infectious diseases in lung, including lung cancer, pulmonary tuberculosis, and COVID-19.
NON_PROBABILITY_SAMPLE
null
{ "allocation": null, "interventionModel": null, "interventionModelDescription": null, "maskingInfo": null, "observationalModel": "COHORT", "primaryPurpose": null, "timePerspective": "PROSPECTIVE" }
[ "Artificial Intelligence", "Deep Learning", "Pathology, Molecular", "Medical Informatics", "Database", "Lung Cancer", "Pulmonary Tuberculosis", "Covid19" ]
null
null
[ { "city": "Wuhan", "country": "China", "facility": "Union Hospital, Tongji Medical College, Huazhong University of Science and Technology", "geoPoint": { "lat": 30.58333, "lon": 114.26667 }, "state": "Hubei" } ]
null
null
{ "other": null, "primary": [ { "description": null, "measure": "The outcome of clinical diagnosis of suspected patients with lung cancer/pulmonary nodular (Benign/Malignant nodule).", "timeFrame": "2021-2024" }, { "description": null, "measure": "The outcome of clinical di...
[ { "affiliation": "union hospital, Tongji Medical college, Huazhonguniversity of science and technology", "name": "Yang Jin, Professor", "role": "STUDY_DIRECTOR" } ]
null
{"versionHolder": "2025-06-18"}
{ "ancestors": [ { "id": "D009164", "term": "Mycobacterium Infections" }, { "id": "D000193", "term": "Actinomycetales Infections" }, { "id": "D016908", "term": "Gram-Positive Bacterial Infections" }, { "id": "D001424", "term": "Bacterial Infe...
{ "ancestors": null, "browseBranches": [ { "abbrev": "Resp", "name": "Respiratory System Agents" }, { "abbrev": "All", "name": "All Drugs and Chemicals" } ], "browseLeaves": [ { "asFound": null, "id": "M21137", "name": "Respiratory System Agents", ...
{ "conditions": [ { "id": "D014376", "term": "Tuberculosis" }, { "id": "D003141", "term": "Communicable Diseases" }, { "id": "D007239", "term": "Infections" }, { "id": "D014397", "term": "Tuberculosis, Pulmonary" } ], "interventions":...
NCT00003666
null
Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
None
INTERVENTIONAL
COMPLETED
1999-11-01T00:00:00
null
null
null
[ "PHASE2" ]
36
18
120
ALL
false
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of irofulven in treating patients with relapsed or refractory non-small cell lung cancer.
OBJECTIVES: I. Determine the response rate to 6-hydroxymethylacylfulvene (HMAF) as salvage chemotherapy in patients with relapsed or refractory non-small cell lung cancer. II. Determine the duration of response to this regimen in this patient population. III. Determine the effect of prior response to chemotherapy on th...
DISEASE CHARACTERISTICS: Histologically or cytologically proven recurrent or refractory non-small cell lung cancer Squamous cell Adenocarcinoma (including bronchoalveolar cell) Large cell anaplastic (giant and clear cell carcinomas) Measurable disease (not bone disease only, pleural or pericardial effusions, or irradia...
Alliance for Clinical Trials in Oncology
OTHER
{ "id": "CALGB-39805", "link": null, "type": null }
Unknown
{ "hasExpandedAccess": false, "nctId": null, "statusForNctId": null }
2004-09-10T00:00:00
{ "date": "2016-07-20", "type": "ESTIMATED" }
{ "date": "2004-09-13", "type": "ESTIMATED" }
[ "ADULT", "OLDER_ADULT" ]
null
null
false
{ "allocation": "NON_RANDOMIZED", "interventionModel": "SINGLE_GROUP", "interventionModelDescription": null, "maskingInfo": { "masking": "NONE", "maskingDescription": null, "whoMasked": null }, "observationalModel": null, "primaryPurpose": "TREATMENT", "timePerspective": null }
[ "Lung Cancer" ]
["recurrent non-small cell lung cancer", "squamous cell lung cancer", "large cell lung cancer", "adenocarcinoma of the lung", "bronchoalveolar cell lung cancer"]
null
[ { "city": "Birmingham", "country": "United States", "facility": "Veterans Affairs Medical Center - Birmingham", "geoPoint": { "lat": 33.52066, "lon": -86.80249 }, "state": "Alabama" }, { "city": "La Jolla", "country": "United States", "facility": "University of Ca...
[ { "class": "NIH", "name": "National Cancer Institute (NCI)" } ]
null
{ "other": null, "primary": [ { "description": null, "measure": "Response", "timeFrame": "ea tx cycle; q 3 mon Yr 1 post tx, then q 6 mon until progression" } ], "secondary": [ { "description": null, "measure": "Toxicity", "timeFrame": "Each tx cycle" } ] }
[ { "affiliation": "Medical University of South Carolina", "name": "Carol A. Sherman, MD", "role": "STUDY_CHAIR" } ]
[{"pmid": "15301880", "type": "RESULT", "citation": "Sherman CA, Herndon JE 2nd, Watson DM, Green MR; Cancer and Leukemia Group B. A phase II trial of 6-hydroxymethylacylfulvene (MGI-114, irofulven) in patients with relapsed or refractory non-small cell lung cancer. Lung Cancer. 2004 Sep;45(3):387-92. doi: 10.1016/j.lu...
{"versionHolder": "2025-06-18"}
{ "ancestors": [ { "id": "D012142", "term": "Respiratory Tract Neoplasms" }, { "id": "D013899", "term": "Thoracic Neoplasms" }, { "id": "D009371", "term": "Neoplasms by Site" }, { "id": "D009369", "term": "Neoplasms" }, { "id": ...
{ "ancestors": [ { "id": "D018906", "term": "Antineoplastic Agents, Alkylating" }, { "id": "D000477", "term": "Alkylating Agents" }, { "id": "D045504", "term": "Molecular Mechanisms of Pharmacological Action" }, { "id": "D000970", "term": "An...
{ "conditions": [ { "id": "D008175", "term": "Lung Neoplasms" }, { "id": "D002289", "term": "Carcinoma, Non-Small-Cell Lung" } ], "interventions": [ { "id": "C102714", "term": "Irofulven" } ] }
NCT05698966
null
Low Dose Antenatal Corticosteroids for Late Preterm Delivery
Low Dose Antenatal Corticosteroids for Late Preterm Delivery (LoDAC Study)
LoDAC
INTERVENTIONAL
RECRUITING
2022-12-31T00:00:00
null
2027-01-01T00:00:00
2028-01-01T00:00:00
[ "NA" ]
1,510
18
45
ALL
false
This is a study proposal for a clinical trial to evaluate the effectiveness of a reduced dose of antenatal betamethasone (a steroid medication) in preventing respiratory problems in late preterm infants (born between 34 and 36 weeks of gestation). The study will be conducted in medical centers in Israel and will involv...
Antenatal corticosteroids (ACS) are a type of steroid medication that is administered to pregnant women at risk of preterm birth in order to reduce the risk of respiratory distress syndrome (RDS) and other complications in the newborn. ACS were first demonstrated to be effective in a controlled trial conducted in the 1...
Inclusion Criteria:- - Singleton pregnancy at 34 weeks 0 days to 36 weeks 5 days of gestation at risk for / high probability of delivery in the late preterm period (34+0-36+5 weeks of gestation). Criteria for determination of late preterm delivery risk: 1. Preterm uterine contractions with intact membranes, and at le...
Rambam Health Care Campus
OTHER
{ "id": "00451890", "link": null, "type": null }
Unknown
{ "hasExpandedAccess": false, "nctId": null, "statusForNctId": null }
2023-01-16T00:00:00
{ "date": "2024-04-10", "type": "ACTUAL" }
{ "date": "2023-01-26", "type": "ACTUAL" }
[ "ADULT" ]
null
null
true
{ "allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "interventionModelDescription": null, "maskingInfo": { "masking": "SINGLE", "maskingDescription": null, "whoMasked": [ "OUTCOMES_ASSESSOR" ] }, "observationalModel": null, "primaryPurpose": "PREVENTION", "timePerspectiv...
[ "Respiratory Morbidity", "Preterm Labor" ]
["corticosteroids", "low dose", "late prerterm"]
null
[ { "city": "Afula", "country": "Israel", "facility": "Emek Medical Center", "geoPoint": { "lat": 32.60907, "lon": 35.2892 }, "state": null }, { "city": "Ashkelon", "country": "Israel", "facility": "Kaplan Medical Center", "geoPoint": { "lat": 31.66926, ...
null
null
{ "other": null, "primary": [ { "description": null, "measure": "Respiratory morbidity", "timeFrame": "first 72 hours after birth" } ], "secondary": [ { "description": null, "measure": "other neonatal morbidities other neonatal morbidities", "timeFrame": "first 30...
null
null
{"versionHolder": "2025-06-18"}
{ "ancestors": [ { "id": "D007744", "term": "Obstetric Labor Complications" }, { "id": "D011248", "term": "Pregnancy Complications" }, { "id": "D005261", "term": "Female Urogenital Diseases and Pregnancy Complications" }, { "id": "D000091642", ...
{ "ancestors": null, "browseBranches": [ { "abbrev": "Infl", "name": "Anti-Inflammatory Agents" }, { "abbrev": "Resp", "name": "Respiratory System Agents" }, { "abbrev": "All", "name": "All Drugs and Chemicals" } ], "browseLeaves": [ { "asFou...
{ "conditions": [ { "id": "D047928", "term": "Premature Birth" }, { "id": "D007752", "term": "Obstetric Labor, Premature" } ], "interventions": [] }
NCT02861066
null
Abbreviating Mindfulness-Based Therapy for Depressive and Anxious Symptoms
Reducing Barriers to Mental Health Care: Abbreviating Mindfulness-Based Therapy for Depressive and Anxious Symptoms in a Heterogeneous Clinical Outpatient Group
None
INTERVENTIONAL
COMPLETED
2016-08-05T00:00:00
null
null
null
[ "NA" ]
54
18
null
ALL
false
Symptoms of depression and anxiety are extremely prevalent in the population. Unfortunately, patients often face barriers to accessing mental health care, particularly psychotherapeutic interventions, including long wait-times and demanding therapeutic protocols. For instance, Mindfulness-Based Therapy (MBT) has demons...
BACKGROUND: ABBREVIATED-MINDFULNESS BASED INTERVENTION (A-MBI) By the age of 40, 1 in 2 Canadians have been or are presently experiencing mental health issues. In particular, anxiety and mood disorders are the most prevalent lifetime mental health illnesses, affecting 11.6% of the population. Mindfulness based treatme...
Inclusion Criteria: * Consenting mood and anxiety outpatients referred to Dr. Selchen in the Sunnybrook Mindfulness-Based Therapy Clinic * Due to the nature of the assessment procedures, which include English-language self-report questionnaires and scales, ability to communicate in written and spoken English is an inc...
Sunnybrook Health Sciences Centre
OTHER
{ "id": "387-2105", "link": null, "type": null }
Unknown
{ "hasExpandedAccess": false, "nctId": null, "statusForNctId": null }
2016-08-05T00:00:00
{ "date": "2018-09-20", "type": "ACTUAL" }
{ "date": "2016-08-10", "type": "ESTIMATED" }
[ "ADULT", "OLDER_ADULT" ]
null
null
false
{ "allocation": "NA", "interventionModel": "SINGLE_GROUP", "interventionModelDescription": null, "maskingInfo": { "masking": "NONE", "maskingDescription": null, "whoMasked": null }, "observationalModel": null, "primaryPurpose": "TREATMENT", "timePerspective": null }
[ "Anxiety", "Depression", "Mood" ]
["Mindfulness-based Intervention", "Wellbeing", "Treatment"]
null
null
null
null
{ "other": null, "primary": [ { "description": null, "measure": "Change from Baseline Depressive Symptoms at 6 Weeks", "timeFrame": "Pre- (Week 0) and Post-Treatment Assessment (Week 6)" }, { "description": null, "measure": "Change from Baseline Anxiety Symptoms at 6 Weeks"...
[ { "affiliation": "Sunnybrook Health Sciences Centre", "name": "Steven Selchen, MD MSt FRCPC", "role": "PRINCIPAL_INVESTIGATOR" } ]
null
{"versionHolder": "2025-06-18"}
{ "ancestors": [ { "id": "D001526", "term": "Behavioral Symptoms" } ], "browseBranches": [ { "abbrev": "BXM", "name": "Behaviors and Mental Disorders" }, { "abbrev": "All", "name": "All Conditions" } ], "browseLeaves": [ { "asFound": "Depre...
null
{ "conditions": [ { "id": "D003863", "term": "Depression" } ], "interventions": null }
NCT04059666
null
Gastrointestinal Tract Microbiome in Healthy Term Infants Receiving Mother'S-own Breast Milk or Cow's Milk-based Infant Formulas
Gastrointestinal Tract Microbiome in Healthy Term Infants Receiving Mother'S-own Breast Milk or Cow's Milk-based Infant Formulas
None
INTERVENTIONAL
TERMINATED
2019-05-08T00:00:00
null
2022-02-02T00:00:00
2022-02-02T00:00:00
[ "NA" ]
57
7
18
ALL
true
This clinical trial will compare stool and oral microbiome composition between infants fed breast milk or one of two infant formulas for a 60 day feeding period.
null
Inclusion Criteria: * 7-18 days of age at Visit 1 * Singleton birth * Gestational age of 37-42 weeks * Birth weight of 2500 g (5 lbs 8 oz) or more * Parent or legal guardian agrees not to enroll infant in another interventional clinical study while participating in this study * Signed informed consent and use of PHI f...
Mead Johnson Nutrition
INDUSTRY
{ "id": "3390-1", "link": null, "type": null }
Slow enrolment
{ "hasExpandedAccess": false, "nctId": null, "statusForNctId": null }
2019-08-14T00:00:00
{ "date": "2022-08-25", "type": "ACTUAL" }
{ "date": "2019-08-16", "type": "ACTUAL" }
[ "CHILD" ]
null
null
false
{ "allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "interventionModelDescription": null, "maskingInfo": { "masking": "TRIPLE", "maskingDescription": null, "whoMasked": [ "PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR" ] }, "observationalModel": null, "primaryPu...
[ "Gastrointestinal Microbiome" ]
null
null
[ { "city": "Birmingham", "country": "United States", "facility": "Birmingham Pediatric Associates", "geoPoint": { "lat": 33.52066, "lon": -86.80249 }, "state": "Alabama" }, { "city": "Altamonte Springs", "country": "United States", "facility": "Children's Research,...
null
null
{ "other": null, "primary": [ { "description": null, "measure": "Comparison of stool microbiome between breast fed and formula fed babies", "timeFrame": "Over 60 days" } ], "secondary": [ { "description": null, "measure": "Oral microbiome at each visit", "timeFram...
null
null
{"versionHolder": "2025-06-18"}
null
{ "ancestors": null, "browseBranches": [ { "abbrev": "Ot", "name": "Other Dietary Supplements" }, { "abbrev": "All", "name": "All Drugs and Chemicals" } ], "browseLeaves": [ { "asFound": null, "id": "T435", "name": "Whey Protein", "relevance": ...
{ "conditions": null, "interventions": [] }
NCT03539666
null
Effect of Diets on the Gut Microbiota Composition and Cardiometabolic Wellbeing
The Effect of Pork and Chicken Diets on Gut Microbiota Composition and Metabolites Related to Cardiometabolic Wellbeing
None
INTERVENTIONAL
COMPLETED
2018-05-16T00:00:00
null
2019-03-14T00:00:00
2019-04-16T00:00:00
[ "NA" ]
38
50
null
ALL
true
The project will characterize human gut microbiome response to two different diets and the possible physiological and biochemical implications of such response on cardiometabolic risk factors. The study will use controlled-feeding, systems-biology, metagenomic, and metabolomic approaches to examine American dietary pat...
The study will use controlled-feeding, systems-biology, metagenomic, and metabolomic approaches to examine American dietary patterns.
Inclusion Criteria: * generally good health status based on one routine physical in the past 15 months, current health status * normal HbA1C, weigh 110 lb or more * Age 50 years or more, generally healthy, all races and both sexes * generally practicing a meat-based dietary pattern, do not have any special dietary req...
South Dakota State University
OTHER
{ "id": "IRB-1804010-EXP", "link": null, "type": null }
Unknown
{ "hasExpandedAccess": false, "nctId": null, "statusForNctId": null }
2018-05-16T00:00:00
{ "date": "2021-11-10", "type": "ACTUAL" }
{ "date": "2018-05-29", "type": "ACTUAL" }
[ "ADULT", "OLDER_ADULT" ]
null
null
false
{ "allocation": "RANDOMIZED", "interventionModel": "CROSSOVER", "interventionModelDescription": null, "maskingInfo": { "masking": "NONE", "maskingDescription": null, "whoMasked": null }, "observationalModel": null, "primaryPurpose": "SCREENING", "timePerspective": null }
[ "Healthy" ]
null
null
[ { "city": "Brookings", "country": "United States", "facility": "South Dakota State University, Wagner Hall 416", "geoPoint": { "lat": 44.31136, "lon": -96.79839 }, "state": "South Dakota" } ]
null
null
{ "other": null, "primary": [ { "description": null, "measure": "Microbiota-dependent TMAO-response, measured as serum concentration", "timeFrame": "10 days per diet arm" }, { "description": null, "measure": "Serum concentration of biogenic amine metabolites", "timeFr...
[ { "affiliation": "South Dakota State University", "name": "Moul Dey, Ph.D", "role": "PRINCIPAL_INVESTIGATOR" } ]
null
{"versionHolder": "2025-06-18"}
null
null
null
NCT04328766
null
Pharmacokinetic Interaction Between DWP14012 and DWC202005 in Healthy Volunteers
An Open-Label, Multiple-Dose Clinical Trial to Evaluate the Safety/Tolerability and Pharmacokinetic Interaction Between DWP14012 and DWC202005 in Healthy Volunteers
None
INTERVENTIONAL
COMPLETED
2020-03-24T00:00:00
null
2020-11-21T00:00:00
2020-11-21T00:00:00
[ "PHASE1" ]
36
19
50
ALL
true
An open-label, multiple-dose clinical trial to evaluate the safety/tolerability and pharmacokinetic interaction between DWP14012 and DWC202005 in healthy volunteers
null
Inclusion Criteria: * Healthy adults aged 19 to 50 years with BMI between 18.5 kg/m2 and 30.0 kg/m2 * Capable of understanding provided information and complying with protocol requirements * Provide written informed consent to participate in the study
Daewoong Pharmaceutical Co. LTD.
INDUSTRY
{ "id": "DW_DWP14012106", "link": null, "type": null }
Unknown
{ "hasExpandedAccess": false, "nctId": null, "statusForNctId": null }
2020-03-30T00:00:00
{ "date": "2021-08-16", "type": "ACTUAL" }
{ "date": "2020-03-31", "type": "ACTUAL" }
[ "ADULT" ]
null
null
null
{ "allocation": "NON_RANDOMIZED", "interventionModel": "PARALLEL", "interventionModelDescription": null, "maskingInfo": { "masking": "NONE", "maskingDescription": null, "whoMasked": null }, "observationalModel": null, "primaryPurpose": "TREATMENT", "timePerspective": null }
[ "Drug-drug Interaction" ]
null
null
[ { "city": "Queensland", "country": "Australia", "facility": "Nucleus Network (QPharm)", "geoPoint": null, "state": null } ]
null
null
{ "other": null, "primary": [ { "description": null, "measure": "Area under the plasma drug concentration-time curve", "timeFrame": "upto 48 hours postdose" }, { "description": null, "measure": "Peak Plasma Concentration (Cmax)", "timeFrame": "upto 48 hours postdose" ...
null
null
{"versionHolder": "2025-06-18"}
null
{ "ancestors": [ { "id": "D005765", "term": "Gastrointestinal Agents" } ], "browseBranches": [ { "abbrev": "Gast", "name": "Gastrointestinal Agents" }, { "abbrev": "All", "name": "All Drugs and Chemicals" } ], "browseLeaves": [ { "asFound":...
{ "conditions": null, "interventions": [ { "id": "C000634065", "term": "Fexuprazan" } ] }
NCT04791566
null
Preoperative High-dose Dexamethasone and Emergency Laparotomy
The Effects of Preoperative High-dose Dexamethasone on Inflammatory Response and Recovery After Emergency Laparotomy, a Randomized, Double-blind, Placebo-controlled Clinical Trial - AHA STEROID TRIAL
None
INTERVENTIONAL
COMPLETED
2021-03-03T00:00:00
null
2022-10-09T00:00:00
2022-12-09T00:00:00
[ "PHASE4" ]
120
18
null
ALL
false
The aim of this trial is to evaluate the effect of high-dose glucocorticoid on inflammatory response and recovery after emergency laparotomy in participants with intestinal obstruction and perforated viscus. Primary outcome is the reduction of C-reactive protein on postoperative day 1. Secondary outcomes are organ spe...
Surgical trauma and accompanying inflammation results in increased capillary permeability leading to tissue edema. Since the vascular endothelium contributes to homeostasis, endothelial damage may increase the risk of cardiovascular and hemodynamic complications. Pre-operative high-dose glucocorticoids provide reducti...
Inclusion Criteria: 1. Adults (18 years or over) undergoing emergency laparotomy (laparotomy or laparoscopy) for following abdominal pathology: 1. Primary perforated viscus (perforated ulcer, small intestine or colon) 2. Primary intestinal obstruction ( small intestine or colon) 2. Provided verbal and written i...
Copenhagen University Hospital, Hvidovre
OTHER
{ "id": "H-20038432", "link": null, "type": null }
Unknown
{ "hasExpandedAccess": false, "nctId": null, "statusForNctId": null }
2021-03-08T00:00:00
{ "date": "2022-12-14", "type": "ACTUAL" }
{ "date": "2021-03-10", "type": "ACTUAL" }
[ "ADULT", "OLDER_ADULT" ]
null
null
true
{ "allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "interventionModelDescription": null, "maskingInfo": { "masking": "QUADRUPLE", "maskingDescription": null, "whoMasked": [ "PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR" ] }, "observati...
[ "Intestinal Obstruction and Ileus", "Perforated Viscus", "Sepsis", "Pathophysiology", "Inflammatory Response" ]
null
null
[ { "city": "Hvidovre", "country": "Denmark", "facility": "Mirjana Cihoric", "geoPoint": { "lat": 55.65719, "lon": 12.47364 }, "state": null } ]
null
null
{ "other": [ { "description": null, "measure": "changes in postoperative inflammatory responses (IL-6, TNF alfa)", "timeFrame": "Preoperatively, 6 hours postoperatively, as well as postoperative day 1,3 and 5" }, { "description": null, "measure": "Change in plasma Syndecain-1...
[ { "affiliation": "Dept. of Anaesthesiology and Intensive Care", "name": "Nicolai Bang Foss, Professor", "role": "STUDY_DIRECTOR" } ]
null
{"versionHolder": "2025-06-18"}
{ "ancestors": [ { "id": "D007410", "term": "Intestinal Diseases" }, { "id": "D005767", "term": "Gastrointestinal Diseases" }, { "id": "D004066", "term": "Digestive System Diseases" } ], "browseBranches": [ { "abbrev": "BC23", "name": "Sy...
{ "ancestors": [ { "id": "D000893", "term": "Anti-Inflammatory Agents" }, { "id": "D000932", "term": "Antiemetics" }, { "id": "D001337", "term": "Autonomic Agents" }, { "id": "D018373", "term": "Peripheral Nervous System Agents" }, { ...
{ "conditions": [ { "id": "D007415", "term": "Intestinal Obstruction" } ], "interventions": [ { "id": "D003907", "term": "Dexamethasone" } ] }
NCT00251966
null
ASTERIX: Low Dose ASA and Nexium
A Randomized Double-Blind Placebo-Controlled Study to Assess the Prevention of Low-Dose Acetylsalicylic Acid (ASA) Associated Gastroduodenal Lesions and Upper Gastrointestinal Symptoms in Patients Taking Esomeprazole 20 mg Once Daily for 26 Weeks.
None
INTERVENTIONAL
COMPLETED
2005-11-09T00:00:00
null
null
null
[ "PHASE3" ]
960
60
null
ALL
false
The purpose of the study is to evaluate the effect of esomeprazole 20 mg od versus placebo for the prevention of gastric and/or duodenal ulcers in patients taking low-dose ASA.
null
Inclusion Criteria: * A clinical diagnosis of a condition (cardiovascular and/or cerebrovascular protection or other reasons) that requires daily intake of low-dose ASA, 75-325 mg, and is expected to continue for the duration of the study (daily is defined as at least 5 days per week). * Age \>= 60 years. * No gastric...
AstraZeneca
INDUSTRY
{ "id": "D9617C00011", "link": null, "type": null }
Unknown
{ "hasExpandedAccess": false, "nctId": null, "statusForNctId": null }
2005-11-09T00:00:00
{ "date": "2009-03-12", "type": "ESTIMATED" }
{ "date": "2005-11-11", "type": "ESTIMATED" }
[ "ADULT", "OLDER_ADULT" ]
null
null
null
{ "allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "interventionModelDescription": null, "maskingInfo": { "masking": "DOUBLE", "maskingDescription": null, "whoMasked": null }, "observationalModel": null, "primaryPurpose": "PREVENTION", "timePerspective": null }
[ "Gastroesophageal Reflux" ]
["Prevention of gastroduodenal lesions", "erosive oesophagitis", "upper GI symptoms"]
null
[ { "city": "Bondi Junction", "country": "Australia", "facility": "Research Site", "geoPoint": { "lat": -33.89275, "lon": 151.24723 }, "state": "New South Wales" }, { "city": "Bracken Ridge", "country": "Australia", "facility": "Research Site", "geoPoint": { ...
null
null
{ "other": null, "primary": [ { "description": null, "measure": "The primary variable is presence of gastric and/or duodenal ulcers at endoscopy over a 26-week period in patients taking low-dose ASA.", "timeFrame": null } ], "secondary": [ { "description": null, "measur...
[ { "affiliation": "AstraZeneca", "name": "AstraZeneca Nexium Medical Science Director, MD", "role": "STUDY_DIRECTOR" }, { "affiliation": "Perth Medical School", "name": "Neville Yeomans, MD", "role": "PRINCIPAL_INVESTIGATOR" } ]
null
{"versionHolder": "2025-06-18"}
{ "ancestors": [ { "id": "D015154", "term": "Esophageal Motility Disorders" }, { "id": "D003680", "term": "Deglutition Disorders" }, { "id": "D004935", "term": "Esophageal Diseases" }, { "id": "D005767", "term": "Gastrointestinal Diseases" ...
{ "ancestors": [ { "id": "D000897", "term": "Anti-Ulcer Agents" }, { "id": "D005765", "term": "Gastrointestinal Agents" }, { "id": "D054328", "term": "Proton Pump Inhibitors" }, { "id": "D004791", "term": "Enzyme Inhibitors" }, { ...
{ "conditions": [ { "id": "D005764", "term": "Gastroesophageal Reflux" } ], "interventions": [ { "id": "D064098", "term": "Esomeprazole" } ] }
NCT02736266
null
Neoadjuvant Pembrolizumab for Muscle-invasive Urothelial Bladder Carcinoma
An Open Label, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab (MK-3475) Before Cystectomy for Patients With Muscle-invasive Urothelial Bladder Cancer.
PURE-01
INTERVENTIONAL
COMPLETED
2016-04-09T00:00:00
null
2018-10-20T00:00:00
2022-09-23T00:00:00
[ "PHASE2" ]
174
18
null
ALL
false
Patients with T2-T4a N0 urothelial bladder carcinoma (UBC) with residual disease after transurethral resection of the bladder (TURB, surgical opinion, cystoscopy or radiological presence) will receive 3 cycles of pembrolizumab (MK-3475) at the dose of 200mg 3 weekly prior to surgery (radical cystectomy). Cystectomy wil...
Patients with T2-T4a N0 urothelial bladder carcinoma (UBC) with residual disease after transurethral resection of the bladder (TURB, surgical opinion, cystoscopy or radiological presence) will receive 3 cycles of pembrolizumab (MK-3475) at the dose of 200mg 3 weekly prior to surgery (radical cystectomy). Cystectomy wil...
Inclusion Criteria: 1. Willing and able to provide written informed consent. 2. Ability to comply with the protocol. 3. Age ≥ 18 years. 4. Histopathologically confirmed transitional cell carcinoma. Patients with mixed histologies are required to have a dominant (i.e. 50% at least) transitional cell pattern. 5. Fit and...
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
OTHER
{ "id": "INT 101/16", "link": null, "type": null }
Unknown
{ "hasExpandedAccess": false, "nctId": null, "statusForNctId": null }
2016-04-09T00:00:00
{ "date": "2023-07-18", "type": "ACTUAL" }
{ "date": "2016-04-13", "type": "ESTIMATED" }
[ "ADULT", "OLDER_ADULT" ]
null
null
true
{ "allocation": "NA", "interventionModel": "SINGLE_GROUP", "interventionModelDescription": null, "maskingInfo": { "masking": "NONE", "maskingDescription": null, "whoMasked": null }, "observationalModel": null, "primaryPurpose": "TREATMENT", "timePerspective": null }
[ "Urothelial Bladder Carcinoma" ]
["Muscle-invasive", "Urothelial bladder carcinoma", "Neoadjuvant therapy", "Radical cystectomy"]
null
[ { "city": "Milano", "country": "Italy", "facility": "Fondazione IRCCS Istituto Nazionale dei Tumori", "geoPoint": { "lat": 45.46427, "lon": 9.18951 }, "state": "Mi" } ]
[ { "class": "INDUSTRY", "name": "Merck Sharp & Dohme LLC" } ]
null
{ "other": null, "primary": [ { "description": null, "measure": "Pathologic complete response", "timeFrame": "At the time of radical cystectomy (within 9 weeks of the first dose of pembrolizumab)" } ], "secondary": [ { "description": null, "measure": "Adverse events", ...
[ { "affiliation": "Fondazione IRCCS Istituto Nazionale dei Tumori, Milano", "name": "Filippo G. de Braud, MD", "role": "PRINCIPAL_INVESTIGATOR" } ]
[{"pmid": "35283158", "type": "DERIVED", "citation": "Martini A, Raggi D, Marandino L, Montorsi F, Ross JS, Gibb EA, Necchi A. The Paradoxical Role of Body Mass Index in Patients with Muscle-invasive Bladder Cancer Receiving Neoadjuvant Immunotherapy. Eur Urol Oncol. 2022 Jun;5(3):370-372. doi: 10.1016/j.euo.2022.02.00...
{"versionHolder": "2025-06-18"}
{ "ancestors": [ { "id": "D009375", "term": "Neoplasms, Glandular and Epithelial" }, { "id": "D009370", "term": "Neoplasms by Histologic Type" }, { "id": "D009369", "term": "Neoplasms" }, { "id": "D014571", "term": "Urologic Neoplasms" },...
{ "ancestors": [ { "id": "D000074322", "term": "Antineoplastic Agents, Immunological" }, { "id": "D000970", "term": "Antineoplastic Agents" }, { "id": "D000082082", "term": "Immune Checkpoint Inhibitors" }, { "id": "D045504", "term": "Molecul...
{ "conditions": [ { "id": "D002277", "term": "Carcinoma" }, { "id": "D001749", "term": "Urinary Bladder Neoplasms" } ], "interventions": [ { "id": "C582435", "term": "Pembrolizumab" } ] }
NCT01857466
null
Ovarian Reserve After Ovarian Hemostasis by Floseal Matrix
Additional Benefit of Hemostatic Sealant in Preserving Ovarian Reserve During Laparoscopic Ovarian Cystectomy: a Randomized Controlled Trial
None
INTERVENTIONAL
COMPLETED
2013-05-16T00:00:00
null
null
null
[ "PHASE3" ]
100
18
45
FEMALE
false
Laparoscopy has become the gold standard for the surgical treatment of benign ovarian cysts and is usually performed by stripping the ovarian cyst wall, followed by bleeding control of the ovarian wound ground using bipolar coagulation. However, the hemostasis with bipolar coagulation could result in the damage of ovar...
null
Inclusion Criteria: * age between 18 and 45 years * maximum diameter of the cyst between 3 and 10 cm * regular menstrual bleeding (defined as cycle length less than 21 or more than 45 days) * appropriate medical status for laparoscopic surgery (American Society of Anesthesiologists Physical Status classification 1 or ...
CHA University
OTHER
{ "id": "KNC13-017", "link": null, "type": null }
Unknown
{ "hasExpandedAccess": false, "nctId": null, "statusForNctId": null }
2013-05-17T00:00:00
{ "date": "2014-06-25", "type": "ESTIMATED" }
{ "date": "2013-05-20", "type": "ESTIMATED" }
[ "ADULT" ]
null
null
false
{ "allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "interventionModelDescription": null, "maskingInfo": { "masking": "TRIPLE", "maskingDescription": null, "whoMasked": [ "PARTICIPANT", "INVESTIGATOR", "OUTCOMES_ASSESSOR" ] }, "observationalModel": null, "prima...
[ "Ovarian Cysts" ]
null
null
[ { "city": "Goyang", "country": "Korea, Republic of", "facility": "National Health Insurance Service Ilsan Hospital", "geoPoint": { "lat": 37.65639, "lon": 126.835 }, "state": null }, { "city": "Seoul", "country": "Korea, Republic of", "facility": "CHA Gangnam Medi...
null
null
{ "other": null, "primary": [ { "description": null, "measure": "Decline rate of serum AMH levels", "timeFrame": "3 months after therapy" } ], "secondary": null }
[ { "affiliation": "CHA Gangnam Medical Center, Seoul, Republic of Korea", "name": "Taejong Song, M.D", "role": "PRINCIPAL_INVESTIGATOR" } ]
[{"pmid": "24903197", "type": "DERIVED", "citation": "Song T, Lee SH, Kim WY. Additional benefit of hemostatic sealant in preservation of ovarian reserve during laparoscopic ovarian cystectomy: a multi-center, randomized controlled trial. Hum Reprod. 2014 Aug;29(8):1659-65. doi: 10.1093/humrep/deu125. Epub 2014 Jun 4."...
{"versionHolder": "2025-06-18"}
{ "ancestors": [ { "id": "D003560", "term": "Cysts" }, { "id": "D009369", "term": "Neoplasms" }, { "id": "D010049", "term": "Ovarian Diseases" }, { "id": "D000291", "term": "Adnexal Diseases" }, { "id": "D005831", "term": ...
{ "ancestors": null, "browseBranches": [ { "abbrev": "Coag", "name": "Coagulants" }, { "abbrev": "All", "name": "All Drugs and Chemicals" } ], "browseLeaves": [ { "asFound": null, "id": "M9576", "name": "Hemostatics", "relevance": "LOW" } ...
{ "conditions": [ { "id": "D010048", "term": "Ovarian Cysts" } ], "interventions": [] }
NCT03221166
null
Thalidomide Versus Infliximab in New Onset Crohn's Disease With Poor Prognostic Factors
Thalidomide, a Novel Immunological Treatment to Modify the Natural History of Paediatric Crohn's Disease: a New Proposal From a Well-established Paediatric Research Network
None
INTERVENTIONAL
TERMINATED
2017-07-05T00:00:00
null
2020-07-31T00:00:00
2020-07-31T00:00:00
[ "PHASE3" ]
9
6
17
ALL
false
Crohn's disease (CD) is a life-long inflammatory bowel disease disease with an unknown pathogenesis. The ultimate goal of therapy is to modify the natural history of CD thus reducing complications. Thalidomide is a small molecule with immunomodulatory and anti-angiogenetic properties. It is currently approved for the t...
null
Inclusion Criteria: * Age at diagnosis \<18 years and \>=6 years * New diagnosis of CD based on Porto criteria * CD with inflammatory phenotype (non-penetrating, non-fistulizing) and with no need for surgery except for perinal fistulas * Presence of at least one of the following risk factors for poor prognosis: * f...
IRCCS Burlo Garofolo
OTHER
{ "id": "NET-2013-02355002", "link": null, "type": null }
Difficulty in recruiting subjects who meet the inclusion/exclusion criteria
{ "hasExpandedAccess": false, "nctId": null, "statusForNctId": null }
2017-07-14T00:00:00
{ "date": "2020-09-04", "type": "ACTUAL" }
{ "date": "2017-07-18", "type": "ACTUAL" }
[ "CHILD" ]
null
null
false
{ "allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "interventionModelDescription": null, "maskingInfo": { "masking": "NONE", "maskingDescription": null, "whoMasked": null }, "observationalModel": null, "primaryPurpose": "TREATMENT", "timePerspective": null }
[ "Crohn Disease" ]
["Children", "Crohn disease", "Thalidomide", "Mucosal healing"]
null
[ { "city": "Napoli", "country": "Italy", "facility": "Dipartimento di Pediatria dell'Università di Napoli \"Federico II\"", "geoPoint": { "lat": 40.85216, "lon": 14.26811 }, "state": "Campania" }, { "city": "Trieste", "country": "Italy", "facility": "IRCCS Burlo Ga...
[ { "class": "OTHER", "name": "Centro di Riferimento Oncologico - Aviano" }, { "class": "OTHER", "name": "Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia" } ]
null
{ "other": null, "primary": [ { "description": null, "measure": "Efficacy in inducing mucosal healing", "timeFrame": "52 weeks" } ], "secondary": [ { "description": null, "measure": "Efficacy in inducing clinical response", "timeFrame": "12 weeks" }, { ...
[ { "affiliation": "IRCCS Burlo Garofolo", "name": "Alessandro Ventura, MD PhD", "role": "STUDY_CHAIR" } ]
null
{"versionHolder": "2025-06-18"}
{ "ancestors": [ { "id": "D015212", "term": "Inflammatory Bowel Diseases" }, { "id": "D005759", "term": "Gastroenteritis" }, { "id": "D005767", "term": "Gastrointestinal Diseases" }, { "id": "D004066", "term": "Digestive System Diseases" ...
{ "ancestors": [ { "id": "D000079424", "term": "Tumor Necrosis Factor Inhibitors" }, { "id": "D000893", "term": "Anti-Inflammatory Agents" }, { "id": "D003879", "term": "Dermatologic Agents" }, { "id": "D005765", "term": "Gastrointestinal Age...
{ "conditions": [ { "id": "D003424", "term": "Crohn Disease" } ], "interventions": [ { "id": "D013792", "term": "Thalidomide" }, { "id": "D000069285", "term": "Infliximab" } ] }
NCT00895466
null
Efficacy and Safety Study of the Therapeutic Vaccine PEP223 in Prostate Cancer Patients
A Phase I-II Open Label Clinical Trial, Evaluating the Efficacy and Safety of Administration of the Therapeutic Vaccine PEP-223/CoVaccine HT, to Hormone Treatment naïve, Immunocompetent Subjects With T1-3, N0-1/x, M0 Prostate Cancer, Eligible for Hormone Therapy.
None
INTERVENTIONAL
UNKNOWN
2009-05-06T00:00:00
null
null
null
[ "PHASE1", "PHASE2" ]
12
null
null
MALE
false
The purpose of this trial is to investigate whether treatment with this new drug will result in lower testosterone levels in men with prostate cancer. At the same time it will be investigated whether the drug induces side effects, and if so, which ones.
Prostate cancer growth is influenced by the male hormone testosterone. Treatment with drugs that stop the production of testosterone often results in a decrease of the tumor or inhibition of its growth. This is particularly important prior to radiotherapy, since radiation can better be focused on the prostate with as a...
Inclusion Criteria: * pathological confirmed prostatic adenocarcinoma, clinical stage (c) cT1-3, cN0-1/x, cM0 * baseline testosterone levels of \> 4 nmol/l * baseline PSA level of \> 10 microg/l * eligible for hormone therapy * willingness to comply with the protocol conditions and procedures * willing and able to giv...
Pepscan Therapeutics
INDUSTRY
{ "id": "PEP223-NL-0701", "link": null, "type": null }
Unknown
{ "hasExpandedAccess": false, "nctId": null, "statusForNctId": null }
2009-05-07T00:00:00
{ "date": "2009-05-08", "type": "ESTIMATED" }
{ "date": "2009-05-08", "type": "ESTIMATED" }
[ "CHILD", "ADULT", "OLDER_ADULT" ]
null
null
true
null
[ "Prostate Cancer" ]
["prostatic diseases", "neoplasms", "prostatic neoplasms", "hormones", "androgen antagonists", "vaccines", "peptide vaccines", "adjuvants, immunological"]
null
[ { "city": "Groningen", "country": "Netherlands", "facility": "UMC Groningen", "geoPoint": { "lat": 53.21917, "lon": 6.56667 }, "state": null }, { "city": "Nijmegen", "country": "Netherlands", "facility": "UMC Nijmegen", "geoPoint": { "lat": 51.8425, ...
[ { "class": "INDUSTRY", "name": "TFS Trial Form Support" } ]
null
{ "other": null, "primary": [ { "description": null, "measure": "Testosterone suppression", "timeFrame": "after 12 weeks treatment as compared to baseline" } ], "secondary": [ { "description": null, "measure": "The time course of testosterone suppression", "timeFr...
null
null
{"versionHolder": "2025-06-18"}
{ "ancestors": [ { "id": "D005834", "term": "Genital Neoplasms, Male" }, { "id": "D014565", "term": "Urogenital Neoplasms" }, { "id": "D009371", "term": "Neoplasms by Site" }, { "id": "D009369", "term": "Neoplasms" }, { "id": "D...
{ "ancestors": null, "browseBranches": [ { "abbrev": "All", "name": "All Drugs and Chemicals" } ], "browseLeaves": [ { "asFound": null, "id": "M17360", "name": "Vaccines", "relevance": "LOW" }, { "asFound": null, "id": "M9789", "name": "H...
{ "conditions": [ { "id": "D011471", "term": "Prostatic Neoplasms" } ], "interventions": [] }
NCT03958266
null
MyIBD Care - Feasibility Study
A Feasibility Study of a Novel Mobile Phone Application in the Long Term Management of Patients With Inflammatory Bowel Diseases
None
OBSERVATIONAL
WITHDRAWN
2019-05-15T00:00:00
null
null
null
null
0
16
80
ALL
false
The aim of this study is appraise the safety and feasibility of utilising a novel mobile phone application and linked clinical platform to replace and enhance traditional outpatient appointments for patients with Inflammatory Bowel Diseases. The goal of this study is to demonstrate whether the platform can reduce the c...
15 million people in the England suffer from long term conditions (LTCs). Furthermore, the number of people with three or more LTC's has risen from 1.9 million people in 2008 to 2.9 million in 2018. And with the growing number of people suffering from these conditions, the pressure grows for health care providers to pr...
Inclusion Criteria: * • Any patient 16-80 years of age at inclusion * Established diagnosis of IBD (including UC, CD, inflammatory bowel disease of uncertain aetiology (IBD-U) and inflammation of an ileo-anal pouch (pouchitis)) * for more than 6 months prior to enrolment * Has a smart phone device with access t...
Barts & The London NHS Trust
OTHER
{ "id": "266567", "link": null, "type": null }
COVID pandemic
{ "hasExpandedAccess": false, "nctId": null, "statusForNctId": null }
2019-05-17T00:00:00
{ "date": "2023-02-10", "type": "ACTUAL" }
{ "date": "2019-05-22", "type": "ACTUAL" }
[ "CHILD", "ADULT", "OLDER_ADULT" ]
Stable patients with Inflammatory Bowel disease as stipulated above recruited in out-patients and infusion clinics
NON_PROBABILITY_SAMPLE
false
{ "allocation": null, "interventionModel": null, "interventionModelDescription": null, "maskingInfo": null, "observationalModel": "COHORT", "primaryPurpose": null, "timePerspective": "PROSPECTIVE" }
[ "Inflammatory Bowel Diseases" ]
null
null
null
[ { "class": "OTHER", "name": "King's College Hospital NHS Trust" } ]
null
{ "other": null, "primary": [ { "description": null, "measure": "Adverse events", "timeFrame": "1 year" } ], "secondary": [ { "description": null, "measure": "Health economic assessment", "timeFrame": "1 year" }, { "description": null, "measure...
[ { "affiliation": "King's College Hospital NHS Trust", "name": "Bu Hayee, PhD, FRCP", "role": "PRINCIPAL_INVESTIGATOR" } ]
[{"pmid": "29050646", "type": "BACKGROUND", "citation": "Ng SC, Shi HY, Hamidi N, Underwood FE, Tang W, Benchimol EI, Panaccione R, Ghosh S, Wu JCY, Chan FKL, Sung JJY, Kaplan GG. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lance...
{"versionHolder": "2025-06-18"}
{ "ancestors": [ { "id": "D005767", "term": "Gastrointestinal Diseases" }, { "id": "D004066", "term": "Digestive System Diseases" }, { "id": "D005759", "term": "Gastroenteritis" } ], "browseBranches": [ { "abbrev": "BC06", "name": "Digest...
null
{ "conditions": [ { "id": "D007410", "term": "Intestinal Diseases" }, { "id": "D015212", "term": "Inflammatory Bowel Diseases" } ], "interventions": null }
NCT06385366
null
Developing & Evaluating Models for Early Predicting Obstetrical Diseases in Pregnant Women by Non-invasive Prenatal Test
Developing and Evaluating Models for Early Prediction of Obstetrical Diseases: Preeclampsia, Spontaneous Preterm Birth, and Gestational Diabetes in The Pregnant Women Performed Non-invasive Prenatal Screening (NIPT)
None
OBSERVATIONAL
NOT_YET_RECRUITING
2024-04-22T00:00:00
null
2025-05-06T00:00:00
2025-06-06T00:00:00
null
1,105
18
80
FEMALE
null
This is Observational study, aiming to investigate the potentiality of cffDNA and cfRNA by a non-invasive test, in combination with clinical characteristics, to establish models for early screening and predicting high-risk pregnancy of PE, SPB, and GDM in Vietnam.
This study is estimated to enroll 663 pregnant women with adverse pregnancy complications, including 221 cases of PE/eclampsia, 221 cases of SPB due to Preterm premature rupture of membranes (PPROM) or preterm labor, and 221 cases of GDM. Furthermore, the control group will enroll 442 participants, who are healthy preg...
Inclusion Criteria: 1. At recruitment, women with singleton pregnancies must fulfill the conditions: Cases: diagnosis of Preeclampsia/eclampsia, Preterm premature rupture of membranes (PPROM)/preterm labor leading to SPB, and/or gestational diabetes mellitus. Controls: healthy pregnancy at ≥ 37 weeks of gestat...
Gene Solutions
INDUSTRY
{ "id": "GS_NP1", "link": null, "type": null }
Unknown
{ "hasExpandedAccess": false, "nctId": null, "statusForNctId": null }
2024-04-22T00:00:00
{ "date": "2024-04-30", "type": "ACTUAL" }
{ "date": "2024-04-26", "type": "ACTUAL" }
[ "ADULT", "OLDER_ADULT" ]
This study population will include women with singleton pregnancies, who are diagnosed Preeclampsia/eclampsia, Preterm premature rupture of membranes (PPROM)/preterm labor leading to SPB, and/or gestational diabetes mellitus or who are healthy pregnancy at ≥ 37 weeks of gestation.
NON_PROBABILITY_SAMPLE
false
{ "allocation": null, "interventionModel": null, "interventionModelDescription": null, "maskingInfo": null, "observationalModel": "COHORT", "primaryPurpose": null, "timePerspective": "PROSPECTIVE" }
[ "Pregnant With Complication", "Preeclampsia", "Preterm Birth", "Gestational Diabetes" ]
["cffDNA", "cfRNA", "Vietnam"]
null
null
[ { "class": "UNKNOWN", "name": "Medical Genetics Institute (MGI)" } ]
null
{ "other": null, "primary": [ { "description": null, "measure": "Characteristics of pregnant women at 1st trimester (9-13 weeks 6 days of gestation)", "timeFrame": "12 months" }, { "description": null, "measure": "Characteristics of pregnant women at recruitment", "ti...
[ { "affiliation": "MGI", "name": "Hoa Giang, PhD", "role": "PRINCIPAL_INVESTIGATOR" } ]
[{"pmid": "21094932", "type": "BACKGROUND", "citation": "Brosens I, Pijnenborg R, Vercruysse L, Romero R. The \"Great Obstetrical Syndromes\" are associated with disorders of deep placentation. Am J Obstet Gynecol. 2011 Mar;204(3):193-201. doi: 10.1016/j.ajog.2010.08.009. Epub 2010 Nov 20."}, {"pmid": "25225057", "type...
{"versionHolder": "2025-06-18"}
{ "ancestors": [ { "id": "D007752", "term": "Obstetric Labor, Premature" }, { "id": "D007744", "term": "Obstetric Labor Complications" }, { "id": "D005261", "term": "Female Urogenital Diseases and Pregnancy Complications" }, { "id": "D000091642", ...
null
{ "conditions": [ { "id": "D047928", "term": "Premature Birth" }, { "id": "D016640", "term": "Diabetes, Gestational" }, { "id": "D011225", "term": "Pre-Eclampsia" }, { "id": "D011248", "term": "Pregnancy Complications" } ], "intervent...
NCT02350166
null
Short-term Effects of LASI Surgery Versus Conventional Laparotomy for Colorectal Liver Metastasis
Short-term Effects of Laparoscopic-assisted Small-incision Surgery Versus Conventional Laparotomy in Treatment of Resectable Colorectal Liver Metastasis
None
INTERVENTIONAL
UNKNOWN
2015-01-19T00:00:00
null
null
null
[ "PHASE3" ]
40
18
80
ALL
false
Surgical resection is still recommended as the optional treatment for colorectal liver metastasis (CLM) patients. There are two main concerns for resectable colorectal liver metastasis which remain controversial: surgical time and surgical type. As for the former, synchronous resection of primary colorectal tumor and l...
Nowadays, colorectal liver metastasis (CLM) is gaining wide population from multi-disciplinary doctors including gastroenterologists, oncologists, and hepatic doctors for its increasing incidence and poor prognosis. Nearly, 15%-25% of colorectal cancer patients present with simultaneous liver metastasis at the time of ...
Inclusion Criteria: 1. Pathologically confirmed resectable upper rectal cancer, sigmoid cancer, and left colon cancer 2. MRI/CT confirmed resectable liver metastasis after muti-disciplinary team assessment 3. No evidence of other metastasis 4. Organs function well to tolerance simultaneous surgery, especially liver fu...
West China Hospital
OTHER
{ "id": "sLRC-201312", "link": null, "type": null }
Unknown
{ "hasExpandedAccess": false, "nctId": null, "statusForNctId": null }
2015-01-24T00:00:00
{ "date": "2015-11-17", "type": "ESTIMATED" }
{ "date": "2015-01-29", "type": "ESTIMATED" }
[ "ADULT", "OLDER_ADULT" ]
null
null
true
{ "allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "interventionModelDescription": null, "maskingInfo": { "masking": "NONE", "maskingDescription": null, "whoMasked": null }, "observationalModel": null, "primaryPurpose": "TREATMENT", "timePerspective": null }
[ "Colorectal Cancer" ]
["colorectal cancer", "hepatectomy", "laparoscopic surgery", "laparotomy", "complications"]
null
[ { "city": "Chengdu", "country": "China", "facility": "West China hospital, Sichuan University", "geoPoint": { "lat": 30.66667, "lon": 104.06667 }, "state": "Sichuan" }, { "city": "Chengdu", "country": "China", "facility": "West China Hospital", "geoPoint": { ...
null
null
{ "other": null, "primary": [ { "description": null, "measure": "30-day complications", "timeFrame": "Postoperative 30 days" } ], "secondary": [ { "description": null, "measure": "Pain score", "timeFrame": "Postoperative 7 days" }, { "description": n...
[ { "affiliation": "West China Hospital", "name": "Ziqiang Wang, MD,PhD", "role": "PRINCIPAL_INVESTIGATOR" } ]
[{"pmid": "21296855", "type": "BACKGROUND", "citation": "Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90. doi: 10.3322/caac.20107. Epub 2011 Feb 4."}, {"pmid": "21685461", "type": "BACKGROUND", "citation": "Siegel R, Ward E, Brawley O, Jemal A...
{"versionHolder": "2025-06-18"}
{ "ancestors": [ { "id": "D007414", "term": "Intestinal Neoplasms" }, { "id": "D005770", "term": "Gastrointestinal Neoplasms" }, { "id": "D004067", "term": "Digestive System Neoplasms" }, { "id": "D009371", "term": "Neoplasms by Site" }, ...
{ "ancestors": null, "browseBranches": [ { "abbrev": "Hemat", "name": "Hematinics" }, { "abbrev": "All", "name": "All Drugs and Chemicals" } ], "browseLeaves": [ { "asFound": null, "id": "M11110", "name": "Liver Extracts", "relevance": "LOW" ...
{ "conditions": [ { "id": "D015179", "term": "Colorectal Neoplasms" } ], "interventions": [] }
NCT05789966
null
Fullscale_Intervention Study: Genetic Risk Communication in Coronary Heart Disease and Wearables
The Effect of Communicating Genetic Risk of Coronary Heart Disease and Wearable Technologies On Wearable-Device-Measured Behavioral Outcomes in East Asians: Protocol of a Randomized Controlled Trial
None
INTERVENTIONAL
NOT_YET_RECRUITING
2023-03-16T00:00:00
null
2026-01-01T00:00:00
2026-06-01T00:00:00
[ "NA" ]
414
60
null
ALL
true
Background: This study aims to determine the effects of communicating genetic risk for Coronary Heart Disease (CHD) alone or in combination with goal setting and prompts from a wearable device on objectively measured sedentary time (ST) in East Asians. It is hypothesized that this combination will lead to significant f...
null
Inclusion Criteria: * East Asian ancestry * Do not meet the WHO-recommended levels of PA (i.e., ≥150 minutes/week of moderate-intensity PA, ≥75 minutes/week of vigorous-intensity PA, or an equivalent combination of the two; determined through the IPAQ-Short Form). Exclusion Criteria: * Previously diagnosed with CHD,...
The University of Hong Kong
OTHER
{ "id": "Fullscale_CHD_RCT", "link": null, "type": null }
Unknown
{ "hasExpandedAccess": false, "nctId": null, "statusForNctId": null }
2023-03-16T00:00:00
{ "date": "2023-03-29", "type": "ACTUAL" }
{ "date": "2023-03-29", "type": "ACTUAL" }
[ "ADULT", "OLDER_ADULT" ]
null
null
false
{ "allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "interventionModelDescription": "parallel-group, open randomized controlled trial", "maskingInfo": { "masking": "DOUBLE", "maskingDescription": "Staff without knowledge of participant information will create a computer-generated list that co...
[ "Fitness Trackers", "Sedentary Time", "Genetic Predisposition to Disease", "Coronary Heart Disease" ]
["Coronary Heart Disease", "Genetic risk", "Sedentary Time", "Wearable Technology", "Randomized Controlled Trial"]
null
null
null
null
{ "other": null, "primary": [ { "description": null, "measure": "Changes in ST (average, in minutes/day) between baseline and Immediate post-intervention, between baseline and 12-month post-intervention, and between baseline and 6-month follow-up", "timeFrame": "Baseline, 12-month post-interve...
[ { "affiliation": "The University of Hong Kong", "name": "Youngwon Kim, Dr", "role": "PRINCIPAL_INVESTIGATOR" } ]
null
{"versionHolder": "2025-06-18"}
{ "ancestors": [ { "id": "D002318", "term": "Cardiovascular Diseases" }, { "id": "D014652", "term": "Vascular Diseases" }, { "id": "D001161", "term": "Arteriosclerosis" }, { "id": "D001157", "term": "Arterial Occlusive Diseases" }, { ...
null
{ "conditions": [ { "id": "D006331", "term": "Heart Diseases" }, { "id": "D003327", "term": "Coronary Disease" }, { "id": "D003324", "term": "Coronary Artery Disease" }, { "id": "D017202", "term": "Myocardial Ischemia" }, { "id"...
NCT01629966
null
Safety, Efficacy and Tolerability of Vilazodone in Generalized Anxiety Disorder
A Double-blind, Placebo-Controlled Fixed-Dose Study of Vilazodone in Patients With Generalized Anxiety Disorder.
VLZ-MD-05
INTERVENTIONAL
COMPLETED
2012-06-26T00:00:00
null
2014-02-28T00:00:00
2014-03-31T00:00:00
[ "PHASE3" ]
680
18
70
ALL
false
The purpose of this study is to evaluate the efficacy, safety and tolerability of vilazodone relative to placebo in the treatment of generalized anxiety disorder (GAD)
null
Inclusion Criteria: * Male and female, 18 - 70 years of age * Currently meet the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) criteria for Generalized Anxiety Disorder (GAD) * Minimum score of 20 on the Hamilton Rating Scale for Anxiety (HAM-A) Exclusion Criteria: ...
Forest Laboratories
INDUSTRY
{ "id": "VLZ-MD-05", "link": null, "type": null }
Unknown
{ "hasExpandedAccess": false, "nctId": null, "statusForNctId": null }
2012-06-27T00:00:00
{ "date": "2019-12-18", "type": "ACTUAL" }
{ "date": "2012-06-28", "type": "ESTIMATED" }
[ "ADULT", "OLDER_ADULT" ]
null
null
false
{ "allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "interventionModelDescription": null, "maskingInfo": { "masking": "TRIPLE", "maskingDescription": null, "whoMasked": [ "PARTICIPANT", "INVESTIGATOR", "OUTCOMES_ASSESSOR" ] }, "observationalModel": null, "prima...
[ "Generalized Anxiety Disorder" ]
["Generalized Anxiety Disorder", "GAD"]
null
[ { "city": "Birmingham", "country": "United States", "facility": "Forest Investigative Site 001", "geoPoint": { "lat": 33.52066, "lon": -86.80249 }, "state": "Alabama" }, { "city": "Beverly Hills", "country": "United States", "facility": "Forest Investigative Site ...
null
null
{ "other": null, "primary": [ { "description": null, "measure": "Change From Baseline in the Hamilton Rating Scale for Anxiety (HAM-A) Total Score", "timeFrame": "Baseline to Week 8" } ], "secondary": [ { "description": null, "measure": "Change From Baseline in the Shee...
[ { "affiliation": "Forest Laboratories", "name": "Giovanna Forero, MA", "role": "STUDY_DIRECTOR" } ]
[{"pmid": "27486544", "type": "DERIVED", "citation": "Khan A, Durgam S, Tang X, Ruth A, Mathews M, Gommoll CP. Post Hoc Analyses of Anxiety Measures in Adult Patients With Generalized Anxiety Disorder Treated With Vilazodone. Prim Care Companion CNS Disord. 2016 Apr 28;18(2):10.4088/PCC.15m01904. doi: 10.4088/PCC.15m01...
{"versionHolder": "2025-06-18"}
{ "ancestors": [ { "id": "D001523", "term": "Mental Disorders" } ], "browseBranches": [ { "abbrev": "BXM", "name": "Behaviors and Mental Disorders" }, { "abbrev": "All", "name": "All Conditions" } ], "browseLeaves": [ { "asFound": "Anxiety ...
{ "ancestors": [ { "id": "D000928", "term": "Antidepressive Agents" }, { "id": "D011619", "term": "Psychotropic Drugs" }, { "id": "D017367", "term": "Selective Serotonin Reuptake Inhibitors" }, { "id": "D014179", "term": "Neurotransmitter Upt...
{ "conditions": [ { "id": "D001008", "term": "Anxiety Disorders" } ], "interventions": [ { "id": "D000069503", "term": "Vilazodone Hydrochloride" } ] }
NCT03303066
null
Efficacy and Safety of FG-4592 for Treatment of Anemia in Participants With Lower Risk Myelodysplastic Syndrome (MDS)
A Phase 2/3 Trial of FG-4592 for Treatment of Anemia in Subjects With Lower Risk Myelodysplastic Syndrome
None
INTERVENTIONAL
COMPLETED
2017-10-02T00:00:00
null
2023-01-11T00:00:00
2023-02-08T00:00:00
[ "PHASE2", "PHASE3" ]
43
18
80
ALL
false
The objective of this study to evaluate the efficacy FG-4592 for the treatment of anemia in Chinese participants with lower risk MDS.
This is a Phase 2/3 trial with sequential Phase 2 and Phase 3 components. In each part, there is an up to 4 weeks screening period followed by a treatment period of 26 weeks and a 4 week follow-up period.
Key Inclusion Criteria: * Diagnosis of primary MDS classified as very low, low or intermediate risk with \<5% blasts (documented within 12 weeks prior to Day 1) * Screening Hb \<10 g/dL and ≥6g/dL * Transfusion independent defined as no red blood cell transfusions within 12 weeks of Day 1 * Erythropoiesis-stimulating ...
FibroGen
INDUSTRY
{ "id": "FGCL-4592-813", "link": null, "type": null }
Unknown
{ "hasExpandedAccess": false, "nctId": null, "statusForNctId": null }
2017-10-02T00:00:00
{ "date": "2023-05-03", "type": "ACTUAL" }
{ "date": "2017-10-05", "type": "ACTUAL" }
[ "ADULT", "OLDER_ADULT" ]
null
null
true
{ "allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "interventionModelDescription": null, "maskingInfo": { "masking": "QUADRUPLE", "maskingDescription": "Phase 2 part is an open label, single arm, dose-escalation study. Phase 3 component is a randomized, double blind, placebo-controlled study...
[ "Anemia", "Myelodysplastic Syndrome" ]
["Myelodysplastic Syndromes", "Anemia", "Hemoglobin (Hb)", "Low Risk Myelodysplastic Syndrome"]
null
[ { "city": "Bengbu", "country": "China", "facility": "The First Affiliated Hospital of Bengbu Medical College", "geoPoint": { "lat": 32.94083, "lon": 117.36083 }, "state": "Anhui" }, { "city": "Hefei", "country": "China", "facility": "Anhui Provincial Hospital", ...
[ { "class": "INDUSTRY", "name": "AstraZeneca" } ]
null
{ "other": null, "primary": [ { "description": null, "measure": "Percentage of Participants With a Hemoglobin (Hb) Response to FG-4592 Without Transfusion", "timeFrame": "26 weeks" } ], "secondary": [ { "description": null, "measure": "Number of Participants With Hb Inc...
null
null
{"versionHolder": "2025-06-18"}
{ "ancestors": [ { "id": "D004194", "term": "Disease" }, { "id": "D010335", "term": "Pathologic Processes" }, { "id": "D006402", "term": "Hematologic Diseases" }, { "id": "D001855", "term": "Bone Marrow Diseases" }, { "id": "D01...
{ "ancestors": null, "browseBranches": [ { "abbrev": "Infl", "name": "Anti-Inflammatory Agents" }, { "abbrev": "ARhu", "name": "Antirheumatic Agents" }, { "abbrev": "Analg", "name": "Analgesics" }, { "abbrev": "All", "name": "All Drugs and ...
{ "conditions": [ { "id": "D011289", "term": "Preleukemia" }, { "id": "D000740", "term": "Anemia" }, { "id": "D009190", "term": "Myelodysplastic Syndromes" }, { "id": "D013577", "term": "Syndrome" } ], "interventions": [] }
NCT02289066
null
Impact of Periodontal Disease on Outcomes in Diabetes
Impact of Periodontal Disease on Outcomes in Diabetes
None
OBSERVATIONAL
COMPLETED
2014-10-23T00:00:00
null
null
null
null
250
18
null
ALL
true
This study examines how periodontal disease affects the complications of diabetes and how treatment for periodontal disease affects biomarkers associated with the complications of diabetes.
The goal is to look for predictive factors of poor oral health and the impact of poor oral health on the complications of diabetes. The prevalence of periodontal disease among patients with diabetes is higher than in the general population. Periodontal disease is associated with dental loss and increased systemic infla...
Inclusion Criteria: All patients 18 years or older with diabetes for more than 2 years who present for their regular clinic visit will be eligible for inclusion in the survey part of the study. Further criteria for enrollment into the subgroup (n = 24) will include; Inclusion criteria * Answers on the questionnaire s...
University of Nevada, Reno
OTHER
{ "id": "1U54GM104944", "link": "https://reporter.nih.gov/quickSearch/1U54GM104944", "type": "NIH" }
Unknown
{ "hasExpandedAccess": false, "nctId": null, "statusForNctId": null }
2014-11-07T00:00:00
{ "date": "2015-12-02", "type": "ESTIMATED" }
{ "date": "2014-11-13", "type": "ESTIMATED" }
[ "ADULT", "OLDER_ADULT" ]
University of Nevada School of Medicine (Las Vegas) Internal medicine and endocrinology clinics
NON_PROBABILITY_SAMPLE
true
{ "allocation": null, "interventionModel": null, "interventionModelDescription": null, "maskingInfo": null, "observationalModel": "CASE_ONLY", "primaryPurpose": null, "timePerspective": "CROSS_SECTIONAL" }
[ "Periodontal Disease", "Diabetes Mellitus" ]
null
null
[ { "city": "Las Vegas", "country": "United States", "facility": "University of Nevada School of Medicine", "geoPoint": { "lat": 36.17497, "lon": -115.13722 }, "state": "Nevada" } ]
[ { "class": "NIH", "name": "National Institute of General Medical Sciences (NIGMS)" } ]
null
{ "other": null, "primary": [ { "description": null, "measure": "Changes in hemoglobin A1c", "timeFrame": "At enrollment, 3 months after enrollment and 6 months after enrollment." }, { "description": null, "measure": "biomarkers of inflammation (high sensitivity C - reactiv...
[ { "affiliation": "University of Nevada, Reno", "name": "Kenneth E Izuora, MD, MBA", "role": "PRINCIPAL_INVESTIGATOR" } ]
[{"pmid": null, "type": "BACKGROUND", "citation": "1. Centers for Disease Control and Prevention. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Pr...
{"versionHolder": "2025-06-18"}
{ "ancestors": [ { "id": "D044882", "term": "Glucose Metabolism Disorders" }, { "id": "D008659", "term": "Metabolic Diseases" }, { "id": "D004700", "term": "Endocrine System Diseases" }, { "id": "D009059", "term": "Mouth Diseases" }, ...
null
{ "conditions": [ { "id": "D010510", "term": "Periodontal Diseases" }, { "id": "D003920", "term": "Diabetes Mellitus" } ], "interventions": null }
NCT05523466
null
Effect of Acupuncture on Heart Rate Variability in Multiple Sclerosis
Effect of Acupuncture on Heart Rate Variability in Individuals With Multiple Sclerosis
None
INTERVENTIONAL
UNKNOWN
2022-07-25T00:00:00
null
null
null
[ "NA" ]
40
18
50
ALL
false
The Objective of this study is to evaluate the heart rate variability in individuals with multiple sclerosis during the applicability of Acupuncture, to analyze the behavior of the autonomic nervous system before, during, and after therapy and the changes of the condition.
A double-blinded randomized sham-controlled crossover trial with a 1:1 allocation ratio will be conducted, 40 individuals without previous illness will be evaluated, who will constitute the control group and 40 individuals with MS will constitute the experimental group, paired by age and gender. All participants will u...
Inclusion Criteria: * Individuals diagnosed with Multiple Sclerosis * Aged over 18 years * Motor and intellectual capacity to understand the evaluations * Light and moderate functional classification levels (EDSS scale) * Who accept to participate in the study through agreement with informed consent form Exclusion Cr...
University of Sao Paulo
OTHER
{ "id": "1239/2018", "link": null, "type": null }
Unknown
{ "hasExpandedAccess": false, "nctId": null, "statusForNctId": null }
2022-08-29T00:00:00
{ "date": "2022-08-31", "type": "ACTUAL" }
{ "date": "2022-08-31", "type": "ACTUAL" }
[ "ADULT" ]
null
null
null
{ "allocation": "RANDOMIZED", "interventionModel": "CROSSOVER", "interventionModelDescription": null, "maskingInfo": { "masking": "DOUBLE", "maskingDescription": null, "whoMasked": [ "PARTICIPANT", "OUTCOMES_ASSESSOR" ] }, "observationalModel": null, "primaryPurpose": "TREATMEN...
[ "Multiple Sclerosis" ]
null
null
null
null
null
{ "other": null, "primary": [ { "description": null, "measure": "Changes in the Heart Rate Variability after intervention", "timeFrame": "84 days" } ], "secondary": null }
[ { "affiliation": "Federal University of São Paulo", "name": "Celso Ferreira, Dr", "role": "PRINCIPAL_INVESTIGATOR" } ]
null
{"versionHolder": "2025-06-18"}
{ "ancestors": [ { "id": "D010335", "term": "Pathologic Processes" }, { "id": "D020278", "term": "Demyelinating Autoimmune Diseases, CNS" }, { "id": "D020274", "term": "Autoimmune Diseases of the Nervous System" }, { "id": "D009422", "term": ...
null
{ "conditions": [ { "id": "D009103", "term": "Multiple Sclerosis" }, { "id": "D012598", "term": "Sclerosis" } ], "interventions": null }
NCT00882466
null
The Effect of Erythropoietin at the Time of Reperfusion in Acute Myocardial Infarction
Phase 4 Study of the Effect of Human Recombinant Erythropoietin at the Time of Reperfusion in Patients With Acute Myocardial Infarction
None
INTERVENTIONAL
COMPLETED
2009-04-15T00:00:00
null
null
null
[ "PHASE4" ]
58
18
null
ALL
false
The purpose of this study is to investigate the effect of intravenous human recombinant erythropoietin on the reperfusion injury at primary percutaneous coronary intervention in patients with acute myocardial infarction.
null
Inclusion Criteria: * Acute myocardial infarction \<12hr * Age \>18yrs * First myocardial infarction * culprit lesion : proximal to mid left anterior descending artery * Baseline coronary flow : TIMI Grade 0\~1 Exclusion Criteria: * Patients with previous myocardial infarction * History of thrombotic complication * ...
Seoul National University Bundang Hospital
OTHER
{ "id": "EPO in AMI", "link": null, "type": null }
Unknown
{ "hasExpandedAccess": false, "nctId": null, "statusForNctId": null }
2009-04-15T00:00:00
{ "date": "2009-04-17", "type": "ESTIMATED" }
{ "date": "2009-04-16", "type": "ESTIMATED" }
[ "ADULT", "OLDER_ADULT" ]
null
null
true
{ "allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "interventionModelDescription": null, "maskingInfo": { "masking": "NONE", "maskingDescription": null, "whoMasked": null }, "observationalModel": null, "primaryPurpose": "TREATMENT", "timePerspective": null }
[ "Acute Myocardial Infarction" ]
["erythropoietin"]
null
[ { "city": "Seongnam", "country": "Korea, Republic of", "facility": "Seoul National University Bundang Hospital", "geoPoint": { "lat": 37.43861, "lon": 127.13778 }, "state": null } ]
null
null
{ "other": null, "primary": [ { "description": null, "measure": "Creatinine kinase (CK), creatinine kinase-MB (CK-MB)", "timeFrame": "4hr, 8hr, 12hr, 24hr, 48hr, 72hr" } ], "secondary": [ { "description": null, "measure": "Infarct size assessed by cardiac MRI", "t...
[ { "affiliation": "Seoul National University Bundang Hospital", "name": "Dong-Ju Choi, MD,PhD", "role": "PRINCIPAL_INVESTIGATOR" } ]
[{"pmid": "20199815", "type": "DERIVED", "citation": "Suh JW, Chung WY, Kim YS, Kim KI, Jeon EJ, Cho YS, Youn TJ, Chae IH, Kim CH, Choi DJ. The effect of intravenous administration of erythropoietin on the infarct size in primary percutaneous coronary intervention. Int J Cardiol. 2011 Jun 2;149(2):216-220. doi: 10.1016...
{"versionHolder": "2025-06-18"}
{ "ancestors": [ { "id": "D007511", "term": "Ischemia" }, { "id": "D010335", "term": "Pathologic Processes" }, { "id": "D009336", "term": "Necrosis" }, { "id": "D017202", "term": "Myocardial Ischemia" }, { "id": "D006331", ...
{ "ancestors": [ { "id": "D006397", "term": "Hematinics" } ], "browseBranches": [ { "abbrev": "Hemat", "name": "Hematinics" }, { "abbrev": "All", "name": "All Drugs and Chemicals" } ], "browseLeaves": [ { "asFound": "r-metHuG-CSF", "i...
{ "conditions": [ { "id": "D009203", "term": "Myocardial Infarction" }, { "id": "D007238", "term": "Infarction" } ], "interventions": [ { "id": "D000068817", "term": "Epoetin Alfa" } ] }
NCT02523066
null
Clinical Study to Evaluate the Performance of Magna Ease Heart Valve in Chinese Patients
Clinical Study to Evaluate the Performance of Magna Ease Heart Valve in Chinese Patients
None
OBSERVATIONAL
TERMINATED
2015-08-06T00:00:00
null
2017-04-29T00:00:00
2025-05-07T00:00:00
null
215
null
null
ALL
false
Clinical Study to Evaluate the Performance of Magna Ease Heart Valve in Chinese patients.
null
Inclusion Criteria: * The patients who implanted with Magna Ease Heart Valve (Type:7300TFX and 3300TFX) in Fuwai Hospital in China. * The patients agree to sign the inform consent form (ICF). Exclusion Criteria: * No specific exclusion criteria.
Edwards Lifesciences
INDUSTRY
{ "id": "Magna Ease CN001", "link": null, "type": null }
Sponsor decision
{ "hasExpandedAccess": false, "nctId": null, "statusForNctId": null }
2015-08-13T00:00:00
{ "date": "2025-05-18", "type": "ACTUAL" }
{ "date": "2015-08-14", "type": "ESTIMATED" }
[ "CHILD", "ADULT", "OLDER_ADULT" ]
The patients who had the heart valves (Type: 7300TFX and 3300TFX), and are willing to participate in the study.
NON_PROBABILITY_SAMPLE
true
{ "allocation": null, "interventionModel": null, "interventionModelDescription": null, "maskingInfo": null, "observationalModel": "CASE_ONLY", "primaryPurpose": null, "timePerspective": "PROSPECTIVE" }
[ "Mitral Valve or Aortic Valve Replacement" ]
null
null
[ { "city": "Beijing", "country": "China", "facility": "The Chinese academy of medical sciences fuwai hospital cardiovascular disease", "geoPoint": { "lat": 39.9075, "lon": 116.39723 }, "state": "Beijing" } ]
null
null
{ "other": null, "primary": [ { "description": null, "measure": "Echocardiography to evaluate the performance of heart valve", "timeFrame": "Up to five years after surgery" } ], "secondary": null }
null
null
{"versionHolder": "2025-06-18"}
null
null
null
NCT00588666
null
Phase II Trial of Gemcitabine, Carboplatin, and Bevacizumab in Chemotherapy Naive Patients With Advanced/Metastatic Urothelial Carcinoma
Phase II Trial of Gemcitabine, Carboplatin, and Bevacizumab in Chemotherapy Naive Patients With Advanced/Metastatic Urothelial Carcinoma
None
INTERVENTIONAL
COMPLETED
2007-12-26T00:00:00
null
null
null
[ "PHASE2" ]
51
18
null
ALL
false
Gemcitabine and carboplatin are two standard chemotherapy drugs used to treat tumors of the urothelial tract. These drugs do not shrink tumors in all patients and when they do, it is generally for a limited amount of time. This has led scientists to look for different ways to treat cancer. New drugs have been develope...
This is a phase II trial of gemcitabine, carboplatin, and bevacizumab in chemotherapy naïve patients with advanced/metastatic transitional cell carcinoma (TCC) of the urothelial tract.
Inclusion Criteria: * Histologic documentation: diagnosis of transitional cell carcinoma of the bladder,urethra, ureter, or renal pelvis. * Unresectable or metastatic disease * Ineligible for cisplatin (or incurable with cisplatin) * ≥ 4 weeks since prior RT * Karnofsky Performance Status ≥ 60% * Age ≥ 18 years of age...
Memorial Sloan Kettering Cancer Center
OTHER
{ "id": "06-006", "link": null, "type": null }
Unknown
{ "hasExpandedAccess": false, "nctId": null, "statusForNctId": null }
2008-01-07T00:00:00
{ "date": "2016-01-22", "type": "ESTIMATED" }
{ "date": "2008-01-08", "type": "ESTIMATED" }
[ "ADULT", "OLDER_ADULT" ]
null
null
null
{ "allocation": "NA", "interventionModel": "SINGLE_GROUP", "interventionModelDescription": null, "maskingInfo": { "masking": "NONE", "maskingDescription": null, "whoMasked": null }, "observationalModel": null, "primaryPurpose": "TREATMENT", "timePerspective": null }
[ "Myeloproliferative Disorder", "Urothelial Carcinoma", "Cancer" ]
["Myeloproliferative Disorder", "urinary bladder", "Cancer", "ureter", "renal pelvis", "chemotherapy"]
null
[ { "city": "Basking Ridge", "country": "United States", "facility": "Memorial Sloan-Kettering at Basking Ridge", "geoPoint": { "lat": 40.70621, "lon": -74.54932 }, "state": "New Jersey" }, { "city": "Basking Ridge", "country": "United States", "facility": "Memoral ...
null
null
{ "other": null, "primary": [ { "description": null, "measure": "Evaluate the Time to Disease Progression", "timeFrame": "3 years" } ], "secondary": [ { "description": null, "measure": "The Response Rate of Combination Therapy With Bevacizumab, Gemcitabine, and Carbopla...
[ { "affiliation": "Memorial Sloan Kettering Cancer Center", "name": "Dean Bajorin, MD", "role": "PRINCIPAL_INVESTIGATOR" } ]
null
{"versionHolder": "2025-06-18"}
{ "ancestors": [ { "id": "D009375", "term": "Neoplasms, Glandular and Epithelial" }, { "id": "D009370", "term": "Neoplasms by Histologic Type" }, { "id": "D009369", "term": "Neoplasms" }, { "id": "D001855", "term": "Bone Marrow Diseases" ...
{ "ancestors": [ { "id": "D000074322", "term": "Antineoplastic Agents, Immunological" }, { "id": "D000970", "term": "Antineoplastic Agents" }, { "id": "D020533", "term": "Angiogenesis Inhibitors" }, { "id": "D043924", "term": "Angiogenesis Mo...
{ "conditions": [ { "id": "D002277", "term": "Carcinoma" }, { "id": "D002295", "term": "Carcinoma, Transitional Cell" }, { "id": "D009196", "term": "Myeloproliferative Disorders" } ], "interventions": [ { "id": "D000068258", "term": "Beva...
NCT00927966
null
RAD001 in Combination With CP-751,871 in Patients Wtih Advanced Sarcomas and Other Malignant Neoplasms
Phase I Clinical Trial of RAD001 in Combination With CP-751,871 in Patients With Advanced Sarcomas and Other Malignant Neoplasms
None
INTERVENTIONAL
COMPLETED
2009-06-24T00:00:00
null
null
null
[ "PHASE1" ]
21
18
null
ALL
false
The purpose of this research study is to determine the safety of the combination of RAD001 and CP-751,871, as well as the highest dose of this combination that can be given to people safely. RAD001 is a newly discovered drug that may stop cancer cells from growing abnormally. This drug has been extensively studied in m...
* In this research study, each "cycle" of study drug dosing lasts 21 days. In the first cycle, participants will come to the clinic on Days 1, 8, and 15. During cycles 2 through 4, participants will come to the clinic on Days 1 and 8. The rest of the clinic visits will occur on Day 1 of every cycle thereafter. * During...
Inclusion Criteria: * Histologically confirmed advanced sarcoma or other advanced malignant solid tumor for which no known curative therapy exists. Patients must have had prior progression on, intolerance or refused approved standard therapies proven to prolong life. * Measurable disease per RECIST. A lesion in a prev...
Dana-Farber Cancer Institute
OTHER
{ "id": "09-091", "link": null, "type": null }
Unknown
{ "hasExpandedAccess": false, "nctId": null, "statusForNctId": null }
2009-06-24T00:00:00
{ "date": "2013-11-14", "type": "ESTIMATED" }
{ "date": "2009-06-25", "type": "ESTIMATED" }
[ "ADULT", "OLDER_ADULT" ]
null
null
true
{ "allocation": "NA", "interventionModel": "SINGLE_GROUP", "interventionModelDescription": null, "maskingInfo": { "masking": "NONE", "maskingDescription": null, "whoMasked": null }, "observationalModel": null, "primaryPurpose": "TREATMENT", "timePerspective": null }
[ "Sarcoma", "Solid Tumor" ]
["RAD001", "CP-751,871", "advanced sarcoma", "advanced malignant solid tumor"]
null
[ { "city": "Boston", "country": "United States", "facility": "Dana-Farber Cancer Institute", "geoPoint": { "lat": 42.35843, "lon": -71.05977 }, "state": "Massachusetts" } ]
[ { "class": "OTHER", "name": "Brigham and Women's Hospital" }, { "class": "INDUSTRY", "name": "Novartis" }, { "class": "INDUSTRY", "name": "Pfizer" } ]
null
{ "other": null, "primary": [ { "description": null, "measure": "To assess the safety and tolerability of daily oral RAD001, administered in combination with CP-751,871 given as an intravenous infusion in patients with advanced sarcomas and other advanced solid tumors that are incurable with any cur...
[ { "affiliation": "Dana-Farber Cancer Institute", "name": "Suzanne George, MD", "role": "PRINCIPAL_INVESTIGATOR" } ]
null
{"versionHolder": "2025-06-18"}
{ "ancestors": [ { "id": "D018204", "term": "Neoplasms, Connective and Soft Tissue" }, { "id": "D009370", "term": "Neoplasms by Histologic Type" } ], "browseBranches": [ { "abbrev": "BC04", "name": "Neoplasms" }, { "abbrev": "All", "name"...
{ "ancestors": [ { "id": "D000091203", "term": "MTOR Inhibitors" }, { "id": "D047428", "term": "Protein Kinase Inhibitors" }, { "id": "D004791", "term": "Enzyme Inhibitors" }, { "id": "D045504", "term": "Molecular Mechanisms of Pharmacologica...
{ "conditions": [ { "id": "D009369", "term": "Neoplasms" }, { "id": "D012509", "term": "Sarcoma" } ], "interventions": [ { "id": "D000068338", "term": "Everolimus" } ] }
NCT05064566
null
Evaluation of Caries Detection Methods
Clinical Performance of Diagnostic Methods in Early Occlusal Caries
None
OBSERVATIONAL
UNKNOWN
2021-05-28T00:00:00
null
2022-10-20T00:00:00
2022-12-20T00:00:00
null
101
18
null
ALL
true
The investigators aim will be to compare the diagnostic performance of clinical visual examination (ICDAS II), intraoral/bite wing radiography (BW), near infrared light transillumination (NIR-LT), and laser fluorescence (LF), in comparison to microcomputed tomography (micro-CT) for the detection of non-cavitated occlus...
Studies regarding comparison of diagnostic techniques for caries detection are generally conducted under in vitro conditions due to ethical concerns. Considering the many recently published in vitro studies which attempted to assess the diagnostic ability of different caries diagnosis systems, it is not possible to kno...
Inclusion Criteria: * According to the American Society of Anesthesiologists (ASA) only status 1/ healthy patients * Completely erupted permanent dentition, * No fixed orthodontic apparatus, prosthetic restoration and filling material, * A minimum age of 18 years, * At least one third erupted molar teeth (third mandib...
Mersin University
OTHER
{ "id": "2017-1-AP1-2000", "link": null, "type": null }
Unknown
{ "hasExpandedAccess": false, "nctId": null, "statusForNctId": null }
2021-09-21T00:00:00
{ "date": "2021-10-01", "type": "ACTUAL" }
{ "date": "2021-10-01", "type": "ACTUAL" }
[ "ADULT", "OLDER_ADULT" ]
The study sample will be comprised of 100 third molars requiring extraction with non-cavitated but suspected occlusal caries from 101 patients.
NON_PROBABILITY_SAMPLE
false
{ "allocation": null, "interventionModel": null, "interventionModelDescription": null, "maskingInfo": null, "observationalModel": "COHORT", "primaryPurpose": null, "timePerspective": "PROSPECTIVE" }
[ "Caries", "Diagnoses Disease" ]
["Caries detection;", "laser fluorescence", "micro-CT", "visual analog scale"]
null
[ { "city": "Yenisehir", "country": "Turkey", "facility": "Mersin University", "geoPoint": { "lat": 40.26444, "lon": 29.65306 }, "state": "Mersin" } ]
[ { "class": "OTHER", "name": "Mersin University" } ]
null
{ "other": null, "primary": [ { "description": null, "measure": "Accuracy", "timeFrame": "1 month" }, { "description": null, "measure": "Receptor operating characteristic (ROC) curves", "timeFrame": "1 month" }, { "description": null, "measure": "I...
[ { "affiliation": "Mersin University", "name": "Nazan Koçak Topbaş, PhD", "role": "PRINCIPAL_INVESTIGATOR" } ]
null
{"versionHolder": "2025-06-18"}
null
{ "ancestors": null, "browseBranches": [ { "abbrev": "Infe", "name": "Anti-Infective Agents" }, { "abbrev": "Derm", "name": "Dermatologic Agents" }, { "abbrev": "All", "name": "All Drugs and Chemicals" } ], "browseLeaves": [ { "asFound": null...
{ "conditions": null, "interventions": [] }
NCT02165566
null
Humalog or Humulin for Intensive Insulin Therapy in Intensive Care Unit
null
None
INTERVENTIONAL
COMPLETED
2014-05-07T00:00:00
null
null
null
[ "PHASE4" ]
28
18
80
ALL
false
Insulin preparation -random assignment to regular insulin lin or lispro insulin as first treatment- was administered at constant infusion rate (0.04 units/Kg/h) in patients presenting blood glucose concentration ≥180 mg/dl and was discontinued when blood glucose concentration ≤140 mg/dl (therapeutic blood glucose conce...
Inclusion criteria: Patients older than 18 years of age receiving full nutritional calories supply who presented blood glucose concentration ≥180 mg/dl. Exclusion criteria: moribund patients and patients enrolled on other studies were excluded. Patients with type 1 diabetes, patients with insulin-dependent diabetes are...
Inclusion Criteria: * critical care patients with blood glucose concentration \>180mg/dl Exclusion Criteria: * insulin dependent diabetes
University of Roma La Sapienza
OTHER
{ "id": "HlogHlin", "link": null, "type": null }
Unknown
{ "hasExpandedAccess": false, "nctId": null, "statusForNctId": null }
2014-06-16T00:00:00
{ "date": "2014-06-17", "type": "ESTIMATED" }
{ "date": "2014-06-17", "type": "ESTIMATED" }
[ "ADULT", "OLDER_ADULT" ]
null
null
true
{ "allocation": "RANDOMIZED", "interventionModel": "CROSSOVER", "interventionModelDescription": null, "maskingInfo": { "masking": "NONE", "maskingDescription": null, "whoMasked": null }, "observationalModel": null, "primaryPurpose": "TREATMENT", "timePerspective": null }
[ "Hyperglycemia" ]
["intensive insulin therapy", "critical care patients", "blood glucose concentration>180 mg/dl"]
null
[ { "city": "Rome", "country": "Italy", "facility": "University of ROme \"La Sapienza\" Rome Italy", "geoPoint": { "lat": 41.89193, "lon": 12.51133 }, "state": null } ]
null
null
{ "other": null, "primary": [ { "description": null, "measure": "Extent of insulin residual effect in critical care patients", "timeFrame": "patients will be followed during insulin infusion in a time frame of minutes/hours, with an expected average time of 6-8 hours" } ], "secondary":...
[ { "affiliation": "Department of Anesthesiology, University of ROme \"La Sapienza\"", "name": "Federico Bilotta, MD, PhD", "role": "PRINCIPAL_INVESTIGATOR" } ]
[{"pmid": "25466315", "type": "DERIVED", "citation": "Bilotta F, Badenes R, Lolli S, Belda FJ, Einav S, Rosa G. Insulin infusion therapy in critical care patients: regular insulin vs short-acting insulin. A prospective, crossover, randomized, multicenter blind study. J Crit Care. 2015 Apr;30(2):437.e1-6. doi: 10.1016/j...
{"versionHolder": "2025-06-18"}
{ "ancestors": [ { "id": "D044882", "term": "Glucose Metabolism Disorders" }, { "id": "D008659", "term": "Metabolic Diseases" } ], "browseBranches": [ { "abbrev": "BC18", "name": "Nutritional and Metabolic Diseases" }, { "abbrev": "All", ...
{ "ancestors": [ { "id": "D007004", "term": "Hypoglycemic Agents" }, { "id": "D045505", "term": "Physiological Effects of Drugs" } ], "browseBranches": [ { "abbrev": "Hypo", "name": "Hypoglycemic Agents" }, { "abbrev": "All", "name": "All...
{ "conditions": [ { "id": "D006943", "term": "Hyperglycemia" } ], "interventions": [ { "id": "D007328", "term": "Insulin" }, { "id": "C557859", "term": "Insulin, Globin Zinc" }, { "id": "D061268", "term": "Insulin Lispro" } ] }
NCT01437566
null
Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Participants Resistant to Aromatase Inhibitor Therapy
A Phase II, Double-Blind, Placebo Controlled, Randomized Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy
None
INTERVENTIONAL
COMPLETED
2011-09-08T00:00:00
null
null
null
[ "PHASE2" ]
318
18
null
FEMALE
false
This is a multicenter, international, randomized, double-blinded, placebo-controlled, Phase II trial. Participants with advanced breast cancer (ABC) or Metastatic Breast Cancer (MBC) who have experienced recurrence or progression of their disease while receiving aromatase inhibitor (AI) therapy or who have relapsed wit...
null
Inclusion Criteria: * Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 * As per national or local treatment guidelines, endocrine therapy (i.e., fulvestrant) is recommended and treatment with cytotoxic chemotherapy is not necessary for participants, at time of entry into the study. * Part I: Post...
Genentech, Inc.
INDUSTRY
{ "id": "GDC4950g", "link": null, "type": null }
Unknown
{ "hasExpandedAccess": false, "nctId": null, "statusForNctId": null }
2011-09-19T00:00:00
{ "date": "2016-11-02", "type": "ESTIMATED" }
{ "date": "2011-09-21", "type": "ESTIMATED" }
[ "ADULT", "OLDER_ADULT" ]
null
null
null
{ "allocation": "RANDOMIZED", "interventionModel": null, "interventionModelDescription": null, "maskingInfo": { "masking": "DOUBLE", "maskingDescription": null, "whoMasked": [ "PARTICIPANT", "INVESTIGATOR" ] }, "observationalModel": null, "primaryPurpose": "TREATMENT", "timeP...
[ "Breast Cancer" ]
null
null
[ { "city": "Birmingham", "country": "United States", "facility": null, "geoPoint": { "lat": 33.52066, "lon": -86.80249 }, "state": "Alabama" }, { "city": "Hayward", "country": "United States", "facility": null, "geoPoint": { "lat": 37.66882, "lon": ...
null
null
{ "other": null, "primary": [ { "description": null, "measure": "Progression Free Survival as Assessed by the Investigator Per modified RECIST v 1.1", "timeFrame": "From Screening to up to approximately 5 years (assessed at Screening, after 8, 16, 24 and 32 weeks of treatment, every 12 weeks t...
[ { "affiliation": "Genentech, Inc.", "name": "Gallia Levy, M.D., Ph.D.", "role": "STUDY_DIRECTOR" } ]
[{"pmid": "27155741", "type": "DERIVED", "citation": "Krop IE, Mayer IA, Ganju V, Dickler M, Johnston S, Morales S, Yardley DA, Melichar B, Forero-Torres A, Lee SC, de Boer R, Petrakova K, Vallentin S, Perez EA, Piccart M, Ellis M, Winer E, Gendreau S, Derynck M, Lackner M, Levy G, Qiu J, He J, Schmid P. Pictilisib for...
{"versionHolder": "2025-06-18"}
{ "ancestors": [ { "id": "D009371", "term": "Neoplasms by Site" }, { "id": "D009369", "term": "Neoplasms" }, { "id": "D001941", "term": "Breast Diseases" }, { "id": "D012871", "term": "Skin Diseases" } ], "browseBranches": [ { ...
{ "ancestors": [ { "id": "D018931", "term": "Antineoplastic Agents, Hormonal" }, { "id": "D000970", "term": "Antineoplastic Agents" }, { "id": "D065171", "term": "Estrogen Receptor Antagonists" }, { "id": "D004965", "term": "Estrogen Antagoni...
{ "conditions": [ { "id": "D001943", "term": "Breast Neoplasms" } ], "interventions": [ { "id": "D000077267", "term": "Fulvestrant" } ] }
NCT05264766
null
The Use of Cooling Helmet for Neuroprotection Management in Open Heart Surgery
The Use of Cooling Helmet for Neuroprotection Management in Patient Undergoing Open Heart Surgery: an Evaluation of Postoperative Neuron-specific Enolase (NSE) and Delirium
None
INTERVENTIONAL
COMPLETED
2022-02-18T00:00:00
null
2021-12-31T00:00:00
2021-12-31T00:00:00
[ "NA" ]
26
18
null
ALL
false
To know the relationship between the use of cooling helmet with the changes of NSE level and postoperative delirium event in open heart surgery
Subjects were assigned into two groups after giving consent to participate in the study using random allocation, 13 subjects per group. Blood sample from CVC were obtained to assess NSE preoperative. After induction, cooling helmet with circulating cold water were placed on patients group A and without circulating cold...
Inclusion Criteria: * Patient undergoing their first open heart surgery using cardiopulmonary bypass * Age ≥18 year-old * Patient with American Society of Anesthesiologists (ASA) III * Patient with Glasgow Coma Scale (GCS) 15, fully aware and oriented * Patient fluent in Indonesia Exclusion Criteria: * Patients did ...
Indonesia University
OTHER
{ "id": "IndonesiaUAnes333", "link": null, "type": null }
Unknown
{ "hasExpandedAccess": false, "nctId": null, "statusForNctId": null }
2022-03-02T00:00:00
{ "date": "2022-03-03", "type": "ACTUAL" }
{ "date": "2022-03-03", "type": "ACTUAL" }
[ "ADULT", "OLDER_ADULT" ]
null
null
null
{ "allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "interventionModelDescription": null, "maskingInfo": { "masking": "TRIPLE", "maskingDescription": null, "whoMasked": [ "PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR" ] }, "observationalModel": null, "primaryPu...
[ "Heart; Surgery, Heart, Functional Disturbance as Result" ]
["cooling helmet", "neuron specific enolase", "delirium", "open heart surgery"]
null
[ { "city": "Jakarta Pusat", "country": "Indonesia", "facility": "Cipto Mangunkusumo Central National Hospital", "geoPoint": { "lat": -6.1818, "lon": 106.8223 }, "state": "DKI Jakarta" } ]
null
null
{ "other": null, "primary": [ { "description": null, "measure": "Neuron-specific enolase", "timeFrame": "6 hours post cardiopulmonary bypass off" }, { "description": null, "measure": "Confusion Assessment Method - Intensive Care Unit (CAM-ICU)", "timeFrame": "Changes ...
null
null
{"versionHolder": "2025-06-18"}
{ "ancestors": null, "browseBranches": [ { "abbrev": "BC10", "name": "Nervous System Diseases" }, { "abbrev": "BC23", "name": "Symptoms and General Pathology" }, { "abbrev": "BXM", "name": "Behaviors and Mental Disorders" }, { "abbrev": "All", ...
null
{ "conditions": [], "interventions": null }
NCT00003766
null
O6-benzylguanine Followed by Surgery in Treating Patients With Solid Tumors That Can Be Removed During Surgery
Determination of Optimal O6-Benzylguanine Dose to Achieve O6-Alkylguanine-DNA Alkyltransferase Depletion in Patients With Surgically Resectable Solid Tumors
None
INTERVENTIONAL
COMPLETED
1999-11-01T00:00:00
null
null
null
[ "PHASE1" ]
25
null
null
ALL
false
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving a chemotherapy drug before surgery may shrink the tumor so that it can be removed during surgery. PURPOSE: Phase II trial to study the effectiveness of O6-benzylguanine followed by surgery in ...
OBJECTIVES: I. Determine the minimal O6-benzylguanine (O6-BG) dose required to deplete tumor activity to less than 10 fmol/mg protein at a specified time after administration in patients with surgically resectable solid tumors. II. Correlate tumor tissue AGT depletion with AGT depletion in peripheral blood mononuclear ...
DISEASE CHARACTERISTICS: Histologically or cytologically confirmed surgically resectable solid tumor PATIENT CHARACTERISTICS: Age: Not specified Performance status: CALGB 0-2 Life expectancy: Not specified Hematopoietic: Not specified Hepatic: Bilirubin no greater than 1.5 times upper limit of normal (ULN) Renal: Crea...
University of Chicago
OTHER
{ "id": "9523", "link": null, "type": null }
Unknown
{ "hasExpandedAccess": false, "nctId": null, "statusForNctId": null }
2004-02-19T00:00:00
{ "date": "2014-03-06", "type": "ESTIMATED" }
{ "date": "2004-02-20", "type": "ESTIMATED" }
[ "CHILD", "ADULT", "OLDER_ADULT" ]
null
null
false
{ "allocation": "NA", "interventionModel": "SINGLE_GROUP", "interventionModelDescription": null, "maskingInfo": { "masking": "NONE", "maskingDescription": null, "whoMasked": null }, "observationalModel": null, "primaryPurpose": "TREATMENT", "timePerspective": null }
[ "Unspecified Adult Solid Tumor, Protocol Specific" ]
["unspecified adult solid tumor, protocol specific"]
null
[ { "city": "Chicago", "country": "United States", "facility": "University of Chicago Cancer Research Center", "geoPoint": { "lat": 41.85003, "lon": -87.65005 }, "state": "Illinois" } ]
[ { "class": "NIH", "name": "National Cancer Institute (NCI)" } ]
null
{ "other": null, "primary": [ { "description": null, "measure": "Determine minimal dose", "timeFrame": "2 years" } ], "secondary": null }
[ { "affiliation": "University of Chicago", "name": "Mark J. Ratain, MD", "role": "STUDY_CHAIR" } ]
null
{"versionHolder": "2025-06-18"}
{ "ancestors": null, "browseBranches": null, "browseLeaves": null, "meshes": [ { "id": "D009369", "term": "Neoplasms" } ] }
{ "ancestors": [ { "id": "D000970", "term": "Antineoplastic Agents" }, { "id": "D004791", "term": "Enzyme Inhibitors" }, { "id": "D045504", "term": "Molecular Mechanisms of Pharmacological Action" } ], "browseBranches": [ { "abbrev": "ANeo", ...
{ "conditions": [ { "id": "D009369", "term": "Neoplasms" } ], "interventions": [ { "id": "C064976", "term": "O(6)-benzylguanine" } ] }
NCT03828266
null
Prediction of Abdominal Complications After GastroEnterological Surgery
Abdominal Infectious Complications After Gastrointestinal Surgery in China: a Multi-centered Prospective Registry
PACAGE
OBSERVATIONAL
UNKNOWN
2019-01-30T00:00:00
null
2019-12-31T00:00:00
2020-12-31T00:00:00
null
4,000
18
null
ALL
false
The aim of this multi-centered study is to understand the epidemiology of infectious complications after gastrointestinal surgery in China. In total, 17 centers from China will prospectively register their patients undergo gastric or colorectal surgeries. Patient demographic data, operation information, and postoperati...
All participating hospital will log in on a website based e-CRF system. Researchers need to register the patient information that three time-points: admission, after surgery, after discharge. The detailed registered information includes: I. Basic and surgical information: Age, height, weight, history of abdominal su...
Inclusion Criteria: * Planned gastrointestinal surgery. * Inform consent received. Exclusion Criteria: * Endoscopic surgery. * Inform consent denied.
Peking University
OTHER
{ "id": "2018YJZ56", "link": null, "type": null }
Unknown
{ "hasExpandedAccess": false, "nctId": null, "statusForNctId": null }
2019-01-31T00:00:00
{ "date": "2019-02-04", "type": "ACTUAL" }
{ "date": "2019-02-04", "type": "ACTUAL" }
[ "ADULT", "OLDER_ADULT" ]
All adult patients undergo gastrointestinal (GI) surgery for GI tumor.
PROBABILITY_SAMPLE
false
{ "allocation": null, "interventionModel": null, "interventionModelDescription": null, "maskingInfo": null, "observationalModel": "COHORT", "primaryPurpose": null, "timePerspective": "PROSPECTIVE" }
[ "Complication", "Anastomotic Leak", "Gastrointestinal Cancer" ]
null
null
[ { "city": "Beijing", "country": "China", "facility": "Peking University Cancer Hospital", "geoPoint": { "lat": 39.9075, "lon": 116.39723 }, "state": "Beijing" }, { "city": "Fuzhou", "country": "China", "facility": "Fujian Medical University Union Hospital", "g...
null
null
{ "other": null, "primary": [ { "description": null, "measure": "Abdominal Infection rate after gastrectomy.", "timeFrame": "From surgery until discharge, up to 90 days." }, { "description": null, "measure": "Abdominal Infection rate after colorectal surgery.", "timeF...
[ { "affiliation": "Peking University Cancer Hospital & Institute", "name": "Ziyu Li, MD PhD", "role": "PRINCIPAL_INVESTIGATOR" } ]
null
{"versionHolder": "2025-06-18"}
{ "ancestors": [ { "id": "D004067", "term": "Digestive System Neoplasms" }, { "id": "D009371", "term": "Neoplasms by Site" }, { "id": "D009369", "term": "Neoplasms" }, { "id": "D004066", "term": "Digestive System Diseases" }, { ...
null
{ "conditions": [ { "id": "D005770", "term": "Gastrointestinal Neoplasms" }, { "id": "D057868", "term": "Anastomotic Leak" } ], "interventions": null }
NCT02777866
null
LAW Trial -The Impact of Local Anesthetics Infiltration in Surgical Wound of Gastrointestinal Procedures
LAW Trial -The Impact of Local Anesthetics Infiltration in Surgical Wound of Gastrointestinal Procedures: A Blind Prospective Randomized Trial
LAW
INTERVENTIONAL
UNKNOWN
2016-05-16T00:00:00
null
null
null
[ "NA" ]
570
18
null
ALL
false
The purpose of this study is to determine if the infiltration of 0.5% Bupivacaine in the surgical wound is effective to diminish the pain and the risk of surgical site infections in patients who go to a open gastrointestinal procedure.
This is an experimental, randomized, prospective, double blind study, in which will compare two groups. First group of participants who will be non urgent operated of an open gastrointestinal surgery, where an opening of the gastrointestinal lumen occurs (bile duct, stomach, small bowel or colon), who will be infiltrat...
Inclusion Criteria: * Patients who are planned to a elective gastrointestinal surgery. * Biliary-pancreatic open procedures: biliodigestive Derivation, Pancreatoduodenectomy, Pancreato-jejunostomy (Puestow procedure, Frey). * Open upper gastrointestinal procedures: total gastrectomy, subtotal gastrectomy (distal gastr...
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
OTHER
{ "id": "CIBH-1566", "link": null, "type": null }
Unknown
{ "hasExpandedAccess": false, "nctId": null, "statusForNctId": null }
2016-05-18T00:00:00
{ "date": "2016-05-19", "type": "ESTIMATED" }
{ "date": "2016-05-19", "type": "ESTIMATED" }
[ "ADULT", "OLDER_ADULT" ]
null
null
true
{ "allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "interventionModelDescription": null, "maskingInfo": { "masking": "TRIPLE", "maskingDescription": null, "whoMasked": [ "PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR" ] }, "observationalModel": null, "primaryPu...
[ "Surgical Site Infection", "Wound Infection", "Postoperative Pain", "Local Anesthetics" ]
null
null
[ { "city": "Tlalpan, Mexico City", "country": "Mexico", "facility": "Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran", "geoPoint": null, "state": "Mexico City" } ]
null
null
{ "other": null, "primary": [ { "description": null, "measure": "Postoperative Surgical Site Infection (SSI) defined by the Centre for Disease Control (CDC) criteria", "timeFrame": "30 days following operation" }, { "description": null, "measure": "Efficacy of 0.5% Bupivaca...
[ { "affiliation": "Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran", "name": "Noel Salgado-Nesme", "role": "PRINCIPAL_INVESTIGATOR" } ]
null
{"versionHolder": "2025-06-18"}
{ "ancestors": [ { "id": "D020969", "term": "Disease Attributes" }, { "id": "D010335", "term": "Pathologic Processes" }, { "id": "D011183", "term": "Postoperative Complications" } ], "browseBranches": [ { "abbrev": "BC26", "name": "Wounds...
{ "ancestors": [ { "id": "D000779", "term": "Anesthetics, Local" }, { "id": "D000777", "term": "Anesthetics" }, { "id": "D002492", "term": "Central Nervous System Depressants" }, { "id": "D045505", "term": "Physiological Effects of Drugs" ...
{ "conditions": [ { "id": "D007239", "term": "Infections" }, { "id": "D003141", "term": "Communicable Diseases" }, { "id": "D013530", "term": "Surgical Wound Infection" }, { "id": "D014946", "term": "Wound Infection" }, { "id": ...
NCT05204966
null
Development of Dysphagia Evaluation Via Video Analysis Based on Deep Learning Method in Neonates and Infants and Correlation Between the Evaluation and the Development
Development of Dysphagia Evaluation Via Video Analysis Based on Deep Learning Method in Neonates and Infants and Correlation Between the Evaluation and the Development
None
INTERVENTIONAL
UNKNOWN
2022-01-03T00:00:00
null
2024-12-31T00:00:00
2024-12-31T00:00:00
[ "NA" ]
50
null
6
ALL
false
The purpose of this study is to develop an evaluation of dysphagia through deep learning-based video analysis in newborns and infants, and to report the correlation with future development.
Although the exact frequency of dysphagia in newborns is not known, according to a paper published by Motion et al. in 2001, the prevalence of eating problems in premature infants under 37 weeks of age was 10.5%, and in 2001, Mercado-Deane et al. reported that about 26% had dysphagia. In 1996, Reilly et al. reported th...
Inclusion Criteria: * Newborns and infants under 6 months of correctional age * Clinically suspected to have dysphagia * In case parental consent is obtained Exclusion Criteria: * In case of cardiopulmonary instability (ECMO, Ventilator, etc. are being applied) * When it is not possible to secure sufficient fields f...
Asan Medical Center
OTHER
{ "id": "S2021-1661-0001", "link": null, "type": null }
Unknown
{ "hasExpandedAccess": false, "nctId": null, "statusForNctId": null }
2022-01-21T00:00:00
{ "date": "2022-01-24", "type": "ACTUAL" }
{ "date": "2022-01-24", "type": "ACTUAL" }
[ "CHILD" ]
null
null
null
{ "allocation": "NA", "interventionModel": "SINGLE_GROUP", "interventionModelDescription": null, "maskingInfo": { "masking": "NONE", "maskingDescription": null, "whoMasked": null }, "observationalModel": null, "primaryPurpose": "DIAGNOSTIC", "timePerspective": null }
[ "Dysphagia of Newborn" ]
null
null
[ { "city": "Seoul", "country": "Korea, Republic of", "facility": "Asan medical Center", "geoPoint": { "lat": 37.566, "lon": 126.9784 }, "state": null } ]
null
null
{ "other": null, "primary": [ { "description": null, "measure": "Correlation between NOMAS evaluation and AI analysis of dysphagia", "timeFrame": "up to 2 years" }, { "description": null, "measure": "Correlation between VFSS evaluation and AI analysis of dysphagia", "...
null
null
{"versionHolder": "2025-06-18"}
{ "ancestors": [ { "id": "D004935", "term": "Esophageal Diseases" }, { "id": "D005767", "term": "Gastrointestinal Diseases" }, { "id": "D004066", "term": "Digestive System Diseases" }, { "id": "D010608", "term": "Pharyngeal Diseases" }, ...
null
{ "conditions": [ { "id": "D003680", "term": "Deglutition Disorders" } ], "interventions": null }
NCT00899366
null
DNA Analysis of Tissue From Patients With T-Cell Acute Lymphoblastic Leukemia
Molecular Mechanisms of NOTCH Induced Transformation in T-ALL
None
OBSERVATIONAL
COMPLETED
2009-05-09T00:00:00
null
2009-07-30T00:00:00
2009-07-30T00:00:00
null
49
18
120
ALL
false
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. PURPOSE: This laboratory study is looking at tissue samples from patients with T-cell acute lymphoblastic leukemia.
OBJECTIVES: * Identify the transcriptional signatures associated with the presence of NOTCH1 mutations in primary T-cell acute lymphoblastic leukemia (T-ALL) cells using oligonucleotide microarrays. * Characterize the global changes on gene expression resulting from the inactivation of NOTCH signaling in human T-ALL l...
DISEASE CHARACTERISTICS: * Confirmed diagnosis of T-cell acute lymphoblastic leukemia * Frozen lymphoblast samples available * NOTCH1-mutated or wild type sample available PATIENT CHARACTERISTICS: * Not specified PRIOR CONCURRENT THERAPY: * Not specified Exclusion Criteria: * Not applicable
Eastern Cooperative Oncology Group
NETWORK
{ "id": "CDR0000529758", "link": null, "type": null }
Unknown
{ "hasExpandedAccess": false, "nctId": null, "statusForNctId": null }
2009-05-09T00:00:00
{ "date": "2020-02-05", "type": "ACTUAL" }
{ "date": "2009-05-12", "type": "ESTIMATED" }
[ "ADULT", "OLDER_ADULT" ]
Samples submitted for research from patients participating in E2993
NON_PROBABILITY_SAMPLE
null
{ "allocation": null, "interventionModel": null, "interventionModelDescription": null, "maskingInfo": null, "observationalModel": "OTHER", "primaryPurpose": null, "timePerspective": "RETROSPECTIVE" }
[ "Leukemia" ]
["T-cell adult acute lymphoblastic leukemia", "T-cell childhood acute lymphoblastic leukemia", "untreated adult acute lymphoblastic leukemia", "untreated childhood acute lymphoblastic leukemia", "recurrent adult acute lymphoblastic leukemia", "recurrent childhood acute lymphoblastic leukemia", "adult acute lymphoblasti...
null
null
[ { "class": "NIH", "name": "National Cancer Institute (NCI)" } ]
null
{ "other": null, "primary": [ { "description": null, "measure": "Transcriptional signatures associated with NOTCH1 mutations in T-cell acute lymphoblastic leukemia (T-ALL) cells", "timeFrame": "1 month" }, { "description": null, "measure": "Global changes on gene expression...
[ { "affiliation": "Herbert Irving Comprehensive Cancer Center", "name": "Adolfo A. Ferrando, MD, PhD", "role": "STUDY_CHAIR" } ]
null
{"versionHolder": "2025-06-18"}
{ "ancestors": [ { "id": "D009370", "term": "Neoplasms by Histologic Type" }, { "id": "D009369", "term": "Neoplasms" }, { "id": "D006402", "term": "Hematologic Diseases" }, { "id": "D007945", "term": "Leukemia, Lymphoid" }, { "i...
null
{ "conditions": [ { "id": "D007938", "term": "Leukemia" }, { "id": "D054198", "term": "Precursor Cell Lymphoblastic Leukemia-Lymphoma" } ], "interventions": null }
NCT05748366
null
Ultrasound Guided Serratus Anterior Plane Block for Rib Fractures
Ultrasound Guided Serratus Anterior Plane Block Versus Standard Therapy for Analgesic Relief of Rib Fractures in the Emergency Department
None
INTERVENTIONAL
RECRUITING
2023-02-14T00:00:00
null
2025-03-31T00:00:00
2025-06-30T00:00:00
[ "NA" ]
60
18
null
ALL
false
This study is a single center, randomized controlled trial examining the effect of serratus anterior plane block (SAPB) on pain, PIC scores and other clinical outcomes in emergency department patients with multiple rib fractures in comparison to the use of analgesic medication alone. Objectives 1. Compare SAPB perfor...
Background Rib fractures are a common injury encountered in the emergency department (ED) affecting an estimated 10% of all trauma patients. They are associated with significant morbidity and mortality, especially in elderly patients. Rib fractures are the leading indication for intensive care unit (ICU) admission in p...
Inclusion Criteria: * Age \>18 years * \>1 Unilateral, acute rib fractures diagnosed on x-ray or CT imaging * Patient presenting to the WellSpan York Hospital ED * Patient requiring IV analgesia or oral opioid to control pain related to rib fractures Exclusion Criteria: * Age \<18 years * Inability to provide inform...
WellSpan Health
OTHER
{ "id": "HE-2023-30", "link": null, "type": null }
Unknown
{ "hasExpandedAccess": false, "nctId": null, "statusForNctId": null }
2023-02-25T00:00:00
{ "date": "2024-07-25", "type": "ACTUAL" }
{ "date": "2023-02-28", "type": "ACTUAL" }
[ "ADULT", "OLDER_ADULT" ]
null
null
false
{ "allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "interventionModelDescription": null, "maskingInfo": { "masking": "NONE", "maskingDescription": null, "whoMasked": null }, "observationalModel": null, "primaryPurpose": "TREATMENT", "timePerspective": null }
[ "Rib Fracture Multiple" ]
null
null
[ { "city": "York", "country": "United States", "facility": "Wellspan Health York Hospital", "geoPoint": { "lat": 39.9626, "lon": -76.72774 }, "state": "Pennsylvania" } ]
null
null
{ "other": [ { "description": null, "measure": "Safety Outcomes", "timeFrame": "30 days" } ], "primary": [ { "description": null, "measure": "Visual Analog Pain Score (VAS) at 2 hours", "timeFrame": "2 hours" } ], "secondary": [ { "description": nu...
[ { "affiliation": "WellSpan Health", "name": "Daniel Kreider, MD", "role": "PRINCIPAL_INVESTIGATOR" } ]
[{"pmid": "30860711", "type": "BACKGROUND", "citation": "Southgate SJ, River GF, Herbst MK. Ultrasound-Guided Serratus Anterior Blocks. 2024 Feb 12. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from http://www.ncbi.nlm.nih.gov/books/NBK538476/"}, {"pmid": "34766933", "typ...
{"versionHolder": "2025-06-18"}
{ "ancestors": [ { "id": "D014947", "term": "Wounds and Injuries" }, { "id": "D013898", "term": "Thoracic Injuries" }, { "id": "D009104", "term": "Multiple Trauma" } ], "browseBranches": [ { "abbrev": "BC26", "name": "Wounds and Injuries"...
{ "ancestors": [ { "id": "D018689", "term": "Sensory System Agents" }, { "id": "D018373", "term": "Peripheral Nervous System Agents" }, { "id": "D045505", "term": "Physiological Effects of Drugs" } ], "browseBranches": [ { "abbrev": "CNSDep", ...
{ "conditions": [ { "id": "D050723", "term": "Fractures, Bone" }, { "id": "D012253", "term": "Rib Fractures" }, { "id": "D000069076", "term": "Fractures, Multiple" } ], "interventions": [ { "id": "D000700", "term": "Analgesics" } ] ...
NCT01792466
null
RCT of the Double Wire Technique for Sphincterotomy
A Randomized Controlled Trial of the Double Wire Technique With or Without Transpancreatic Sphincterotomy for Difficult Common Bile Duct Cannulation
None
INTERVENTIONAL
TERMINATED
2013-02-11T00:00:00
null
null
null
[ "NA" ]
16
18
100
ALL
false
Endoscopic cholangiography is a procedure which is performed to image the bile duct and perform therapy like removal of bile duct stones. It is currently standard of care to remove stones from the bile duct when found as they frequently cause complications like infections which can sometime be life threatening. Therap...
This will be a prospective, non blinded randomized controlled trial. We will screen and offer enrollment to all patients presenting to Mayo Clinic Arizona for an ERCP who have a native papilla and an indication for cholangiography and sphincterotomy. Informed consent will be obtained in the preoperative area after obta...
Inclusion criteria 1. All patients presenting to Mayo Clinic Arizona for an ERCP who have a native papilla 2. Failure to deeply cannulate the CBD in over 5 minutes and with more than 5 attempts 3. Stable wire placement into the Pancreatic duct (PD) exclusion criteria 1. Any contraindication to undergoing an ERCP. 2. ...
Mayo Clinic
OTHER
{ "id": "12-007021", "link": null, "type": null }
Inadequate recruitment
{ "hasExpandedAccess": false, "nctId": null, "statusForNctId": null }
2013-02-13T00:00:00
{ "date": "2017-07-21", "type": "ACTUAL" }
{ "date": "2013-02-15", "type": "ESTIMATED" }
[ "ADULT", "OLDER_ADULT" ]
null
null
false
{ "allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "interventionModelDescription": null, "maskingInfo": { "masking": "NONE", "maskingDescription": null, "whoMasked": null }, "observationalModel": null, "primaryPurpose": "TREATMENT", "timePerspective": null }
[ "Cholangiopancreatography, Endoscopic Retrograde", "Sphincterotomy, Endoscopic", "VATER'S AMPULLA" ]
["difficult biliary cannulation"]
null
[ { "city": "Scottsdale", "country": "United States", "facility": "Mayo Clinic in Arizona", "geoPoint": { "lat": 33.50921, "lon": -111.89903 }, "state": "Arizona" } ]
null
null
{ "other": null, "primary": [ { "description": null, "measure": "Number of attempts needed to achieve deep cannulation with a second wire.", "timeFrame": "Day one" } ], "secondary": [ { "description": null, "measure": "Time from randomization to deep cannulation.", ...
[ { "affiliation": "Mayo Clinic", "name": "Douglas Faigel, MD", "role": "PRINCIPAL_INVESTIGATOR" } ]
null
{"versionHolder": "2025-06-18"}
null
null
null
NCT05617066
null
Stress, Scleroderma and Quality of Life
Psychological Stress and Systemic Sclerosis
None
INTERVENTIONAL
COMPLETED
2022-11-09T00:00:00
null
2023-03-31T00:00:00
2023-09-01T00:00:00
[ "NA" ]
150
18
null
ALL
false
150 patients of legal age will participate in this project, diagnosed with systemic sclerosis. Patients will be randomly assigned, as will be detailed later, to one of the following three groups: Therapy Group (GT): This group will be made up of 50 patients who will receive cognitive behavioral therapy of coping with...
150 elderly patients diagnosed with systemic sclerosis in any of its variants, both diffuse, limited or sine scleroderma. The inclusion criteria are: diagnosis made by a medical specialist, good command of the Spanish language (oral and written comprehension) and have an internet connection. As exclusion criteria they...
Inclusion Criteria: * Diagnosis made by a specialist doctor, good command of the Spanish language (oral and written comprehension) and have an internet connection. Exclusion Criteria: * No psychiatric illness.
Asociación Española de Esclerodermia
OTHER
{ "id": "AEE", "link": null, "type": null }
Unknown
{ "hasExpandedAccess": false, "nctId": null, "statusForNctId": null }
2022-11-09T00:00:00
{ "date": "2024-02-01", "type": "ACTUAL" }
{ "date": "2022-11-15", "type": "ACTUAL" }
[ "ADULT", "OLDER_ADULT" ]
null
null
false
{ "allocation": "RANDOMIZED", "interventionModel": "SINGLE_GROUP", "interventionModelDescription": null, "maskingInfo": { "masking": "SINGLE", "maskingDescription": null, "whoMasked": [ "INVESTIGATOR" ] }, "observationalModel": null, "primaryPurpose": "OTHER", "timePerspective": nu...
[ "Scleroderma" ]
["scleroderma, stress, cognitive behavioral therapy"]
null
[ { "city": "Granada", "country": "Spain", "facility": "Universidad de Granada", "geoPoint": { "lat": 37.18817, "lon": -3.60667 }, "state": null } ]
null
null
{ "other": null, "primary": [ { "description": null, "measure": "Cortisol y psychological stress levels", "timeFrame": "3 months" } ], "secondary": [ { "description": null, "measure": "Quality of life and psychological status", "timeFrame": "3 months" } ] }
null
null
{"versionHolder": "2025-06-18"}
{ "ancestors": [ { "id": "D003240", "term": "Connective Tissue Diseases" }, { "id": "D012871", "term": "Skin Diseases" } ], "browseBranches": [ { "abbrev": "BC23", "name": "Symptoms and General Pathology" }, { "abbrev": "All", "name": "Al...
null
{ "conditions": [ { "id": "D012595", "term": "Scleroderma, Systemic" }, { "id": "D045743", "term": "Scleroderma, Diffuse" } ], "interventions": null }
NCT02415166
null
Influenza Challenge in Mood Disorders
Influenza Challenge in Mood Disorders
None
INTERVENTIONAL
TERMINATED
2015-04-08T00:00:00
null
null
null
[ "NA" ]
6
18
55
FEMALE
true
The aim of this project is to evaluate the efficacy of the influenza vaccine in individuals with major depressive disorder (MDD) as well as to elucidate the nature of the immunological abnormalities in MDD using a quasi-experimental design. Specifically, the investigators plan to induce transient, mild inflammation in ...
Psychological stress has been shown to impair the efficacy of the influenza vaccine, particularly in older individuals (\> 60 years). However, the effect of depression (as opposed to stress per se) on vaccine response has not been measured, especially in younger people. One possible cause of this putative impaired vacc...
Inclusion Criteria: Major Depressive Disorder Patient Group - Currently Depressed: Subjects will have met Diagnostic and Statistical Manual of the American Psychiatric Association (DSM-V) criteria for primary MDD in a current major depressive episode and current Hamilton Depression Rating Scale (HAM-D) or Montgomery A...
Laureate Institute for Brain Research, Inc.
OTHER
{ "id": "LIBR # 2015-001-00", "link": null, "type": null }
Unknown
{ "hasExpandedAccess": false, "nctId": null, "statusForNctId": null }
2015-04-13T00:00:00
{ "date": "2018-01-23", "type": "ACTUAL" }
{ "date": "2015-04-14", "type": "ESTIMATED" }
[ "ADULT" ]
null
null
false
{ "allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "interventionModelDescription": null, "maskingInfo": { "masking": "DOUBLE", "maskingDescription": null, "whoMasked": [ "PARTICIPANT", "INVESTIGATOR" ] }, "observationalModel": null, "primaryPurpose": "BASIC_SCIENCE"...
[ "MAJOR DEPRESSIVE DISORDER" ]
null
null
[ { "city": "Tulsa", "country": "United States", "facility": "Laureate Institute for Brian Research", "geoPoint": { "lat": 36.15398, "lon": -95.99277 }, "state": "Oklahoma" } ]
null
null
{ "other": [ { "description": null, "measure": "IL-6 AND TNF PRODUCTION BY STIMULATED AND UNSTIMULATED MONOCYTE CELLS", "timeFrame": "2 DAYS" }, { "description": null, "measure": "DIFFERENCES IN RESTING STATE CEREBRAL BLOOD FLOW BETWEEN MDD AND HC GROUPS", "timeFrame": ...
[ { "affiliation": "Laureate Institute for Brain Research", "name": "Jonathan B Savitz, PhD", "role": "PRINCIPAL_INVESTIGATOR" } ]
[{"pmid": "17360153", "type": "BACKGROUND", "citation": "Irwin MR, Miller AH. Depressive disorders and immunity: 20 years of progress and discovery. Brain Behav Immun. 2007 May;21(4):374-83. doi: 10.1016/j.bbi.2007.01.010. Epub 2007 Mar 13."}, {"pmid": "20955778", "type": "BACKGROUND", "citation": "Blume J, Douglas SD,...
{"versionHolder": "2025-06-18"}
{ "ancestors": [ { "id": "D001523", "term": "Mental Disorders" } ], "browseBranches": [ { "abbrev": "BXM", "name": "Behaviors and Mental Disorders" }, { "abbrev": "All", "name": "All Conditions" }, { "abbrev": "BC01", "name": "Infections"...
{ "ancestors": null, "browseBranches": [ { "abbrev": "All", "name": "All Drugs and Chemicals" } ], "browseLeaves": [ { "asFound": null, "id": "M17360", "name": "Vaccines", "relevance": "LOW" } ], "meshes": null }
{ "conditions": [ { "id": "D003866", "term": "Depressive Disorder" }, { "id": "D003865", "term": "Depressive Disorder, Major" }, { "id": "D019964", "term": "Mood Disorders" } ], "interventions": [] }
NCT03340766
null
Study Investigating the Safety and Efficacy of Blinatumomab in Combination With Pembrolizumab in Adults With Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)
A Phase 1b Open Label Study Investigating the Safety and Efficacy of Blinatumomab in Combination With Pembrolizumab in Adult Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
HARBOUR
INTERVENTIONAL
COMPLETED
2017-10-23T00:00:00
null
2020-11-06T00:00:00
2023-08-14T00:00:00
[ "PHASE1" ]
31
18
100
ALL
false
The primary objective of the study is to determine the maximum tolerated dose (MTD) of blinatumomab in combination with pembrolizumab in adults with relapsed or refractory (r/r) DLBCL.
The study was planned as 2 parts: * Part 1 will test the safety of up to 3 different blinatumomab target dose levels in combination with pembrolizumab in a rolling 6 design. A Dose Level Review Team (DLRT) will review the safety data to evaluate possible drug effects and dose-limiting toxicities (DLTs). * Part 2 will ...
Inclusion Criteria: * Have histologically confirmed diffuse large B-cell lymphoma that is either: * Refractory after at least one regimen of systemic chemotherapy and/or targeted therapy, or * In first or later relapse if have received at least 2 systemic regimens since time of diagnosis, or * Relapsed post-autologous...
Amgen
INDUSTRY
{ "id": "20150290", "link": null, "type": null }
Unknown
{ "hasExpandedAccess": true, "nctId": "NCT02187354", "statusForNctId": "NO_LONGER_AVAILABLE" }
2017-11-08T00:00:00
{ "date": "2024-10-17", "type": "ACTUAL" }
{ "date": "2017-11-14", "type": "ACTUAL" }
[ "ADULT", "OLDER_ADULT" ]
null
null
false
{ "allocation": "NON_RANDOMIZED", "interventionModel": "SEQUENTIAL", "interventionModelDescription": null, "maskingInfo": { "masking": "NONE", "maskingDescription": null, "whoMasked": null }, "observationalModel": null, "primaryPurpose": "TREATMENT", "timePerspective": null }
[ "Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)" ]
["DLBCL Relapsed post-autologous or allogeneic hematopoietic stem cell transplantation (HSCT)", "Antibodies", "Bispecific in combination with PD-1/PD-L1 inhibitor"]
null
[ { "city": "La Jolla", "country": "United States", "facility": "Research Site", "geoPoint": { "lat": 32.84727, "lon": -117.2742 }, "state": "California" }, { "city": "Charleston", "country": "United States", "facility": "Research Site", "geoPoint": { "lat...
[ { "class": "INDUSTRY", "name": "Merck Sharp & Dohme LLC" } ]
null
{ "other": null, "primary": [ { "description": null, "measure": "Number of Participants With Dose Limiting Toxicities (DLTs)", "timeFrame": "The DLT evaluation period was 42 days from initiation of pembrolizumab treatment (Day 15 for Cohort Ia and Day 19 for Cohorts IIa and IIIa)" } ], ...
[ { "affiliation": "Amgen", "name": "MD", "role": "STUDY_DIRECTOR" } ]
null
{"versionHolder": "2025-06-18"}
{ "ancestors": [ { "id": "D009370", "term": "Neoplasms by Histologic Type" }, { "id": "D009369", "term": "Neoplasms" }, { "id": "D008232", "term": "Lymphoproliferative Disorders" }, { "id": "D008206", "term": "Lymphatic Diseases" }, {...
{ "ancestors": [ { "id": "D000074322", "term": "Antineoplastic Agents, Immunological" }, { "id": "D000970", "term": "Antineoplastic Agents" }, { "id": "D000082082", "term": "Immune Checkpoint Inhibitors" }, { "id": "D045504", "term": "Molecul...
{ "conditions": [ { "id": "D008223", "term": "Lymphoma" }, { "id": "D016393", "term": "Lymphoma, B-Cell" }, { "id": "D016403", "term": "Lymphoma, Large B-Cell, Diffuse" } ], "interventions": [ { "id": "C582435", "term": "Pembrolizumab" ...
NCT01232166
null
Which is the Best Bedside Test to Detect Endobronchial Intubation?
Endotracheal Tube Insertion Depth Better Detects Endobronchial Intubation Than Bilateral Auscultation or Observation of Chest Movements - a Prospective Randomised Trial
None
INTERVENTIONAL
COMPLETED
2010-10-29T00:00:00
null
null
null
[ "NA" ]
160
19
75
ALL
false
Background: Endotracheal intubation has become a well established standard in protecting the airway during surgical procedures, and in emergency situations. Serious complications can occur from the incorrect placement of an endotracheal tube in a mainstem bronchus. If unrecognized it can lead to hypoxemia secondary to ...
null
Inclusion Criteria: ASA I or II patients, aged 19-75 years, scheduled for elective gynaecological or urological surgery that needs endotracheal intubation. Exclusion Criteria: * Pre-existing lung disease, pleural effusion, anticipated difficult airway, known endobronchial or tracheal lesions, or patients at risk for...
Medical University of Vienna
OTHER
{ "id": "MUW464/2003", "link": null, "type": null }
Unknown
{ "hasExpandedAccess": false, "nctId": null, "statusForNctId": null }
2010-11-01T00:00:00
{ "date": "2010-11-02", "type": "ESTIMATED" }
{ "date": "2010-11-02", "type": "ESTIMATED" }
[ "ADULT", "OLDER_ADULT" ]
null
null
null
{ "allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "interventionModelDescription": null, "maskingInfo": { "masking": "SINGLE", "maskingDescription": null, "whoMasked": [ "INVESTIGATOR" ] }, "observationalModel": null, "primaryPurpose": "DIAGNOSTIC", "timePerspective": n...
[ "Endobronchial Intubation" ]
null
null
null
null
null
{ "other": null, "primary": [ { "description": null, "measure": "Sensitivity/Specificity to detect endobronchial intubation", "timeFrame": "1-5 minutes after intubation" } ], "secondary": null }
null
[{"pmid": "21062875", "type": "DERIVED", "citation": "Sitzwohl C, Langheinrich A, Schober A, Krafft P, Sessler DI, Herkner H, Gonano C, Weinstabl C, Kettner SC. Endobronchial intubation detected by insertion depth of endotracheal tube, bilateral auscultation, or observation of chest movements: randomised trial. BMJ. 20...
{"versionHolder": "2025-06-18"}
null
null
null
NCT05875766
null
Evaluation of Osteopathic Care After Rupture of the Antero-external Cruciate Ligament of the Knee (DIDT OSTEO)
Evaluation of Osteopathic Care After Rupture of the Antero-external Cruciate Ligament of the Knee
DIDT OSTEO
INTERVENTIONAL
UNKNOWN
2023-05-16T00:00:00
null
2024-04-07T00:00:00
2024-12-07T00:00:00
[ "NA" ]
94
18
35
ALL
false
The antero-external cruciate ligament (ACL) is the ligament located inside the knee, which allows the rotation of the knee by stabilizing the femur and the tibia. Rupture of the ACL is common during the practice of certain so-called "pivot" sports, whether contact or not. It is manifested by acute pain or instability o...
null
Inclusion Criteria: * Patient, male or female, aged 18 to 35 inclusive * Patient with a BMI between 18.5 and 30 kg/m² (limits included). * Patient presenting with a total rupture of the unilateral anterior cruciate ligament (ACL). * Candidate patient for reconstruction of the ACL with the DIDT method. * Affiliated pat...
Ramsay Générale de Santé
OTHER
{ "id": "2022-A00450-43", "link": null, "type": null }
Unknown
{ "hasExpandedAccess": false, "nctId": null, "statusForNctId": null }
2023-05-16T00:00:00
{ "date": "2023-05-25", "type": "ACTUAL" }
{ "date": "2023-05-25", "type": "ACTUAL" }
[ "ADULT" ]
null
null
null
{ "allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "interventionModelDescription": null, "maskingInfo": { "masking": "NONE", "maskingDescription": null, "whoMasked": null }, "observationalModel": null, "primaryPurpose": "SUPPORTIVE_CARE", "timePerspective": null }
[ "Cruciate Ligament Rupture", "Knee Ligament Injury", "Osteopathia" ]
null
null
[ { "city": "Lyon", "country": "France", "facility": "Hopital privé Jean Mermoz", "geoPoint": { "lat": 45.74848, "lon": 4.84669 }, "state": null } ]
null
null
{ "other": null, "primary": [ { "description": null, "measure": "assess the functionality of the knee", "timeFrame": "6 months" } ], "secondary": null }
null
null
{"versionHolder": "2025-06-18"}
{ "ancestors": [ { "id": "D014947", "term": "Wounds and Injuries" } ], "browseBranches": [ { "abbrev": "BC26", "name": "Wounds and Injuries" }, { "abbrev": "All", "name": "All Conditions" }, { "abbrev": "BC05", "name": "Musculoskeletal Di...
null
{ "conditions": [ { "id": "D012421", "term": "Rupture" } ], "interventions": null }
NCT00556166
null
Enterra Therapy Gastric Stimulation System
Enterra Therapy Gastric Stimulation System
Enterra
INTERVENTIONAL
TERMINATED
2007-11-08T00:00:00
null
null
null
[ "PHASE4" ]
4
18
99
ALL
false
Enterra Therapy Gastric Simulation System (Enterra Therapy) is indicated for the treatment of patients with long term, uncontrolled (not helped by medication) nausea and vomiting from gastroparesis of diabetic or idiopathic origin. In March 2000, the Food and Drug Administration (FDA) gave approval of a humanitarian D...
Gastroparesis is a debilitating disease in which patients suffer from a number of upper gastrointestinal (GI) symptoms including nausea, vomiting, early satiety, bloating, postprandial fullness, epigastric pain and burning, and cardiac pain and burning. Severe symptoms, particularly vomiting and nausea, can significant...
Inclusion Criteria: * Chronic(long term, lasting greater than 3 months) * Intractable (drug refractory, failed medical management with prokinetic and antiemetic drugs * Failed dietary modifications, and/or requiring enteral feeding) nausea and vomiting secondary to gastroparesis of diabetic or idiopathic etiology Exc...
Columbia University
OTHER
{ "id": "AAAA5072", "link": null, "type": null }
Principal investigator left institution.
{ "hasExpandedAccess": false, "nctId": null, "statusForNctId": null }
2007-11-08T00:00:00
{ "date": "2016-08-02", "type": "ESTIMATED" }
{ "date": "2007-11-09", "type": "ESTIMATED" }
[ "ADULT", "OLDER_ADULT" ]
null
null
false
{ "allocation": "NA", "interventionModel": "SINGLE_GROUP", "interventionModelDescription": null, "maskingInfo": { "masking": "NONE", "maskingDescription": null, "whoMasked": null }, "observationalModel": null, "primaryPurpose": "TREATMENT", "timePerspective": null }
[ "Gastroparesis" ]
["Enterra therapy", "Gastric Simulation System"]
null
[ { "city": "New York", "country": "United States", "facility": "Columbia University College of Physicians and Surgeons", "geoPoint": { "lat": 40.71427, "lon": -74.00597 }, "state": "New York" } ]
null
null
{ "other": null, "primary": [ { "description": null, "measure": "Number of Episodes of Nausea and Vomiting", "timeFrame": "1 year" } ], "secondary": [ { "description": null, "measure": "Number of Episodes of Abdominal Pain, Bloating, and Early Satiety", "timeFrame...
[ { "affiliation": "Columbia University", "name": "Dennis L. Fowler, M.D.", "role": "PRINCIPAL_INVESTIGATOR" } ]
null
{"versionHolder": "2025-06-18"}
{ "ancestors": [ { "id": "D013272", "term": "Stomach Diseases" }, { "id": "D005767", "term": "Gastrointestinal Diseases" }, { "id": "D004066", "term": "Digestive System Diseases" }, { "id": "D010243", "term": "Paralysis" }, { "i...
null
{ "conditions": [ { "id": "D018589", "term": "Gastroparesis" } ], "interventions": null }
NCT01472666
null
Dairy Lipids, Proteins, and the Metabolic Syndrome - "DairyHealth"
Dairy Lipids, Proteins, and the Metabolic Syndrome - "DairyHealth"
None
INTERVENTIONAL
COMPLETED
2011-11-01T00:00:00
null
null
null
[ "NA" ]
63
18
null
ALL
false
Dairy food contains a large amount of long-chain saturated fat, which traditionally has been linked to increased risk of cardiovascular disease (CVD). However, recent data indicates a more neutral role. Milk fat contains large amounts of medium-chain saturated fatty acids (MC-SFA), which may have beneficial effects on ...
See above.
Inclusion Criteria: Metabolic syndrome * Central obesity (Waist: female ≥ 80 cm; male ≥ 94 cm) * with two or more of the following * Fasting triglyceride \> 1.7 mmol/l * HDL-cholesterol; male \< 1.03 mmol/l, female \< 1.29 mmol/l * BP ≥ 130/85 * Fasting plasma glucose ≥ 5,6 mmol/l (but not diabetes) Or abdominal obe...
University of Aarhus
OTHER
{ "id": "CERN-DairyHealth", "link": null, "type": null }
Unknown
{ "hasExpandedAccess": false, "nctId": null, "statusForNctId": null }
2011-11-15T00:00:00
{ "date": "2016-03-01", "type": "ESTIMATED" }
{ "date": "2011-11-16", "type": "ESTIMATED" }
[ "ADULT", "OLDER_ADULT" ]
null
null
false
{ "allocation": "RANDOMIZED", "interventionModel": "FACTORIAL", "interventionModelDescription": null, "maskingInfo": { "masking": "QUADRUPLE", "maskingDescription": null, "whoMasked": [ "PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR" ] }, "observat...
[ "Metabolic Syndrome", "Type 2 Diabetes", "Cardiovascular Disease", "Abdominal Obesity" ]
["Medium chain fatty acids", "Saturated fatty acids", "Whey protein", "Casein protein", "Metabolic syndrome", "Type 2 diabetes", "Cardiovascular disease", "Dairy products", "Dietary intervention"]
null
[ { "city": "Aarhus", "country": "Denmark", "facility": "Aarhus University Hospital", "geoPoint": { "lat": 56.15674, "lon": 10.21076 }, "state": "Aarhus C" } ]
[ { "class": "OTHER", "name": "Aarhus University Hospital" }, { "class": "INDUSTRY", "name": "Arla Foods" }, { "class": "OTHER", "name": "Wageningen University" }, { "class": "OTHER", "name": "University of Dublin, Trinity College" } ]
null
{ "other": null, "primary": [ { "description": null, "measure": "Postprandial triglyceride response", "timeFrame": "Change from week 0 to week 12" } ], "secondary": [ { "description": null, "measure": "24 hour blood pressure (BP)", "timeFrame": "Change from week 0...
[ { "affiliation": "Aarhus University Hospital", "name": "Kjeld Hermansen, Professor", "role": "PRINCIPAL_INVESTIGATOR" }, { "affiliation": "Department of Food Science, University of Aarhus", "name": "Hanne C Bertram, Scientist", "role": "STUDY_CHAIR" }, { "affiliation": "School of...
[{"pmid": "25833983", "type": "DERIVED", "citation": "Bohl M, Bjornshave A, Rasmussen KV, Schioldan AG, Amer B, Larsen MK, Dalsgaard TK, Holst JJ, Herrmann A, O'Neill S, O'Driscoll L, Afman L, Jensen E, Christensen MM, Gregersen S, Hermansen K. Dairy proteins, dairy lipids, and postprandial lipemia in persons with abdo...
{"versionHolder": "2025-06-18"}
{ "ancestors": [ { "id": "D004194", "term": "Disease" }, { "id": "D010335", "term": "Pathologic Processes" }, { "id": "D003920", "term": "Diabetes Mellitus" }, { "id": "D044882", "term": "Glucose Metabolism Disorders" }, { "id":...
{ "ancestors": [ { "id": "D002614", "term": "Chelating Agents" }, { "id": "D064449", "term": "Sequestering Agents" }, { "id": "D045504", "term": "Molecular Mechanisms of Pharmacological Action" } ], "browseBranches": [ { "abbrev": "All", ...
{ "conditions": [ { "id": "D002318", "term": "Cardiovascular Diseases" }, { "id": "D003924", "term": "Diabetes Mellitus, Type 2" }, { "id": "D024821", "term": "Metabolic Syndrome" }, { "id": "D056128", "term": "Obesity, Abdominal" }, ...
NCT02315066
null
Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566
A PHASE 1, OPEN-LABEL, DOSE ESCALATION STUDY OF PF-04518600 AS A SINGLE AGENT AND IN COMBINATION WITH PF-05082566 IN PATIENTS WITH SELECTED LOCALLY ADVANCED OR METASTATIC CANCERS
None
INTERVENTIONAL
COMPLETED
2014-12-04T00:00:00
null
2020-11-12T00:00:00
2020-11-12T00:00:00
[ "PHASE1" ]
174
18
null
ALL
false
To assess the safety and tolerability at increasing dose levels of PF-04518600 alone or in combination wtih PF-05082566 in patients with select advanced or metastatic carcinoma in order to determine the maximum tolerated dose and select the recommended Phase 2 dose.
null
Inclusion Criteria: * Part A1 only: Patients with histological or cytological diagnosis of HNSCC, HCC, melanoma, or clear cell RCC who progressed on or are intolerant to standard therapy, for which no standard therapy is available or who decline standard therapy. * Part A2 only: Patients with histological or cytologic...
Pfizer
INDUSTRY
{ "id": "B0601002", "link": null, "type": null }
Unknown
{ "hasExpandedAccess": false, "nctId": null, "statusForNctId": null }
2014-12-09T00:00:00
{ "date": "2022-04-21", "type": "ACTUAL" }
{ "date": "2014-12-11", "type": "ESTIMATED" }
[ "ADULT", "OLDER_ADULT" ]
null
null
false
{ "allocation": "NON_RANDOMIZED", "interventionModel": "SINGLE_GROUP", "interventionModelDescription": null, "maskingInfo": { "masking": "NONE", "maskingDescription": "Open-label", "whoMasked": null }, "observationalModel": null, "primaryPurpose": "TREATMENT", "timePerspective": null }
[ "Neoplasms" ]
["Immunotherapy", "PF-04518600", "PF-05082566", "solid tumors", "tumors", "neoplasm metastasis", "Phase 1", "hepatocellular carcinoma", "HCC", "liver cancer", "ocular melanoma", "melanoma", "clear cell renal cell carcinoma", "RCC", "kidney cancer", "head and neck squamous cell carcinoma", "HNSCC", "head and neck cancer...
null
[ { "city": "Los Angeles", "country": "United States", "facility": "The Angeles Clinic And Research Institute, A Cedars-Sinai Affiliate", "geoPoint": { "lat": 34.05223, "lon": -118.24368 }, "state": "California" }, { "city": "Los Angeles", "country": "United States", ...
null
null
{ "other": null, "primary": [ { "description": null, "measure": "Number of Participants With Dose Limiting Toxicities (DLTs) in Part A1", "timeFrame": "The first 2 cycles of treatment (Day 1 up to Day 28)" }, { "description": null, "measure": "Number of Participants With Al...
[ { "affiliation": "Pfizer", "name": "Pfizer CT.gov Call Center", "role": "STUDY_DIRECTOR" } ]
[{"pmid": "36302562", "type": "DERIVED", "citation": "Hamid O, Chiappori AA, Thompson JA, Doi T, Hu-Lieskovan S, Eskens FALM, Ros W, Diab A, Spano JP, Rizvi NA, Wasser JS, Angevin E, Ott PA, Forgie A, Yang W, Guo C, Chou J, El-Khoueiry AB. First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic an...
{"versionHolder": "2025-06-18"}
{ "ancestors": null, "browseBranches": [ { "abbrev": "BC04", "name": "Neoplasms" }, { "abbrev": "BC23", "name": "Symptoms and General Pathology" }, { "abbrev": "All", "name": "All Conditions" }, { "abbrev": "BC06", "name": "Digestive System...
{ "ancestors": [ { "id": "D007155", "term": "Immunologic Factors" }, { "id": "D045505", "term": "Physiological Effects of Drugs" } ], "browseBranches": [ { "abbrev": "All", "name": "All Drugs and Chemicals" }, { "abbrev": "Hemat", "name":...
{ "conditions": [ { "id": "D009369", "term": "Neoplasms" } ], "interventions": [ { "id": "D000911", "term": "Antibodies, Monoclonal" }, { "id": "D007074", "term": "Immunoglobulin G" } ] }
NCT01459666
null
Forehead Scars Following Mohs Micrographic Surgery and Reconstruction for Skin Cancer
A Prospective, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy of AbobotulinumtoxinA (BTX-A) in Improving Forehead Wounds After Mohs Micrographic Surgery and Reconstruction for Skin Cancer
None
INTERVENTIONAL
TERMINATED
2011-10-18T00:00:00
null
null
null
[ "PHASE4" ]
9
18
null
ALL
false
This study will test if the use of DysportTM (abobotulinumtoxinA) improves wound healing and scarring after Mohs surgery. Research in the laboratory as well as previous studies in humans have shown improved wound healing and scarring with the use of a similar medication called Botox. Dysport may improve wound healing ...
Primary Objective: -To evaluate the efficacy of using aboBTX-A to improve wound healing prior to Mohs micrographic surgery and reconstruction for skin cancer as measured by the Visual Analogue Scale (VAS) at 6 weeks post surgery. Secondary Objectives: * To evaluate efficacy of using aboBTX-A to improve wound healing...
Inclusion Criteria: Patients must meet all of the following inclusion criteria to be eligible for enrollment: * Ability to understand the risks, benefits, and alternative to participation and give informed consent * Have biopsy proven skin cancer on the medial forehead that is amenable to Mohs surgery. Medial forehea...
University Hospitals Cleveland Medical Center
OTHER
{ "id": "CASE1Z12", "link": null, "type": null }
Investigator left institution for private practice
{ "hasExpandedAccess": false, "nctId": null, "statusForNctId": null }
2011-10-25T00:00:00
{ "date": "2022-05-26", "type": "ACTUAL" }
{ "date": "2011-10-26", "type": "ESTIMATED" }
[ "ADULT", "OLDER_ADULT" ]
null
null
true
{ "allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "interventionModelDescription": null, "maskingInfo": { "masking": "DOUBLE", "maskingDescription": null, "whoMasked": [ "PARTICIPANT", "INVESTIGATOR" ] }, "observationalModel": null, "primaryPurpose": "TREATMENT", ...
[ "Scar" ]
["Scar", "Forehead", "Skin Cancer", "MOHS Surgery", "Dermatology"]
null
[ { "city": "Cleveland", "country": "United States", "facility": "University Hospitals Cleveland Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center", "geoPoint": { "lat": 41.4995, "lon": -81.69541 }, "state": "Ohio" }, { "city": "We...
null
null
{ "other": null, "primary": [ { "description": null, "measure": "Visual Analogue Scale (VAS)", "timeFrame": "6 weeks post surgery" } ], "secondary": [ { "description": null, "measure": "Patient and Observer Assessment Scale (POSAS)", "timeFrame": "at week 1, 6, an...
[ { "affiliation": "University Hospitals Cleveland Medical Center", "name": "Margaret Mann, MD", "role": "PRINCIPAL_INVESTIGATOR" } ]
null
{"versionHolder": "2025-06-18"}
{ "ancestors": [ { "id": "D009371", "term": "Neoplasms by Site" }, { "id": "D009369", "term": "Neoplasms" }, { "id": "D012871", "term": "Skin Diseases" } ], "browseBranches": [ { "abbrev": "BC26", "name": "Wounds and Injuries" }, ...
{ "ancestors": [ { "id": "D065087", "term": "Acetylcholine Release Inhibitors" }, { "id": "D049990", "term": "Membrane Transport Modulators" }, { "id": "D045504", "term": "Molecular Mechanisms of Pharmacological Action" }, { "id": "D018678", ...
{ "conditions": [ { "id": "D012878", "term": "Skin Neoplasms" } ], "interventions": [ { "id": "D006388", "term": "Hemagglutinins" }, { "id": "C542869", "term": "abobotulinumtoxinA" }, { "id": "D019274", "term": "Botulinum Toxins, Type A" ...
NCT03140566
null
Ultrasound Evaluation of the IVC in Addition to Clinical Assessment to Guide Decongestion in ADHF
Ultrasound Evaluation of the Inferior Vena Cava in Addition to Clinical Assessment to Guide Decongestion in Acute Decompensated Heart Failure: a Pilot Study
CAVA-ADHF
INTERVENTIONAL
COMPLETED
2017-04-25T00:00:00
null
2019-09-24T00:00:00
2019-09-24T00:00:00
[ "NA" ]
388
18
null
ALL
false
CAVA-ADHF is designed as a prospective, randomized, controlled, patient-blinded, multicenter, parallel-group trial. The objective is to test whether evaluation of the inferior vena cava diameter in addition to clinical assessment is superior compared to clinical assessment alone with respect to the surrogate endpoint o...
Only limited evidence is available on the best method to monitor and guide decongestion in acute decompensated heart failure. Therefore, no specific guideline recommendations are made in this regard. It is unknown whether an objective congestion marker can be used to guide decongestion or such marker is only of prognos...
Inclusion Criteria: * Hospitalization for ADHF with dyspnea ≥NYHA III, peripheral edema, and pulmonary congestion (rales on auscultation or pulmonary vascular congestion on chest radiograph) * Age ≥18 years * NT-proBNP \>300 ng/l within 24 h after admission * Sufficient ultrasound visualization to evaluate IVC * IVCma...
University of Luebeck
OTHER
{ "id": "CAVA-ADHF-DZHK10", "link": null, "type": null }
Unknown
{ "hasExpandedAccess": false, "nctId": null, "statusForNctId": null }
2017-05-02T00:00:00
{ "date": "2019-09-25", "type": "ACTUAL" }
{ "date": "2017-05-04", "type": "ACTUAL" }
[ "ADULT", "OLDER_ADULT" ]
null
null
true
{ "allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "interventionModelDescription": null, "maskingInfo": { "masking": "DOUBLE", "maskingDescription": null, "whoMasked": [ "PARTICIPANT", "CARE_PROVIDER" ] }, "observationalModel": null, "primaryPurpose": "TREATMENT", ...
[ "Heart Failure" ]
["heart failure", "acute decompensated heart failure", "congestion", "inferior vena cava"]
null
[ { "city": "Lübeck", "country": "Germany", "facility": "Universitäres Herzzentrum Lübeck", "geoPoint": { "lat": 53.86893, "lon": 10.68729 }, "state": null } ]
[ { "class": "OTHER", "name": "Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK)" } ]
null
{ "other": null, "primary": [ { "description": null, "measure": "Change in NT-proBNP from baseline to discharge", "timeFrame": "Measured at baseline (within 24 hours of admission to index hospitalization) and on the day of discharge from index hospitalization (discharge planning is at the disc...
null
null
{"versionHolder": "2025-06-18"}
{ "ancestors": [ { "id": "D006331", "term": "Heart Diseases" }, { "id": "D002318", "term": "Cardiovascular Diseases" } ], "browseBranches": [ { "abbrev": "BC14", "name": "Heart and Blood Diseases" }, { "abbrev": "All", "name": "All Condit...
{ "ancestors": null, "browseBranches": [ { "abbrev": "HB", "name": "Herbal and Botanical" }, { "abbrev": "All", "name": "All Drugs and Chemicals" } ], "browseLeaves": [ { "asFound": "Cystectomy", "id": "T204", "name": "Kava", "relevance": "HIGH...
{ "conditions": [ { "id": "D006333", "term": "Heart Failure" } ], "interventions": [] }
NCT05545566
null
Evaluation of Thoracic Ultrasound in Monitoring Pleural Drainage in Postoperative Thoracic Surgery
Evaluation of Thoracic Ultrasound in Monitoring Pleural Drainage in Postoperative Thoracic Surgery
EchTHor
INTERVENTIONAL
COMPLETED
2022-09-10T00:00:00
null
2023-02-28T00:00:00
2023-02-28T00:00:00
[ "NA" ]
60
18
null
ALL
false
The investigator would like to conduct a study in patients undergoing thoracic surgery to evaluate the effectiveness of thoracic ultrasound in the decision to discharge the patient after pleural drain removal.
Thoracic drainage is a common and almost systematic practice after thoracic surgery requiring daily management and monitoring until and after its removal. It allows, after opening the pleura, the evacuation of liquid and/or air retained in the pleural cavity. The overall monitoring of the patient after thoracic surge...
Inclusion Criteria: Patients undergoing thoracic surgery (lung resection, pleural symphysis, biopsy or resection of a mediastinal tumor or ganglion, pleural decortication/decalcification) admitted immediately after surgery in the thoracic surgery department (standard care or continuous care) of the University Hospital...
University Hospital, Limoges
OTHER
{ "id": "87RI22_0022 (EchTHor)", "link": null, "type": null }
Unknown
{ "hasExpandedAccess": false, "nctId": null, "statusForNctId": null }
2022-09-14T00:00:00
{ "date": "2023-03-16", "type": "ACTUAL" }
{ "date": "2022-09-19", "type": "ACTUAL" }
[ "ADULT", "OLDER_ADULT" ]
null
null
false
{ "allocation": "NA", "interventionModel": "SINGLE_GROUP", "interventionModelDescription": null, "maskingInfo": { "masking": "NONE", "maskingDescription": null, "whoMasked": null }, "observationalModel": null, "primaryPurpose": "DIAGNOSTIC", "timePerspective": null }
[ "Thoracic Ultrasound", "Pleural Drain Removal" ]
["postoperative thoracic surgery", "discharge decision", "thoracic ultrasound", "pleural drain removal", "chest X-ray", "thoracic surgery monitoring"]
null
[ { "city": "Limoges", "country": "France", "facility": "Limoges Univesity Hospital", "geoPoint": { "lat": 45.83153, "lon": 1.25781 }, "state": null } ]
null
null
{ "other": null, "primary": [ { "description": null, "measure": "Theoretical patient discharge", "timeFrame": "At the study completion, an average of 10 days" } ], "secondary": [ { "description": null, "measure": "Pain du to examination", "timeFrame": "Day 0, Day ...
null
null
{"versionHolder": "2025-06-18"}
{ "ancestors": [ { "id": "D000094665", "term": "Dissection, Blood Vessel" }, { "id": "D000783", "term": "Aneurysm" }, { "id": "D014652", "term": "Vascular Diseases" }, { "id": "D002318", "term": "Cardiovascular Diseases" }, { "i...
null
{ "conditions": [ { "id": "D000784", "term": "Aortic Dissection" } ], "interventions": null }
NCT03232866
null
Effects of Load Monitoring on Pilates Training
Effects of Load Monitoring on Pilates Training: a Randomized Clinical Trial
None
INTERVENTIONAL
COMPLETED
2017-07-25T00:00:00
null
2019-05-01T00:00:00
2019-12-01T00:00:00
[ "NA" ]
47
18
36
MALE
true
There has been an increasing awareness about the need to practice some physical activity, including several objectives, mainly as a preventive character. From this perspective, notice the use of the Pilates method as an instrument of therapeutic exercise for the protection and promotion of health. However, despite bein...
null
Inclusion Criteria: * male sex * healthy * aged between 18 and 36 years Exclusion Criteria: * smokers * alcoholics * use drugs that influenced cardiac autonomic activity * cardiovascular, metabolic or endocrine diseases.
Paulista University
OTHER
{ "id": "69459517.8.0000.5402", "link": null, "type": null }
Unknown
{ "hasExpandedAccess": false, "nctId": null, "statusForNctId": null }
2017-07-25T00:00:00
{ "date": "2020-03-03", "type": "ACTUAL" }
{ "date": "2017-07-28", "type": "ACTUAL" }
[ "ADULT" ]
null
null
true
{ "allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "interventionModelDescription": null, "maskingInfo": { "masking": "NONE", "maskingDescription": null, "whoMasked": null }, "observationalModel": null, "primaryPurpose": "OTHER", "timePerspective": null }
[ "Pilates Method", "Exercise" ]
["Exercise Movement Techniques", "Exercise", "Monitoring, Physiologic", "Heart Rate", "Autonomic Nervous System", "Heart rate variability"]
null
[ { "city": "Presidente Prudente", "country": "Brazil", "facility": "Franciele Marques Vanderlei", "geoPoint": { "lat": -22.12556, "lon": -51.38889 }, "state": "São Paulo" } ]
null
null
{ "other": null, "primary": [ { "description": null, "measure": "Change from baseline in the indices of heart rate variability in different levels of pilates (basic, intermediate and advanced)", "timeFrame": "Eight (transition from basic to intermediate level) and twelfth week (transition from...
null
[{"pmid": "34672201", "type": "DERIVED", "citation": "Cavina AP, Silva NM, Biral TM, Lemos LK, Junior EP, Pastre CM, Vanderlei LC, Vanderlei FM. Effects of 12-week Pilates training program on cardiac autonomic modulation: a randomized controlled clinical trial. J Comp Eff Res. 2021 Dec;10(18):1363-1372. doi: 10.2217/ce...
{"versionHolder": "2025-06-18"}
null
null
null
NCT01342666
null
Tomato Consumption and High Density Lipoprotein-cholesterol
Effect of Tomato Consumption on Serum High Density Lipoprotein-cholesterol Levels. A Randomized, Open-label, Single Blind, Clinical Trial
None
INTERVENTIONAL
COMPLETED
2011-04-26T00:00:00
null
null
null
[ "NA" ]
50
18
65
ALL
false
* This is a randomized, open-label, single blind, clinical trial * The study evaluated the effect of tomato consumption in serum HDL-cholesterol levels. * The hypothesis was that two daily tomatoes during one month will increase the HDL-c levels. * Since a placebo of tomatoes cannot be done, the control group will rece...
Cardiovascular disease (CVD) is a main cause of death worldwide (1) and there are well recognized risk factors associated with its development. Low high density lipoprotein-cholesterol (HDL-c) rank among the most common lipid abnormalities associated with CVD (2). Low HDL-c is currently defined as an HDL-c value below ...
Inclusion Criteria: * Males with HDL-c less than 40 mg/dl * Females with HDL-c less than 50 mg/dl * Age between 18 to 65 years old * Acceptance for participation with signed informed consent Exclusion Criteria: Previous diagnosis of: * Diabetes, * Hypertension, * Kidney, liver or heart insufficiency, * Hyperuricemi...
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
OTHER
{ "id": "REF2039", "link": null, "type": null }
Unknown
{ "hasExpandedAccess": false, "nctId": null, "statusForNctId": null }
2011-04-26T00:00:00
{ "date": "2013-02-28", "type": "ESTIMATED" }
{ "date": "2011-04-27", "type": "ESTIMATED" }
[ "ADULT", "OLDER_ADULT" ]
null
null
true
{ "allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "interventionModelDescription": null, "maskingInfo": { "masking": "SINGLE", "maskingDescription": null, "whoMasked": [ "OUTCOMES_ASSESSOR" ] }, "observationalModel": null, "primaryPurpose": "TREATMENT", "timePerspective...
[ "Hypoalphalipoproteinemia" ]
["High density lipoprotein cholesterol", "Tomato", "Lycopene", "Hypoalphalipoproteinemia", "Dyslipidemia"]
null
[ { "city": "Mexico", "country": "Mexico", "facility": "Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran", "geoPoint": { "lat": 19.42847, "lon": -99.12766 }, "state": "Tlalpan" } ]
[ { "class": "OTHER", "name": "Instituto Nacional de Cardiologia Ignacio Chavez" } ]
null
{ "other": null, "primary": [ { "description": null, "measure": "High Density Lipoprotein Cholesterol (HDL-c)", "timeFrame": "Baseline and after one month" } ], "secondary": null }
[ { "affiliation": "Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran", "name": "Francisco J Gomez-Perez, MD, FACE", "role": "PRINCIPAL_INVESTIGATOR" } ]
[{"pmid": "19148834", "type": "BACKGROUND", "citation": "Ali MM, Agha FG. Amelioration of streptozotocin-induced diabetes mellitus, oxidative stress and dyslipidemia in rats by tomato extract lycopene. Scand J Clin Lab Invest. 2009;69(3):371-9. doi: 10.1080/00365510802658473."}, {"pmid": "9832077", "type": "BACKGROUND"...
{"versionHolder": "2025-06-18"}
{ "ancestors": [ { "id": "D007009", "term": "Hypolipoproteinemias" }, { "id": "D008052", "term": "Lipid Metabolism, Inborn Errors" }, { "id": "D008661", "term": "Metabolism, Inborn Errors" }, { "id": "D030342", "term": "Genetic Diseases, Inbo...
{ "ancestors": null, "browseBranches": [ { "abbrev": "Infl", "name": "Anti-Inflammatory Agents" }, { "abbrev": "ANeo", "name": "Antineoplastic Agents" }, { "abbrev": "All", "name": "All Drugs and Chemicals" }, { "abbrev": "HB", "name": "Her...
{ "conditions": [ { "id": "D052456", "term": "Hypoalphalipoproteinemias" } ], "interventions": [] }
NCT00859066
null
Evaluation of Radiology Resident Anxiety When Beginning Emergency Room (ER) Call
Evaluation of Radiology Resident Anxiety When Beginning ER Call
None
OBSERVATIONAL
TERMINATED
2009-03-09T00:00:00
null
null
null
null
19
null
null
ALL
true
The purpose of this study is to quantify levels of resident anxiety under the current system (take call alone) and compare results to a modified system.
The study purpose is to quantify resident perceptions and feelings under the current 1700 call system (take call alone) and compare those with resident perceptions and feelings under a modified system where two partial shifts are taken with an experienced resident ("buddy call") prior to taking call alone.
Inclusion Criteria: * first year radiology residents
University of Michigan
OTHER
{ "id": "HUM00026874", "link": null, "type": null }
Original Principal Investigator (Andrew Trout M.D.) left the University.
{ "hasExpandedAccess": false, "nctId": null, "statusForNctId": null }
2009-03-09T00:00:00
{ "date": "2012-04-30", "type": "ESTIMATED" }
{ "date": "2009-03-10", "type": "ESTIMATED" }
[ "CHILD", "ADULT", "OLDER_ADULT" ]
First year radiology residents
NON_PROBABILITY_SAMPLE
true
{ "allocation": null, "interventionModel": null, "interventionModelDescription": null, "maskingInfo": null, "observationalModel": "CASE_CONTROL", "primaryPurpose": null, "timePerspective": "PROSPECTIVE" }
[ "Anxiety", "Stress" ]
null
null
[ { "city": "Ann Arbor", "country": "United States", "facility": "University of Michigan Hospital", "geoPoint": { "lat": 42.27756, "lon": -83.74088 }, "state": "Michigan" } ]
null
null
{ "other": null, "primary": [ { "description": null, "measure": "Improve resident well-being by decreasing anxiety surrounding beginning ER call as a first year radiology resident.", "timeFrame": "12 months" } ], "secondary": null }
[ { "affiliation": "University of Michigan Hospital", "name": "Richard Cohan, M.D.", "role": "PRINCIPAL_INVESTIGATOR" } ]
null
{"versionHolder": "2025-06-18"}
{ "ancestors": [ { "id": "D001523", "term": "Mental Disorders" } ], "browseBranches": [ { "abbrev": "BC23", "name": "Symptoms and General Pathology" }, { "abbrev": "All", "name": "All Conditions" }, { "abbrev": "BXM", "name": "Behaviors a...
null
{ "conditions": [ { "id": "D001008", "term": "Anxiety Disorders" } ], "interventions": null }
NCT01291966
null
Efficacy of a Intervention to Reduce Medication Errors and Improve Adherence
Efficacy of a Intervention to Reduce Medication Errors and Therapeutic Failure in Patients Over 65 Years Polypharmacy
ATEM-AP
INTERVENTIONAL
COMPLETED
2011-01-26T00:00:00
null
null
null
[ "NA" ]
154
65
null
ALL
true
The purpose of this study is to demonstrate that an intervention based on the motivational interview directed to patients with polypharmacy to improve the Therapeutic Adherence and to reduce the errors of Medication in major measure that the habitual intervention.
null
Inclusion Criteria: * Patients with polypharmacy (5 or more medicines) * That detects to them a problem of Therapeutic Adherence * That agree to take part in the study Exclusion Criteria: * Immobilized patients or with an index of Barthel lower than 60 points * Incapable to fulfill ABVD * Patients with cognitive det...
Hospital Universitario Reina Sofia de Cordoba
OTHER_GOV
{ "id": "PI-0101/2008", "link": null, "type": null }
Unknown
{ "hasExpandedAccess": false, "nctId": null, "statusForNctId": null }
2011-02-08T00:00:00
{ "date": "2011-02-09", "type": "ESTIMATED" }
{ "date": "2011-02-09", "type": "ESTIMATED" }
[ "OLDER_ADULT" ]
null
null
false
{ "allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "interventionModelDescription": null, "maskingInfo": { "masking": "NONE", "maskingDescription": null, "whoMasked": null }, "observationalModel": null, "primaryPurpose": "PREVENTION", "timePerspective": null }
[ "Medication Adherence", "Patient Compliance" ]
["medication errors", "Patient Compliance", "patient safety", "polypharmacy"]
null
[ { "city": "Córdoba", "country": "Spain", "facility": "Unidad Docente de Medicina Familiar y Comunitaria", "geoPoint": { "lat": 37.89155, "lon": -4.77275 }, "state": null } ]
[ { "class": "UNKNOWN", "name": "Sociedad Andaluza de Medicina Familiar y Comunitaria" }, { "class": "UNKNOWN", "name": "Sociedad Española de Medicina Familiar y Comunitaria" } ]
null
{ "other": null, "primary": [ { "description": null, "measure": "medication errors in the patients", "timeFrame": "Baseline, 1, 3 and 6 months" } ], "secondary": [ { "description": null, "measure": "Percentage of adherence", "timeFrame": "Baseline and 6 months" ...
[ { "affiliation": "Andalusian Health Service", "name": "Luis A Perula, PH D", "role": "PRINCIPAL_INVESTIGATOR" } ]
[{"pmid": "25858633", "type": "DERIVED", "citation": "Moral RR, Torres LA, Ortega LP, Larumbe MC, Villalobos AR, Garcia JA, Rejano JM; Collaborative Group ATEM-AP Study. Effectiveness of motivational interviewing to improve therapeutic adherence in patients over 65 years old with chronic diseases: A cluster randomized ...
{"versionHolder": "2025-06-18"}
null
null
null
NCT07009366
null
Comparison of Methods of Weaning From Nasal CPAP in Preterm Infants: A Randomized Controlled Trial
Comparison of Methods of Weaning From Nasal CPAP in Preterm Infants: A Randomized Controlled Trial
None
INTERVENTIONAL
COMPLETED
2025-05-29T00:00:00
null
2024-12-31T00:00:00
2024-12-31T00:00:00
[ "NA" ]
75
1
24
ALL
false
This study aimed to determine the efficacy of different NCPAP weaning strategies in pre-term infants presenting with respiratory distress, and ultimately establishing the best method to withdraw from NCPAP.
Pakistan, as well as other developing countries, lacks data regarding the weaning protocol of NCPAP. Ascertaining the best weaning method that could facilitate a shorter duration on nasal CPAP and the least length of hospital stay is very much needed. Findings of this study would help clinicians to achieve better outco...
Inclusion Criteria: * Preterm infants * Any gender * Low birth weight * Gestational ages between 28 to below 37 weeks * Presented with respiratory distress * Neonates with radiological findings suggestive of respiratory distress, congenital pneumonia/sepsis, or transient tachypnea of the newborn (TTN) Exclusion Crite...
RESnTEC, Institute of Research
OTHER
{ "id": "DRRABIAZUK", "link": null, "type": null }
Unknown
{ "hasExpandedAccess": false, "nctId": null, "statusForNctId": null }
2025-05-29T00:00:00
{ "date": "2025-06-06", "type": "ACTUAL" }
{ "date": "2025-06-06", "type": "ACTUAL" }
[ "CHILD" ]
null
null
false
{ "allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "interventionModelDescription": null, "maskingInfo": { "masking": "NONE", "maskingDescription": null, "whoMasked": null }, "observationalModel": null, "primaryPurpose": "SUPPORTIVE_CARE", "timePerspective": null }
[ "Respiratory Distress Syndrome, Newborn" ]
null
null
[ { "city": "Karachi", "country": "Pakistan", "facility": "Ziauddin University", "geoPoint": { "lat": 24.8608, "lon": 67.0104 }, "state": "Sindh" } ]
null
null
{ "other": null, "primary": [ { "description": null, "measure": "Successful weaning", "timeFrame": "4 days" } ], "secondary": [ { "description": null, "measure": "Comparison of total days on NCPAP", "timeFrame": "4 days" }, { "description": null, ...
[ { "affiliation": "Ziauddin University Karachi", "name": "Rabia Asif", "role": "PRINCIPAL_INVESTIGATOR" }, { "affiliation": "Ziauddin University Karachi", "name": "Heena Rais, FCPS", "role": "STUDY_DIRECTOR" } ]
null
{"versionHolder": "2025-06-18"}
{ "ancestors": [ { "id": "D008171", "term": "Lung Diseases" }, { "id": "D012140", "term": "Respiratory Tract Diseases" }, { "id": "D012120", "term": "Respiration Disorders" }, { "id": "D007235", "term": "Infant, Premature, Diseases" }, ...
null
{ "conditions": [ { "id": "D012128", "term": "Respiratory Distress Syndrome" }, { "id": "D012127", "term": "Respiratory Distress Syndrome, Newborn" } ], "interventions": null }
NCT02367066
null
A Phase I Study to Assess the Pharmacodynamics of Oral AR-C165395XX in Subjects With Type 2 Diabetes Mellitus (T2DM)
A Single Centre, Double-blind, Randomised, Placebo-controlled, Cross-over Phase I Study to Assess the Pharmacodynamics of Oral AR-C165395XX After Administration of Repeated Doses for 3 Days in Subjects With Type 2 Diabetes Mellitus
None
INTERVENTIONAL
COMPLETED
2015-02-13T00:00:00
null
null
null
[ "PHASE1" ]
30
18
130
ALL
false
A study to assess the Pharmacodynamics of oral AR-C165395XX after Administration of Repeated Doses for 3 days in Subjects with Type 2 Diabetes Mellitus
A Single Centre, Double-blind, Randomised, Placebo-controlled, Cross-over Phase I Study to Assess the Pharmacodynamics of oral AR-C165395XX after Administration of Repeated Doses for 3 days in Subjects with Type 2 Diabetes Mellitus
Inclusion Criteria * Provision of informed consent * Male or female of non-childbearing potential (postmenopausal, and/or have undergone hysterectomy and/or bilateral oophorectomy or salpingectomy/tubal ligation) aged ≥18. * Patients with HbA1c ≥7.5 but ≤11% at enrolment visit (Visit 1) * ody mass index \>19 to \<38 k...
AstraZeneca
INDUSTRY
{ "id": "D6420C00001", "link": null, "type": null }
Unknown
{ "hasExpandedAccess": false, "nctId": null, "statusForNctId": null }
2015-02-19T00:00:00
{ "date": "2016-06-23", "type": "ESTIMATED" }
{ "date": "2015-02-20", "type": "ESTIMATED" }
[ "ADULT", "OLDER_ADULT" ]
null
null
false
{ "allocation": "RANDOMIZED", "interventionModel": "CROSSOVER", "interventionModelDescription": null, "maskingInfo": { "masking": "TRIPLE", "maskingDescription": null, "whoMasked": [ "PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR" ] }, "observationalModel": null, "primaryP...
[ "Type 2 Diabetes Mellitus" ]
["patients", "glycaemic control on metformin"]
null
[ { "city": "Chula Vista", "country": "United States", "facility": "Research Site", "geoPoint": { "lat": 32.64005, "lon": -117.0842 }, "state": "California" } ]
null
null
{ "other": null, "primary": [ { "description": null, "measure": "Change From Baseline to Endpoint MMTT AUC(0-4h) for Plasma Glucose", "timeFrame": "Day -1 to Day 3 and Day 6 to Day 9" }, { "description": null, "measure": "Change From Baseline to Endpoint MMTT C_max for Plas...
[ { "affiliation": "Profil Institute for Clinical Research, Inc.", "name": "Liliana Uribe-Bruce, MD, MCI", "role": "PRINCIPAL_INVESTIGATOR" }, { "affiliation": "AstraZeneca R&D Mölndal", "name": "Stanko Skrtic, MD, PhD", "role": "STUDY_DIRECTOR" } ]
[{"pmid": "30557325", "type": "DERIVED", "citation": "Skrtic S, Tyrberg B, Broberg M, Ericsson H, Schnecke V, Kjaer M, Hompesch M, Andersson EM, Ryberg E, Aivazidis A, Wennberg Huldt C, Lofgren L, Morrow L, Parkinson J, Ryden-Bergsten T, Watkins E, Sorhede Winzell M. Exploring the insulin secretory properties of the PG...
{"versionHolder": "2025-06-18"}
{ "ancestors": [ { "id": "D044882", "term": "Glucose Metabolism Disorders" }, { "id": "D008659", "term": "Metabolic Diseases" }, { "id": "D004700", "term": "Endocrine System Diseases" } ], "browseBranches": [ { "abbrev": "BC18", "name": "...
{ "ancestors": null, "browseBranches": [ { "abbrev": "Hypo", "name": "Hypoglycemic Agents" }, { "abbrev": "All", "name": "All Drugs and Chemicals" } ], "browseLeaves": [ { "asFound": null, "id": "M11667", "name": "Metformin", "relevance": "LOW"...
{ "conditions": [ { "id": "D003920", "term": "Diabetes Mellitus" }, { "id": "D003924", "term": "Diabetes Mellitus, Type 2" } ], "interventions": [] }
NCT06137066
null
The Effect of Green Coffee Extract on Blood Glucose Homeostasis in Healthy Adults
The Effect of Green Coffee Extract With Alpha-lipoic Acid or Dihydroberberine on Blood Glucose Homeostasis in Healthy Adults
None
INTERVENTIONAL
COMPLETED
2023-11-13T00:00:00
null
2024-05-08T00:00:00
2024-05-08T00:00:00
[ "NA" ]
20
18
45
ALL
true
Green coffee extract (GCE) supplementation has been shown to induce favourable health benefits on glucose metabolism and weight management. Previous literature suggests that the benefits of GCE are due to the high bioavailability of chlorogenic acid (CGA) which is known for its antioxidant and anti-inflammatory propert...
Green coffee extract (GCE) supplementation has been shown to induce favourable benefits on glucose metabolism and weight management. These effects are attributed to its high chlorogenic acid (CGA) content, recognized for its anti-inflammatory properties. Chronic CGA supplementation (4-12 weeks) has been linked to reduc...
Inclusion Criteria: * Males and females 18-45 years * BMI between 18.5-30 kg/m2 * No history of smoking or cardiovascular and metabolic diseases (stroke, hypertension, type II diabetes) or other diseases that could impact the study outcomes * Weight stable (within ±2kg for 6 months) * Generally healthy as assessed by ...
Queen's University
OTHER
{ "id": "6039146", "link": null, "type": null }
Unknown
{ "hasExpandedAccess": false, "nctId": null, "statusForNctId": null }
2023-11-13T00:00:00
{ "date": "2024-05-10", "type": "ACTUAL" }
{ "date": "2023-11-18", "type": "ACTUAL" }
[ "ADULT" ]
null
null
false
{ "allocation": "RANDOMIZED", "interventionModel": "CROSSOVER", "interventionModelDescription": "Four-arm study. All participants receive all acute nutritional interventions: placebo (microcrystalline cellulose with 5mg magnesium stearate and 5mg silicon dioxide), 200mg GCE +200mg ALA, 200mg GCE + 400mg ALA, 200m...
[ "Healthy" ]
["Green Coffee Extract", "Chlorogenic Acid", "Alpha-Lipoic Acid", "Dihydroberberine"]
null
[ { "city": "Kingston", "country": "Canada", "facility": "Queen's University", "geoPoint": { "lat": 44.22976, "lon": -76.48101 }, "state": "Ontario" } ]
[ { "class": "INDUSTRY", "name": "Iovate Health Sciences International Inc" } ]
null
{ "other": null, "primary": [ { "description": null, "measure": "2-hour plasma glucose incremental area under the curve", "timeFrame": "2 hours" } ], "secondary": [ { "description": null, "measure": "2- hour plasma insulin incremental area under the curve", "timeF...
[ { "affiliation": "Queen's University", "name": "Chris McGlory", "role": "PRINCIPAL_INVESTIGATOR" } ]
null
{"versionHolder": "2025-06-18"}
null
{ "ancestors": null, "browseBranches": [ { "abbrev": "Micro", "name": "Micronutrients" }, { "abbrev": "All", "name": "All Drugs and Chemicals" }, { "abbrev": "Ot", "name": "Other Dietary Supplements" } ], "browseLeaves": [ { "asFound": null, ...
{ "conditions": null, "interventions": [] }
NCT01130766
null
Asymptomatic Brain Metastasis in Non-small Cell Lung Cancer (NSCLC)
Randomized Phase III Trial of Stereotactic Radiosurgery (SRS) Versus Observation for Patients With Asymptomatic Cerebral Oligo-metastases in Non-small Cell Lung Cancer (NSCLC)
None
INTERVENTIONAL
UNKNOWN
2010-05-25T00:00:00
null
null
null
[ "PHASE3" ]
176
18
null
ALL
false
The prognosis of NSCLC patients with asymptomatic brain metastasis, who are not treated with SRS or WBRT has not been fully investigated yet. This randomized phase III trial is conducted to determine the exact role of SRS in NSCLC patients with asymptomatic oligo brain metastases whether early treatment with SRS would ...
null
Inclusion Criteria: * Histologically confirmed non-small cell lung cancer with synchronous brain metastases (diagnosis of brain lesion before or within 2 months from diagnosis of the primary site tumor) * One to 4 intraparenchymal brain metastases by contrast-enhanced MRI, meeting the following criteria: 1. We...
Samsung Medical Center
OTHER
{ "id": "2009-01-059", "link": null, "type": null }
Unknown
{ "hasExpandedAccess": false, "nctId": null, "statusForNctId": null }
2010-05-25T00:00:00
{ "date": "2010-05-26", "type": "ESTIMATED" }
{ "date": "2010-05-26", "type": "ESTIMATED" }
[ "ADULT", "OLDER_ADULT" ]
null
null
true
{ "allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "interventionModelDescription": null, "maskingInfo": { "masking": "NONE", "maskingDescription": null, "whoMasked": null }, "observationalModel": null, "primaryPurpose": "TREATMENT", "timePerspective": null }
[ "Non-small Cell Lung Cancer" ]
["Non-small Cell Lung Cancer", "Asymptomatic brain metastasis", "Stereotactic radiosurgery (SRS)"]
null
[ { "city": "Seoul,", "country": "Korea, Republic of", "facility": "Samsung Medical Center", "geoPoint": { "lat": 37.566, "lon": 126.9784 }, "state": null } ]
null
null
{ "other": null, "primary": [ { "description": null, "measure": "Overall survival", "timeFrame": "36 months" } ], "secondary": [ { "description": null, "measure": "time to CNS progression", "timeFrame": "36 months" }, { "description": null, "me...
[ { "affiliation": "Samsung Medical Center", "name": "Myungju Ahn, M.D., Ph.D.", "role": "PRINCIPAL_INVESTIGATOR" } ]
null
{"versionHolder": "2025-06-18"}
{ "ancestors": [ { "id": "D012142", "term": "Respiratory Tract Neoplasms" }, { "id": "D013899", "term": "Thoracic Neoplasms" }, { "id": "D009371", "term": "Neoplasms by Site" }, { "id": "D009369", "term": "Neoplasms" }, { "id": ...
{ "ancestors": null, "browseBranches": [ { "abbrev": "Micro", "name": "Micronutrients" }, { "abbrev": "All", "name": "All Drugs and Chemicals" } ], "browseLeaves": [ { "asFound": null, "id": "M6265", "name": "Cobalt", "relevance": "LOW" } ...
{ "conditions": [ { "id": "D008175", "term": "Lung Neoplasms" }, { "id": "D002289", "term": "Carcinoma, Non-Small-Cell Lung" }, { "id": "D009362", "term": "Neoplasm Metastasis" } ], "interventions": [] }
NCT07006766
null
Bucatini Pasta, Japanese Shirataki Konjac Noodles, and Artificial Vessels: In Search of the Ideal Low-cost Vessel Simulator for Microsurgical Education
Bucatini Pasta, Japanese Shirataki Konjac Noodles, and Artificial Vessels: In Search of the Ideal Low-cost Vessel Simulator for Microsurgical Education
None
OBSERVATIONAL
COMPLETED
2025-05-27T00:00:00
null
2025-02-15T00:00:00
2025-02-15T00:00:00
null
10
18
null
ALL
true
The aim of this study is to assess the strengths and weaknesses of training models that are accessible, reproducible, and geared toward new learners. Specifically, the investigators aim to compare the four following models: Japanese shirataki konjac noodle, "Dragon skin" silicone vessel, standard silicone vessel, and t...
The significant benefit Japanese shirataki konjac noodle as a model for microsurgical simulation training is that they are very cost effective and allow for acquisition of microsurgical skills in a low stake environment. This is particularly useful for the microsurgery novice to become familiar with the tools and basic...
Inclusion Criteria: * Participant is able to commit 1-2 hours to the study. * Participants must either be a surgical resident or an individual with no formal surgery/microsurgery education. Five participants will be placed into each of these two categories. Exclusion Criteria: * Participant is unable to commit 1-2 h...
University of Wisconsin, Madison
OTHER
{ "id": "2023-1534", "link": null, "type": null }
Unknown
{ "hasExpandedAccess": false, "nctId": null, "statusForNctId": null }
2025-05-27T00:00:00
{ "date": "2025-06-05", "type": "ACTUAL" }
{ "date": "2025-06-05", "type": "ACTUAL" }
[ "ADULT", "OLDER_ADULT" ]
Surgical residents or individual with no formal microsurgical education.
NON_PROBABILITY_SAMPLE
null
{ "allocation": null, "interventionModel": null, "interventionModelDescription": null, "maskingInfo": null, "observationalModel": "COHORT", "primaryPurpose": null, "timePerspective": "PROSPECTIVE" }
[ "Surgical Procedure, Unspecified" ]
["microsuture", "microsurgery", "surgical training", "microsurgical education", "global", "accessibility", "noodle", "synthetic", "vessel", "anastomosis", "patency", "education", "outreach", "low-cost", "microsurgical simulation", "simulation", "vessel simulator"]
null
[ { "city": "Madison", "country": "United States", "facility": "UW School of Medicine and Public Health", "geoPoint": { "lat": 43.07305, "lon": -89.40123 }, "state": "Wisconsin" } ]
null
null
{ "other": null, "primary": [ { "description": null, "measure": "Time to Perform Anastomosis", "timeFrame": "up to 30 min" }, { "description": null, "measure": "Number of Stitches", "timeFrame": "up to 30 min" }, { "description": null, "measure": "...
[ { "affiliation": "UW School of Medicine and Public Health", "name": "Samuel Poore, MD, PhD", "role": "PRINCIPAL_INVESTIGATOR" } ]
[{"pmid": "24603055", "type": "BACKGROUND", "citation": "Prunieres GJ, Taleb C, Hendriks S, Miyamoto H, Kuroshima N, Liverneaux PA, Facca S. Use of the Konnyaku Shirataki noodle as a low fidelity simulation training model for microvascular surgery in the operating theatre. Chir Main. 2014 Apr;33(2):106-11. doi: 10.1016...
{"versionHolder": "2025-06-18"}
null
null
null
NCT06905366
null
Cognitive Function and Postoperative Quality of Recovery
Association Between Cognitive Function and Postoperative Quality of Recovery - a Prospective Cohort Study
KoSQoR
OBSERVATIONAL
NOT_YET_RECRUITING
2025-03-25T00:00:00
null
null
null
null
140
65
null
ALL
false
This study aims to assess the association between perioperative cognitive function and postoperative quality of recovery.
null
Inclusion Criteria: * elective non-cardiac surgery * age ≥65 years * duration of surgery ≥60 years Exclusion Criteria: * inability to give informed consent
Universitätsklinikum Hamburg-Eppendorf
OTHER
{ "id": "2025-101433-BO-ff", "link": null, "type": null }
Unknown
{ "hasExpandedAccess": false, "nctId": null, "statusForNctId": null }
2025-03-25T00:00:00
{ "date": "2025-04-01", "type": "ACTUAL" }
{ "date": "2025-04-01", "type": "ACTUAL" }
[ "OLDER_ADULT" ]
patients aged 65 years or older, who are scheduled for elective non-cardiac surgery
NON_PROBABILITY_SAMPLE
false
{ "allocation": null, "interventionModel": null, "interventionModelDescription": null, "maskingInfo": null, "observationalModel": "COHORT", "primaryPurpose": null, "timePerspective": "PROSPECTIVE" }
[ "Perioperative Neurocognitive Disorders", "Postoperative Quality of Recovery" ]
["cognitive function"]
null
null
null
null
{ "other": null, "primary": [ { "description": null, "measure": "QoR-15GE", "timeFrame": "first postoperative day" } ], "secondary": null }
null
null
{"versionHolder": "2025-06-18"}
{ "ancestors": [ { "id": "D001523", "term": "Mental Disorders" } ], "browseBranches": [ { "abbrev": "BXM", "name": "Behaviors and Mental Disorders" }, { "abbrev": "All", "name": "All Conditions" } ], "browseLeaves": [ { "asFound": "Neurocog...
null
{ "conditions": [ { "id": "D019965", "term": "Neurocognitive Disorders" } ], "interventions": null }
NCT04034966
null
Utility of Telemedicine in the Follow-Up of Patients in Peritoneal Dialysis
Utility of Telemedicine in the Follow-Up of Patients in Peritoneal Dialysis
None
INTERVENTIONAL
UNKNOWN
2018-10-31T00:00:00
null
null
null
[ "NA" ]
750
18
80
ALL
false
Peritoneal dialysis (PD) technology is available but has not been tested in the real world. Therefore, the aim of this study is to test the utility of telemedicine in reducing mortality, hospitalizations, unscheduled visits, and cost derived from preventable complications. Incident patients to PD treatment will be foll...
Study Background \& Rationale: (background information including previous studies as applicable ) Chronic kidney disease (CKD) is a growing problem world-wide which increases in parallel with some risk factors such as chronic diseases, mainly diabetes mellitus and hypertension. CKD imposes elevated costs both from the...
Inclusion Criteria: Hospitals will be randomly assigned to control (without telemedicine device) or intervention groups (with telemedicine device). Hospitals will be selected and matched according their basic infrastructure (Outpatient dialysis clinic, Emergency Room, Laboratory and Radiology Departments, Hospitalizati...
Coordinación de Investigación en Salud, Mexico
OTHER_GOV
{ "id": "R-2018-785-035", "link": null, "type": null }
Unknown
{ "hasExpandedAccess": false, "nctId": null, "statusForNctId": null }
2019-07-24T00:00:00
{ "date": "2019-07-29", "type": "ACTUAL" }
{ "date": "2019-07-29", "type": "ACTUAL" }
[ "ADULT", "OLDER_ADULT" ]
null
null
false
{ "allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "interventionModelDescription": "The Project will consist in the conventional clinical treatment of the APD patient cared for in IMSS regarding the kind of dialysis solution, handling of laboratory and office procedures, as well as the handling of com...
[ "Chronic Kidney Disease Stage 5", "Peritoneal Dialysis Complication" ]
["peritoneal dialysis", "Claria", "telemedicine"]
null
[ { "city": "Mexico City", "country": "Mexico", "facility": "Unidad de Investigacion Medica en Enfermedades Nefrologicas, Hospital de Especialidades Centro Medico Nacional Siglo XXI", "geoPoint": { "lat": 19.42847, "lon": -99.12766 }, "state": null } ]
null
null
{ "other": null, "primary": [ { "description": null, "measure": "MORTALITY RATE", "timeFrame": "2 years" }, { "description": null, "measure": "DAYS OF HOSPITALIZATION", "timeFrame": "2 years" }, { "description": null, "measure": "DAYS OF PREVENTABL...
[ { "affiliation": "Instituto Mexicano del Seguro Social", "name": "Fabio Salamanca, PhD", "role": "STUDY_CHAIR" } ]
[{"pmid": "17568785", "type": "BACKGROUND", "citation": "Levey AS, Atkins R, Coresh J, Cohen EP, Collins AJ, Eckardt KU, Nahas ME, Jaber BL, Jadoul M, Levin A, Powe NR, Rossert J, Wheeler DC, Lameire N, Eknoyan G. Chronic kidney disease as a global public health problem: approaches and initiatives - a position statemen...
{"versionHolder": "2025-06-18"}
{ "ancestors": [ { "id": "D014570", "term": "Urologic Diseases" }, { "id": "D052776", "term": "Female Urogenital Diseases" }, { "id": "D005261", "term": "Female Urogenital Diseases and Pregnancy Complications" }, { "id": "D000091642", "term":...
null
{ "conditions": [ { "id": "D007674", "term": "Kidney Diseases" }, { "id": "D051436", "term": "Renal Insufficiency, Chronic" } ], "interventions": null }
NCT01436266
null
Effect of Preoperative Buccal Misoprostol on Blood Loss in Second-trimester Dilation and Evacuation Abortion
Effect of Preoperative Buccal Misoprostol on Blood Loss in Second-trimester
PreopMiso
INTERVENTIONAL
TERMINATED
2011-09-15T00:00:00
null
null
null
[ "PHASE3" ]
3
18
50
FEMALE
false
Misoprostol is a medication used extensively in obstetrics and gynecology for its ability to aid in softening the cervix as well as decreasing blood loss after abortion or vaginal delivery. Opinions vary as to its usefulness in aiding in cervical dilation, and in decreasing blood loss. The investigators propose to cond...
This project is a placebo-controlled, double-blinded randomized controlled trial comparing the effect of misoprostol 400mcg buccally to placebo on blood loss in second trimester surgical abortion between 16-21 weeks gestation. The probability of group assignment is 50% with half of the women randomized to misoprostol a...
Inclusion Criteria: * English or Spanish speaking * Gestational age between 16 weeks 6 days and 20 weeks 6 days gestation by ultrasound dating on the day of enrollment * Ultrasound used for dating purposes must be within the last two weeks. * Women 18-50 years of age undergoing surgical termination of pregnancy Exclu...
Boston University
OTHER
{ "id": "H-30452", "link": null, "type": null }
Slow enrollment
{ "hasExpandedAccess": false, "nctId": null, "statusForNctId": null }
2011-09-16T00:00:00
{ "date": "2017-05-30", "type": "ACTUAL" }
{ "date": "2011-09-19", "type": "ESTIMATED" }
[ "ADULT" ]
null
null
false
{ "allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "interventionModelDescription": null, "maskingInfo": { "masking": "QUADRUPLE", "maskingDescription": null, "whoMasked": [ "PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR" ] }, "observati...
[ "Abortion", "Blood Loss" ]
null
null
[ { "city": "Boston", "country": "United States", "facility": "Boston Medical Center", "geoPoint": { "lat": 42.35843, "lon": -71.05977 }, "state": "Massachusetts" } ]
null
null
{ "other": null, "primary": [ { "description": null, "measure": "Blood Loss", "timeFrame": "one day following the procedure" } ], "secondary": null }
[ { "affiliation": "Boston Medical Center", "name": "Sarita Sonalkar, MD", "role": "PRINCIPAL_INVESTIGATOR" } ]
null
{"versionHolder": "2025-06-18"}
{ "ancestors": [ { "id": "D010335", "term": "Pathologic Processes" } ], "browseBranches": [ { "abbrev": "BC23", "name": "Symptoms and General Pathology" }, { "abbrev": "All", "name": "All Conditions" } ], "browseLeaves": [ { "asFound": "Blo...
{ "ancestors": [ { "id": "D014815", "term": "Vitamins" }, { "id": "D018977", "term": "Micronutrients" }, { "id": "D045505", "term": "Physiological Effects of Drugs" }, { "id": "D000020", "term": "Abortifacient Agents, Nonsteroidal" }, ...
{ "conditions": [ { "id": "D006470", "term": "Hemorrhage" } ], "interventions": [ { "id": "D005492", "term": "Folic Acid" }, { "id": "D016595", "term": "Misoprostol" } ] }
NCT05555966
null
CardioInsight 1 RBBB
Electrical Activation Mapping Guided Tailor Made Approach for Cardiac Resynchronization Therapy
CardioInsight1
INTERVENTIONAL
UNKNOWN
2022-09-15T00:00:00
null
2024-08-31T00:00:00
2024-12-31T00:00:00
[ "NA" ]
93
18
null
ALL
false
Cardiac resynchronization therapy (CRT) is an established therapy for symptomatic heart failure patients. However, there are still 30 to 40% of studied patients being nonresponder to CRT. The plausible reasons of lack of effect of CRT in these patients include relative less baseline electrical dyssynchrony. The aim of ...
null
Inclusion Criteria: * Adult (aged 18 or above) of both sexes * Ischemic or non-ischemic cause of heart failure * QRS duration \> 120 ms, non-left bundle branch block (LBBB) type of conduction disturbance * NYHA class III or above * Informed consent by the patient * Already received stable dose of guideline directed me...
Chinese University of Hong Kong
OTHER
{ "id": "2017.316", "link": null, "type": null }
Unknown
{ "hasExpandedAccess": false, "nctId": null, "statusForNctId": null }
2022-09-22T00:00:00
{ "date": "2022-09-27", "type": "ACTUAL" }
{ "date": "2022-09-27", "type": "ACTUAL" }
[ "ADULT", "OLDER_ADULT" ]
null
null
null
{ "allocation": "NA", "interventionModel": "SINGLE_GROUP", "interventionModelDescription": null, "maskingInfo": { "masking": "NONE", "maskingDescription": null, "whoMasked": null }, "observationalModel": null, "primaryPurpose": "TREATMENT", "timePerspective": null }
[ "Heart Failure" ]
null
null
[ { "city": "Shatin", "country": "Hong Kong", "facility": "The Chinese University of Hong Kong", "geoPoint": { "lat": 22.38333, "lon": 114.18333 }, "state": null } ]
null
null
{ "other": null, "primary": [ { "description": null, "measure": "Left Ventricle (LV) end systolic volume reduction", "timeFrame": "6 months" } ], "secondary": [ { "description": null, "measure": "Electrical dyssynchrony index", "timeFrame": "During procedure" ...
[ { "affiliation": "Chinese University of Hong Kong", "name": "Bryan Yan", "role": "PRINCIPAL_INVESTIGATOR" } ]
null
{"versionHolder": "2025-06-18"}
{ "ancestors": [ { "id": "D006331", "term": "Heart Diseases" }, { "id": "D002318", "term": "Cardiovascular Diseases" } ], "browseBranches": [ { "abbrev": "BC14", "name": "Heart and Blood Diseases" }, { "abbrev": "All", "name": "All Condit...
null
{ "conditions": [ { "id": "D006333", "term": "Heart Failure" } ], "interventions": null }
NCT01411566
null
Clinical Intervention Psychosis and Addiction
Evaluation of an Integrative Therapeutic Concept for Schizophrenic Patients With Comorbid Substance Use Disorder
KLIPS
INTERVENTIONAL
UNKNOWN
2011-03-02T00:00:00
null
null
null
[ "EARLY_PHASE1" ]
122
18
60
ALL
false
The purpose of this study is to evaluate an integrative therapeutic concept for schizophrenic patients with comorbid substance use disorder.
null
Inclusion Criteria: * Schizophrenia * Addiction * Written statement of agreement * Majority Exclusion Criteria: * Acute psychosis * Further neuropsychiatric disorder
University of Cologne
OTHER
{ "id": "Koeln-Fortune 104/2010", "link": null, "type": null }
Unknown
{ "hasExpandedAccess": false, "nctId": null, "statusForNctId": null }
2011-08-05T00:00:00
{ "date": "2011-08-08", "type": "ESTIMATED" }
{ "date": "2011-08-08", "type": "ESTIMATED" }
[ "ADULT" ]
null
null
false
{ "allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "interventionModelDescription": null, "maskingInfo": { "masking": "TRIPLE", "maskingDescription": null, "whoMasked": [ "PARTICIPANT", "INVESTIGATOR", "OUTCOMES_ASSESSOR" ] }, "observationalModel": null, "prima...
[ "Psychosis", "Substance Abuse" ]
["KLIPS"]
null
[ { "city": "Cologne", "country": "Germany", "facility": "LVR Clinic Cologne - Academic Clinic of the University of Cologne", "geoPoint": { "lat": 50.93333, "lon": 6.95 }, "state": null } ]
null
null
{ "other": null, "primary": [ { "description": null, "measure": "Substance use", "timeFrame": "one year" }, { "description": null, "measure": "Substance use", "timeFrame": "3 months" }, { "description": null, "measure": "Substance use", "time...
[ { "affiliation": "University of Cologne", "name": "Joerg Daumann, PhD", "role": "STUDY_CHAIR" } ]
null
{"versionHolder": "2025-06-18"}
{ "ancestors": [ { "id": "D019967", "term": "Schizophrenia Spectrum and Other Psychotic Disorders" }, { "id": "D064419", "term": "Chemically-Induced Disorders" } ], "browseBranches": [ { "abbrev": "BXM", "name": "Behaviors and Mental Disorders" }, { ...
null
{ "conditions": [ { "id": "D019966", "term": "Substance-Related Disorders" }, { "id": "D011618", "term": "Psychotic Disorders" }, { "id": "D001523", "term": "Mental Disorders" } ], "interventions": null }
NCT02909166
null
Role of ALiskiren, a Direct Renin Inhibitor, in Preventing Atrial Fibrillation in Patients With a Pacemaker; RALF.
Role of ALiskiren, a Direct Renin Inhibitor, in Preventing Atrial Fibrillation in Patients With a Pacemaker; RALF. A Double-blind, Randomized, Parallel-group, Single Centre Study
RALF
INTERVENTIONAL
UNKNOWN
2016-09-16T00:00:00
null
null
null
[ "PHASE3" ]
70
18
85
ALL
false
The aim of the study is to find out whether aliskiren reduces atrial fibrillation burden measured with a pacemaker device
The aim of the study is to find out the effect of a direct renin inhibitor, aliskiren, in reduction of AF with patients who have a pacemaker due to sinus node disease and paroxysmal atrial fibrillation. Hypothesis is that there is a possibility to reduce atrial remodeling due to AF and also to enhance atrial reverse r...
Inclusion Criteria: * age between 18 and 85 years * sinus node disease and paroxysmal AF * provided signed informed consent according to the Declaration of Helsinki for study participation * a previously implanted St. Jude Medical Identity / Victory / Zephyr ADX or any newer model of SJM DDDR pacemaker with ability to...
Helsinki University Central Hospital
OTHER
{ "id": "RALF", "link": null, "type": null }
Unknown
{ "hasExpandedAccess": false, "nctId": null, "statusForNctId": null }
2016-09-20T00:00:00
{ "date": "2016-09-21", "type": "ESTIMATED" }
{ "date": "2016-09-21", "type": "ESTIMATED" }
[ "ADULT", "OLDER_ADULT" ]
null
null
false
{ "allocation": "RANDOMIZED", "interventionModel": "CROSSOVER", "interventionModelDescription": null, "maskingInfo": { "masking": "QUADRUPLE", "maskingDescription": null, "whoMasked": [ "PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR" ] }, "observat...
[ "Atrial Fibrillation" ]
null
null
[ { "city": "Helsinki", "country": "Finland", "facility": "Helsinki University Central Hospital", "geoPoint": { "lat": 60.16952, "lon": 24.93545 }, "state": null } ]
null
null
{ "other": null, "primary": [ { "description": null, "measure": "burden of atrial fibrillation", "timeFrame": "From the start of the study to the end of the study; 0 - 12 months" } ], "secondary": [ { "description": null, "measure": "number of AF episodes", "timeF...
null
null
{"versionHolder": "2025-06-18"}
{ "ancestors": [ { "id": "D001145", "term": "Arrhythmias, Cardiac" }, { "id": "D006331", "term": "Heart Diseases" }, { "id": "D002318", "term": "Cardiovascular Diseases" }, { "id": "D010335", "term": "Pathologic Processes" } ], "brows...
{ "ancestors": [ { "id": "D000092502", "term": "Renin Inhibitors" }, { "id": "D011480", "term": "Protease Inhibitors" }, { "id": "D004791", "term": "Enzyme Inhibitors" }, { "id": "D045504", "term": "Molecular Mechanisms of Pharmacological Act...
{ "conditions": [ { "id": "D001281", "term": "Atrial Fibrillation" } ], "interventions": [ { "id": "C446481", "term": "Aliskiren" } ] }
NCT05501366
null
Strategies to Augment Ketosis: Optimization of Ketone Delivery Strategies
Strategies to Augment Ketosis: Optimization of Ketone Delivery Strategies
STAK: OK'd
INTERVENTIONAL
ACTIVE_NOT_RECRUITING
2022-08-01T00:00:00
null
null
null
[ "NA" ]
14
20
30
MALE
true
One important difference between KE compounds is the ketone-promoting components, which determines the circulating ratio of blood ketone bodies, BHB and AcAc, and may in turn lead to important metabolic and signaling differences. Whereas some actions of the ketone bodies BHB and AcAc are shared, R-BHB has a broad range...
BHB Monoester, C8 Diester, and (R) 1,3 Butanediol are commercially available in the products 'deltaG' (TdeltaS Global, FL, USA), 'Cognitive Switch' (Juvenescence Ltd, NJ, USA) and 'Avela' (Genomatica, CA, USA), respectively. The AcAc Diester is commercially available and is currently being used in clinical studies of A...
Inclusion Criteria: * Male * BMI between 18 and 29 kg/m2 * Aged 20 - 30 years * Participant is willing and able to comply with all study procedures including the following prior to Test Days: fasting (\>10 h; water only), no alcohol (\>24 h), no exercise (\>24 h), no acute illness and controlled feeding before each Te...
Ohio State University
OTHER
{ "id": "2022H0160", "link": null, "type": null }
Unknown
{ "hasExpandedAccess": false, "nctId": null, "statusForNctId": null }
2022-08-11T00:00:00
{ "date": "2025-05-29", "type": "ACTUAL" }
{ "date": "2022-08-15", "type": "ACTUAL" }
[ "ADULT" ]
null
null
true
{ "allocation": "RANDOMIZED", "interventionModel": "CROSSOVER", "interventionModelDescription": null, "maskingInfo": { "masking": "NONE", "maskingDescription": null, "whoMasked": null }, "observationalModel": null, "primaryPurpose": "BASIC_SCIENCE", "timePerspective": null }
[ "Ketosis" ]
null
null
[ { "city": "Columbus", "country": "United States", "facility": "The Ohio State University", "geoPoint": { "lat": 39.96118, "lon": -82.99879 }, "state": "Ohio" } ]
null
null
{ "other": null, "primary": [ { "description": null, "measure": "Total Plasma Ketone AUC", "timeFrame": "Up to ~ 4 weeks" } ], "secondary": [ { "description": null, "measure": "Capillary d-BHB concentrations", "timeFrame": "Up to ~ 4 weeks" }, { "des...
[ { "affiliation": "Ohio State University", "name": "Jeff S Volek, PhD", "role": "PRINCIPAL_INVESTIGATOR" } ]
null
{"versionHolder": "2025-06-18"}
{ "ancestors": [ { "id": "D000138", "term": "Acidosis" }, { "id": "D000137", "term": "Acid-Base Imbalance" }, { "id": "D008659", "term": "Metabolic Diseases" } ], "browseBranches": [ { "abbrev": "BC18", "name": "Nutritional and Metabolic ...
{ "ancestors": null, "browseBranches": [ { "abbrev": "CNSDep", "name": "Central Nervous System Depressants" }, { "abbrev": "All", "name": "All Drugs and Chemicals" }, { "abbrev": "Ot", "name": "Other Dietary Supplements" } ], "browseLeaves": [ { ...
{ "conditions": [ { "id": "D007662", "term": "Ketosis" } ], "interventions": [] }
NCT06419166
null
An Exploratory Clinical Study of GC012F Injection for Refractory gMG
An Exploratory Clinical Study of GC012F Injection for the Treatment of Refractory Generalized Myasthenia Gravis
gMG
INTERVENTIONAL
NOT_YET_RECRUITING
2024-04-25T00:00:00
null
2027-06-01T00:00:00
2027-10-01T00:00:00
[ "EARLY_PHASE1" ]
18
18
75
ALL
false
This study is a single-arm, open-label early exploratory clinical trial designed to evaluate the safety, tolerability, and preliminary efficacy of GC012F injection in subjects with refractory GMG. Additionally, the study aims to assess the pharmacokinetic (PK), pharmacodynamic (PD) characteristics, and immunogenicity o...
This study is a single-arm, open-label early exploratory clinical trial designed to evaluate the safety, tolerability, and preliminary efficacy of GC012F injection in subjects with refractory GMG. Additionally, the study aims to assess the pharmacokinetic (PK), pharmacodynamic (PD) characteristics, and immunogenicity o...
Inclusion Criteria: 1. Subjects or his/her legal proxy/guardian voluntary signing the ICF, and willing and able to follow the procedure in this study. 2. Aged ≥18 years old, no gender limitation; 3. Patients with confirmed refractory GMG, and the clinical classification is IIa-IVb (including IIa, IIb, IIIa, IIIb, IVa ...
Zhejiang University
OTHER
{ "id": "TXB2024002", "link": null, "type": null }
Unknown
{ "hasExpandedAccess": false, "nctId": null, "statusForNctId": null }
2024-05-13T00:00:00
{ "date": "2024-07-29", "type": "ACTUAL" }
{ "date": "2024-05-17", "type": "ACTUAL" }
[ "ADULT", "OLDER_ADULT" ]
null
null
null
{ "allocation": "NA", "interventionModel": "SINGLE_GROUP", "interventionModelDescription": null, "maskingInfo": { "masking": "NONE", "maskingDescription": null, "whoMasked": null }, "observationalModel": null, "primaryPurpose": "TREATMENT", "timePerspective": null }
[ "Refractory Generalized Myasthenia Gravis" ]
null
null
[ { "city": "Hanzhou", "country": "China", "facility": "The First Affiliated Hospital,College of Medicine, Zhejiang University", "geoPoint": { "lat": 26.4965, "lon": 99.437 }, "state": "Zhejiang" } ]
[ { "class": "INDUSTRY", "name": "Gracell Biotechnologies (Shanghai) Co., Ltd." } ]
null
{ "other": [ { "description": null, "measure": "• Detection rate of CAR-T cell antibodies in peripheral blood within 24 weeks post-GC012F infusion;", "timeFrame": "within 24 weeks post-GC012F infusion;" }, { "description": null, "measure": "• Changes in serum immunoglobulin l...
null
null
{"versionHolder": "2025-06-18"}
{ "ancestors": [ { "id": "D009422", "term": "Nervous System Diseases" }, { "id": "D020361", "term": "Paraneoplastic Syndromes, Nervous System" }, { "id": "D009423", "term": "Nervous System Neoplasms" }, { "id": "D009371", "term": "Neoplasms b...
null
{ "conditions": [ { "id": "D009157", "term": "Myasthenia Gravis" } ], "interventions": null }
NCT00990366
null
Treatment of Biliary Obstruction Using Biliary Stent With or Without Antireflux Valve
Treatment of Biliary Obstruction Using Biliary Stent With or Without Antireflux Valve
None
INTERVENTIONAL
TERMINATED
2009-10-05T00:00:00
null
null
null
[ "NA" ]
15
18
89
ALL
false
Biliary obstruction can be relieved by biliary stent. Ascending infection of biliary passage (cholangitis) causes hospitalization and obstruction of stents. Reflux of intestinal fluids through a stent is thought to be one of the causes of cholangitis. Stents with antireflux valves are designed to reduce the reflux from...
null
Inclusion Criteria: * age 18-89 * biliary obstruction in the lower two thirds of the choledochus Exclusion Criteria: * allergy to contrast media * future pancreaticoduodenectomy * refusal from the study * previous stent
Turku University Hospital
OTHER_GOV
{ "id": "58/180/2009", "link": null, "type": null }
Interim analysis results, study terminated 5/2010
{ "hasExpandedAccess": false, "nctId": null, "statusForNctId": null }
2009-10-05T00:00:00
{ "date": "2011-10-12", "type": "ESTIMATED" }
{ "date": "2009-10-06", "type": "ESTIMATED" }
[ "ADULT", "OLDER_ADULT" ]
null
null
false
{ "allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "interventionModelDescription": null, "maskingInfo": { "masking": "NONE", "maskingDescription": null, "whoMasked": null }, "observationalModel": null, "primaryPurpose": "TREATMENT", "timePerspective": null }
[ "Biliary Obstruction", "Cholangitis" ]
["antireflux valve", "biliary obstruction", "cholangitis", "biliary stent"]
null
[ { "city": "Turku", "country": "Finland", "facility": "Turku University Hospital", "geoPoint": { "lat": 60.45148, "lon": 22.26869 }, "state": null } ]
null
null
{ "other": null, "primary": [ { "description": null, "measure": "patency of a biliary stent", "timeFrame": "one year" } ], "secondary": [ { "description": null, "measure": "Cholangitis", "timeFrame": "one year" } ] }
[ { "affiliation": "Turku University Hospital", "name": "Paulina Salminen, MD", "role": "PRINCIPAL_INVESTIGATOR" } ]
null
{"versionHolder": "2025-06-18"}
{ "ancestors": [ { "id": "D001649", "term": "Bile Duct Diseases" }, { "id": "D001660", "term": "Biliary Tract Diseases" }, { "id": "D004066", "term": "Digestive System Diseases" } ], "browseBranches": [ { "abbrev": "BC06", "name": "Digest...
null
{ "conditions": [ { "id": "D002761", "term": "Cholangitis" } ], "interventions": null }
NCT05462366
null
Omics Sequencing of Specimen Derived From Mother-Infant-Pairs
Omics Sequencing of Specimen Derived From Mother-Infant-Pairs
None
OBSERVATIONAL
RECRUITING
2022-07-06T00:00:00
null
2024-12-30T00:00:00
2026-12-30T00:00:00
null
100
null
40
ALL
true
The investigators aim to collect breast-milk and feces from the participants, and apply culture techniques as well as omics sequencing technology to probe into the microbial and metabolomic signature of the specimens.
null
Inclusion Criteria: * healthy pregnant women aged between 20y and 40y. * Vaginal birth * BMI\<23.5 before pregnancy * Infants' birth weight, between 2500g and 4000g. Exclusion Criteria: * gestational diabetes * diagnosis of depressive disorder during pregnancy * gestational hypertension * diagnosis of other diseases...
Zhujiang Hospital
OTHER
{ "id": "ZhujiangHFCYXZX", "link": null, "type": null }
Unknown
{ "hasExpandedAccess": false, "nctId": null, "statusForNctId": null }
2022-07-13T00:00:00
{ "date": "2023-07-25", "type": "ACTUAL" }
{ "date": "2022-07-18", "type": "ACTUAL" }
[ "CHILD", "ADULT" ]
This study intends to screen pregnant women in the Obstetrics and Gynecology Center of Zhujiang Hospital, Southern Medical University, and preliminarily recruit subjects that meet the inclusion criteria according to clinical diagnosis and auxiliary examination results. According to the specific conditions of vaginal de...
NON_PROBABILITY_SAMPLE
false
{ "allocation": null, "interventionModel": null, "interventionModelDescription": null, "maskingInfo": null, "observationalModel": "FAMILY_BASED", "primaryPurpose": null, "timePerspective": "PROSPECTIVE" }
[ "Healthy", "Breast-milk Collection", "Feces" ]
null
null
[ { "city": "Guangzhou", "country": "China", "facility": "Zhujiang Hospital", "geoPoint": { "lat": 23.11667, "lon": 113.25 }, "state": "Guangdong" } ]
null
null
{ "other": null, "primary": [ { "description": null, "measure": "Compare the omics differences of the specimens between the experimental and control groups", "timeFrame": "2021.7.1-2026.12.30" }, { "description": null, "measure": "Compare the microbial feature differences o...
null
null
{"versionHolder": "2025-06-18"}
null
null
null
NCT04778566
null
Evaluating the Cologuard Test for Use in Lynch Syndrome
Evaluating the Cologuard Test for Use in Lynch Syndrome
None
OBSERVATIONAL
WITHDRAWN
2021-02-26T00:00:00
null
null
null
null
0
18
89
ALL
false
This study is aiming to enroll 90 patients with genetically confirmed Lynch Syndrome (LS) from Geisinger's High Risk Colorectal Cancer Clinic (HRC). Upon enrollment in the study, a Cologuard test will be ordered and the results will be blinded until data analysis. Patients enrolled in the study will also undergo a colo...
The primary aim is to perform a pilot study to gain information toward the implementation of a larger prospective study that will compare the performance of Cologuard with the gold-standard colonoscopy in identifying advanced adenomas and colorectal cancers in LS. Data regarding rate of consent, and adherence to the pr...
Inclusion Criteria: * Patients age 18-89 * Diagnosis of genetically confirmed LS * Scheduled for standard of care colonoscopy within 60 days of enrollment Exclusion Criteria: * Diagnosis of other inherited genetic disorders that increase risk for Colorectal Cancer (CRC) (Familial Adenomatous Polyposis (FAP), Cowden'...
Geisinger Clinic
OTHER
{ "id": "2020-0239", "link": null, "type": null }
Recent discovery of a novel assay that is more likely to be beneficial for patients with Lynch Syndrome. Investing into current version of Cologuard test would provide little clinical benefit.
{ "hasExpandedAccess": false, "nctId": null, "statusForNctId": null }
2021-02-26T00:00:00
{ "date": "2021-11-17", "type": "ACTUAL" }
{ "date": "2021-03-03", "type": "ACTUAL" }
[ "ADULT", "OLDER_ADULT" ]
Adult patients being followed in the HRC with a diagnosis of LS
NON_PROBABILITY_SAMPLE
false
{ "allocation": null, "interventionModel": null, "interventionModelDescription": null, "maskingInfo": null, "observationalModel": "COHORT", "primaryPurpose": null, "timePerspective": "PROSPECTIVE" }
[ "Lynch Syndrome", "Colorectal Cancer", "Colonic Adenoma", "Colonic Polyp" ]
["Lynch Syndrome", "Colorectal Cancer", "Hereditary non-polyposis colon cancer", "High-Risk Colon Cancer", "Health-Related Quality of Life", "Bowel Prep Tolerability", "Colonoscopy", "Procedural anxiety"]
null
[ { "city": "Danville", "country": "United States", "facility": "Geisinger Health", "geoPoint": { "lat": 40.96342, "lon": -76.61273 }, "state": "Pennsylvania" } ]
null
null
{ "other": null, "primary": [ { "description": null, "measure": "Evaluate the feasibility of the Cologuard test for Lynch Syndrome", "timeFrame": "3 months" } ], "secondary": [ { "description": null, "measure": "Evaluate patient satisfaction with Cologuard", "time...
[ { "affiliation": "Geisinger Clinic", "name": "Rajiv Panikkar, MD", "role": "PRINCIPAL_INVESTIGATOR" } ]
null
{"versionHolder": "2025-06-18"}
{ "ancestors": [ { "id": "D004194", "term": "Disease" }, { "id": "D010335", "term": "Pathologic Processes" }, { "id": "D007414", "term": "Intestinal Neoplasms" }, { "id": "D005770", "term": "Gastrointestinal Neoplasms" }, { "id"...
{ "ancestors": null, "browseBranches": [ { "abbrev": "HB", "name": "Herbal and Botanical" }, { "abbrev": "All", "name": "All Drugs and Chemicals" } ], "browseLeaves": [ { "asFound": null, "id": "T120", "name": "Cola", "relevance": "LOW" } ...
{ "conditions": [ { "id": "D015179", "term": "Colorectal Neoplasms" }, { "id": "D000236", "term": "Adenoma" }, { "id": "D003123", "term": "Colorectal Neoplasms, Hereditary Nonpolyposis" }, { "id": "D013577", "term": "Syndrome" }, { ...
NCT01645566
null
Task Focusing Strategy During a Simulated Cardiopulmonary Resuscitation
Impact of a Task Focusing Strategy on Perceived Stress Levels and Performance During a Simulated Cardiopulmonary Resuscitation: A Randomized Controlled Trial
None
INTERVENTIONAL
COMPLETED
2012-07-15T00:00:00
null
null
null
[ "NA" ]
124
18
null
ALL
true
This is a prospective randomized controlled study. The aim of this study is to 1. describe the stress patterns experienced during a CPR situation; 2. investigate whether the perceived stress was associated with CPR performance in terms of hands-on time and time to start CPR; 3. to investigate whether this task focusin...
null
Inclusion Criteria: * 4th year medical students Exclusion Criteria: * No informed consent
University Hospital, Basel, Switzerland
OTHER
{ "id": "BS1330978", "link": null, "type": null }
Unknown
{ "hasExpandedAccess": false, "nctId": null, "statusForNctId": null }
2012-07-19T00:00:00
{ "date": "2012-07-20", "type": "ESTIMATED" }
{ "date": "2012-07-20", "type": "ESTIMATED" }
[ "ADULT", "OLDER_ADULT" ]
null
null
false
{ "allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "interventionModelDescription": null, "maskingInfo": { "masking": "SINGLE", "maskingDescription": null, "whoMasked": [ "PARTICIPANT" ] }, "observationalModel": null, "primaryPurpose": null, "timePerspective": null }
[ "Mental Stress" ]
["cardiopulmonary resuscitation", "stress", "intervention"]
null
[ { "city": "Basel", "country": "Switzerland", "facility": "University Hospital Basel", "geoPoint": { "lat": 47.55839, "lon": 7.57327 }, "state": "BS" } ]
null
null
{ "other": null, "primary": [ { "description": null, "measure": "perceived levels of stress and feeling overwhelmed (stress/overload)", "timeFrame": "time from start of CPR until scenario is finished (usually 5-10min)" } ], "secondary": [ { "description": null, "measure...
[ { "affiliation": "University Hospital Basel, Medical Intensive Care Unit", "name": "Sabina Hunziker, MD, MPH", "role": "PRINCIPAL_INVESTIGATOR" } ]
[{"pmid": "22115935", "type": "BACKGROUND", "citation": "Hunziker S, Semmer NK, Tschan F, Schuetz P, Mueller B, Marsch S. Dynamics and association of different acute stress markers with performance during a simulated resuscitation. Resuscitation. 2012 May;83(5):572-8. doi: 10.1016/j.resuscitation.2011.11.013. Epub 2011...
{"versionHolder": "2025-06-18"}
{ "ancestors": [ { "id": "D001526", "term": "Behavioral Symptoms" } ], "browseBranches": [ { "abbrev": "BXM", "name": "Behaviors and Mental Disorders" }, { "abbrev": "All", "name": "All Conditions" } ], "browseLeaves": [ { "asFound": "Menta...
null
{ "conditions": [ { "id": "D013315", "term": "Stress, Psychological" } ], "interventions": null }
NCT04720066
null
Hip POCUS for the Diagnosis of Pediatric Hip Effusion.
Accuracy of Point of Care Ultrasound (POCUS) for the Diagnosis of Hip Effusion Among Children in the Pediatric Emergency Department
None
OBSERVATIONAL
UNKNOWN
2021-01-19T00:00:00
null
null
null
null
100
0
18
ALL
false
Limping is a common complaint among children presenting in the Pediatric ED the evaluation of a limp among infants and toddlers is challenging doe to the lack of specific history and the difficulty in locating the pain - therefore hip sonography is frequently used in the clinical evaluation of these children. Sonograp...
Children (0-18 years) presenting to the PED in Meir medical center with limp pain (not due to trauma) or a limp are recruited After consenting to participate in the study and completing the registration process the primary physician who is an approved researcher by the institutes IRB will perform hip POCUS as part of t...
Inclusion Criteria: pediatric patients presenting to the PED with the complaint of a limp or a lower limb pain - Exclusion Criteria: * trauma patients * patients with an obvious diagnosis other than pain resulting from the hip joint on their physical examination.
Meir Medical Center
OTHER
{ "id": "0119-20-MMC", "link": null, "type": null }
Unknown
{ "hasExpandedAccess": false, "nctId": null, "statusForNctId": null }
2021-01-21T00:00:00
{ "date": "2021-10-26", "type": "ACTUAL" }
{ "date": "2021-01-22", "type": "ACTUAL" }
[ "CHILD", "ADULT" ]
* pediatric patients (age 0-18 years) presenting to the PED with the complaint of a limp or a lower limb pain
NON_PROBABILITY_SAMPLE
null
{ "allocation": null, "interventionModel": null, "interventionModelDescription": null, "maskingInfo": null, "observationalModel": "CASE_ONLY", "primaryPurpose": null, "timePerspective": "PROSPECTIVE" }
[ "Hip Effusion" ]
["Hip Effusion, point of care sonography, pediatric,"]
null
[ { "city": "Kfar Saba", "country": "Israel", "facility": "Ayelet Shles", "geoPoint": { "lat": 32.175, "lon": 34.90694 }, "state": null } ]
null
null
{ "other": null, "primary": [ { "description": null, "measure": "accuracy of POCUS examination for the detection of hip effusion among limping children", "timeFrame": "both examination are performed during the same 1 day ED visit." } ], "secondary": null }
null
null
{"versionHolder": "2025-06-18"}
{ "ancestors": null, "browseBranches": [ { "abbrev": "BC23", "name": "Symptoms and General Pathology" }, { "abbrev": "All", "name": "All Conditions" } ], "browseLeaves": [ { "asFound": null, "id": "M7796", "name": "Emergencies", "relevance": "L...
null
{ "conditions": [], "interventions": null }
NCT04820166
null
The Effect of Monitoring PVP on Clinical Outcomes in Patients With PH
The Effect of Monitoring Portal Venous Pressure on Clinical Outcomes in Patients With Portal Hypertension: a Prospective, Single-center, Observational Study
None
OBSERVATIONAL
RECRUITING
2021-03-18T00:00:00
null
2025-12-31T00:00:00
2025-12-31T00:00:00
null
200
18
80
ALL
null
The complications associated with portal hypertension in cirrhosis are the main cause of death in patients with cirrhosis. The level of portal venous pressure is closely related to the prognosis of patients. HVPG (hepatic venous pressure gradient) is the "gold standard" for predicting portal venous pressure and an impo...
null
Inclusion Criteria: * With chronic liver disease * Age 18-80 years * Patients who require a portal pressure measurement at the discretion of the treating physician * Voluntarily signed informed consent Exclusion Criteria: * With serious cardiopulmonary disease or other diseases affect survival * With severe renal dy...
Nanfang Hospital, Southern Medical University
OTHER
{ "id": "NFEC-2021-062", "link": null, "type": null }
Unknown
{ "hasExpandedAccess": false, "nctId": null, "statusForNctId": null }
2021-03-26T00:00:00
{ "date": "2021-03-29", "type": "ACTUAL" }
{ "date": "2021-03-29", "type": "ACTUAL" }
[ "ADULT", "OLDER_ADULT" ]
patients with portal hypertension
PROBABILITY_SAMPLE
null
{ "allocation": null, "interventionModel": null, "interventionModelDescription": null, "maskingInfo": null, "observationalModel": "COHORT", "primaryPurpose": null, "timePerspective": "PROSPECTIVE" }
[ "Portal Hypertension" ]
null
null
[ { "city": "Guangzhou", "country": "China", "facility": "Nanfang Hospital", "geoPoint": { "lat": 23.11667, "lon": 113.25 }, "state": "Guangdong" } ]
null
null
{ "other": null, "primary": [ { "description": null, "measure": "Gastroesophageal varices bleeding", "timeFrame": "three years" }, { "description": null, "measure": "Ascites", "timeFrame": "three years" }, { "description": null, "measure": "Hepatic...
null
null
{"versionHolder": "2025-06-18"}
{ "ancestors": [ { "id": "D014652", "term": "Vascular Diseases" }, { "id": "D002318", "term": "Cardiovascular Diseases" }, { "id": "D008107", "term": "Liver Diseases" }, { "id": "D004066", "term": "Digestive System Diseases" } ], "bro...
null
{ "conditions": [ { "id": "D006975", "term": "Hypertension, Portal" }, { "id": "D006973", "term": "Hypertension" } ], "interventions": null }
NCT01876966
null
Interaction Between Etravirine or Darunavir/Ritonavir and Artemether / Lumefantrine
A Phase I, Partially Randomized, Open Label, Two-way, Two Period Cross-over Study to Investigate the Pharmacokinetic Interaction Between Etravirine or Darunavir/Rtv and Artemether/Lumefantrine at Steady-state in Healthy HIV-negative Subjects
DDI Coartem
INTERVENTIONAL
COMPLETED
2012-11-19T00:00:00
null
null
null
[ "PHASE1" ]
33
18
55
ALL
true
The purpose of this study is to investigate the pharmacokinetic interaction between etravirine and artemether/lumefantrine and darunavir/ritonavir and artemether/lumefantrine in healthy Human Immunodeficiency Virus- (HIV-)negative patients. 'Pharmacokinetic interaction' means that one medication can influence the absor...
This is a Phase I, partially randomized, open-label, single-center, two-way, two-period cross-over study to investigate the pharmacokinetic interaction between etravirine (ETR) or darunavir/ritonavir (DRV/rtv) and the antimalarial drugs artemether/lumefantrine at steady-state in healthy human immunodeficiency virus (HI...
Inclusion Criteria: * if of childbearing potential or if male, use a highly effective method of birth control. * Able to comply with protocol requirements. * A BMI (weight in kg divided by the square of height in meters) of 18.5 to 30.0 kg/m2, extremes included. * healthy on the basis of a medical evaluation * Non-smo...
Janssen Pharmaceutica N.V., Belgium
INDUSTRY
{ "id": "CR018409", "link": null, "type": null }
Unknown
{ "hasExpandedAccess": false, "nctId": null, "statusForNctId": null }
2013-06-11T00:00:00
{ "date": "2013-06-13", "type": "ESTIMATED" }
{ "date": "2013-06-13", "type": "ESTIMATED" }
[ "ADULT" ]
null
null
false
{ "allocation": "RANDOMIZED", "interventionModel": "CROSSOVER", "interventionModelDescription": null, "maskingInfo": { "masking": "NONE", "maskingDescription": null, "whoMasked": null }, "observationalModel": null, "primaryPurpose": "HEALTH_SERVICES_RESEARCH", "timePerspective": null }
[ "HIV" ]
["HIV", "pharmacokinetic interaction", "healthy HIV-negative person"]
null
null
null
null
{ "other": null, "primary": [ { "description": null, "measure": "effect of ETR or DRV/rtv on the plasma concentrations of artemether, lumefantrine and dihydroartemisinin", "timeFrame": "Treatment A: Day 1-2 & Day 4-15; Treatment B: Day 8-9 & Day 11-22" }, { "description": null, ...
null
[{"pmid": "23441978", "type": "RESULT", "citation": "Kakuda TN, DeMasi R, van Delft Y, Mohammed P. Pharmacokinetic interaction between etravirine or darunavir/ritonavir and artemether/lumefantrine in healthy volunteers: a two-panel, two-way, two-period, randomized trial. HIV Med. 2013 Aug;14(7):421-9. doi: 10.1111/hiv....
{"versionHolder": "2025-06-18"}
{ "ancestors": null, "browseBranches": [ { "abbrev": "BC01", "name": "Infections" }, { "abbrev": "BXS", "name": "Urinary Tract, Sexual Organs, and Pregnancy Conditions" }, { "abbrev": "BC20", "name": "Immune System Diseases" }, { "abbrev": "All",...
{ "ancestors": [ { "id": "D017320", "term": "HIV Protease Inhibitors" }, { "id": "D000084762", "term": "Viral Protease Inhibitors" }, { "id": "D011480", "term": "Protease Inhibitors" }, { "id": "D004791", "term": "Enzyme Inhibitors" }, ...
{ "conditions": [], "interventions": [ { "id": "D019438", "term": "Ritonavir" }, { "id": "D000069454", "term": "Darunavir" }, { "id": "D000078102", "term": "Lumefantrine" }, { "id": "D000077549", "term": "Artemether" }, { "id"...
NCT05425966
null
Adapting a Web-Based Professional Development for Mexican School Mental Health Providers Delivering Evidence-Based Intervention for ADHD and ODD
Adapting a Remote Training for Mexican School Clinicians Delivering Evidence-Based Intervention for ADHD and ODD
None
INTERVENTIONAL
COMPLETED
2022-06-15T00:00:00
null
2022-06-30T00:00:00
2022-06-30T00:00:00
[ "NA" ]
67
5
null
ALL
false
Neurodevelopmental disorders of inattention and disruptive behavior, such as Attention-Deficit/ Hyperactivity Disorder (ADHD) and Oppositional Defiant Disorder (ODD), are among the most common youth mental health conditions across cultures. An efficacious and feasible solution to improving affected youth's ADHD/ODD is ...
null
Inclusion Criteria: * Students meeting the following criteria are eligible: * at least six inattention symptoms and/or six hyperactive/impulsive symptoms endorsed by parent or teacher as occurring often or very often, * at least one area of impairment rated as concerning by both parent and teacher, and * a pare...
University of California, San Francisco
OTHER
{ "id": "CLSRFUERTE", "link": null, "type": null }
Unknown
{ "hasExpandedAccess": false, "nctId": null, "statusForNctId": null }
2022-06-15T00:00:00
{ "date": "2024-03-18", "type": "ACTUAL" }
{ "date": "2022-06-21", "type": "ACTUAL" }
[ "CHILD", "ADULT", "OLDER_ADULT" ]
null
null
null
{ "allocation": "NA", "interventionModel": "SINGLE_GROUP", "interventionModelDescription": null, "maskingInfo": { "masking": "NONE", "maskingDescription": null, "whoMasked": null }, "observationalModel": null, "primaryPurpose": "TREATMENT", "timePerspective": null }
[ "ADHD", "Oppositional Defiant Disorder" ]
null
null
[ { "city": "San Francisco", "country": "United States", "facility": "UCSF", "geoPoint": { "lat": 37.77493, "lon": -122.41942 }, "state": "California" } ]
[ { "class": "NIH", "name": "National Institute of Mental Health (NIMH)" } ]
null
{ "other": null, "primary": [ { "description": null, "measure": "Change in Child Symptom Inventory-4 (CSI-4) Parent Checklist ADHD Combined Type Symptom Severity Score", "timeFrame": "Baseline and post treatment (8 weeks)" }, { "description": null, "measure": "Change in Chi...
[ { "affiliation": "University of California, San Francisco", "name": "Lauren M Haack, PhD", "role": "PRINCIPAL_INVESTIGATOR" } ]
null
{"versionHolder": "2025-06-18"}
{ "ancestors": [ { "id": "D019958", "term": "Attention Deficit and Disruptive Behavior Disorders" }, { "id": "D065886", "term": "Neurodevelopmental Disorders" }, { "id": "D001523", "term": "Mental Disorders" } ], "browseBranches": [ { "abbrev":...
null
{ "conditions": [ { "id": "D000096865", "term": "Oppositional Defiant Disorder" } ], "interventions": null }
NCT01654666
null
Protective Effects of Long-term Remote Limb Ischemic Preconditioning For Carotid Artery Stenting
Protective Effects of Long-term Remote Limb Ischemic Preconditioning For Carotid Artery Stenting
None
INTERVENTIONAL
COMPLETED
2012-07-23T00:00:00
null
null
null
[ "PHASE2" ]
189
18
80
ALL
false
Remote limb ischemic preconditioning (RIPC) has neuro-protective and anti-inflammatory effects on ischemia- reperfusion injury. As the extent of its effect is unknown, the investigators will use clinical outcome, serum biochemical markers and brain magnetic resonance imaging (MRI) to determine whether RIPC has neuro-pr...
BACKGROUND: Brain ischemia and injury contributed to perioperative morbidity and mortality in Carotid Artery Stenting. Remote ischemic preconditioning (RIPC), brief periods of ischemia followed by reperfusion, can provide systemic protection for prolonged ischemia. Our previous study found no significant protection to ...
Inclusion Criteria: 1. Symptomatic or asymptomatic carotid artery stenosis. In symptomatic patients the degree of stenosis should more than 60% (Based on NASCET Criteria), in asymptomatic patients the degree of stenosis should more than 70% (Based on NASCET Criteria); 2. Tolerance to any of the study medications, incl...
Capital Medical University
OTHER
{ "id": "RIPC2012", "link": null, "type": null }
Unknown
{ "hasExpandedAccess": false, "nctId": null, "statusForNctId": null }
2012-07-28T00:00:00
{ "date": "2015-11-11", "type": "ESTIMATED" }
{ "date": "2012-08-01", "type": "ESTIMATED" }
[ "ADULT", "OLDER_ADULT" ]
null
null
true
{ "allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "interventionModelDescription": null, "maskingInfo": { "masking": "DOUBLE", "maskingDescription": null, "whoMasked": [ "INVESTIGATOR", "OUTCOMES_ASSESSOR" ] }, "observationalModel": null, "primaryPurpose": "TREATMEN...
[ "Carotid Artery Stenosis" ]
["Remote ischemic preconditioning", "Stroke secondary prevention", "Carotid artery stenting", "Carotid stenosis", "Inflammation"]
null
[ { "city": "Beijing", "country": "China", "facility": "Baojun Hou", "geoPoint": { "lat": 39.9075, "lon": 116.39723 }, "state": "Beijing" } ]
null
null
{ "other": null, "primary": [ { "description": null, "measure": "Number of Patients With Cerebrovascular Events, Cardiovascular Events or Death.", "timeFrame": "Within six months after carotid artery stenting" }, { "description": null, "measure": "Participants Who Got New D...
[ { "affiliation": "Capital Medical University", "name": "Xunming Ji M.D., Ph.D.", "role": "PRINCIPAL_INVESTIGATOR" } ]
[{"pmid": "28174194", "type": "DERIVED", "citation": "Zhao W, Meng R, Ma C, Hou B, Jiao L, Zhu F, Wu W, Shi J, Duan Y, Zhang R, Zhang J, Sun Y, Zhang H, Ling F, Wang Y, Feng W, Ding Y, Ovbiagele B, Ji X. Safety and Efficacy of Remote Ischemic Preconditioning in Patients With Severe Carotid Artery Stenosis Before Caroti...
{"versionHolder": "2025-06-18"}
{ "ancestors": [ { "id": "D002340", "term": "Carotid Artery Diseases" }, { "id": "D002561", "term": "Cerebrovascular Disorders" }, { "id": "D001927", "term": "Brain Diseases" }, { "id": "D002493", "term": "Central Nervous System Diseases" ...
null
{ "conditions": [ { "id": "D016893", "term": "Carotid Stenosis" } ], "interventions": null }
NCT02619266
null
The Safety and Effect Study of Acupuncture for Anorexia in Patients With Gastrointestinal Tract and Lung Cancers
The Traditional Chinese Medicine Department of Xin Qiao Hospital
None
INTERVENTIONAL
UNKNOWN
2015-11-23T00:00:00
null
null
null
[ "PHASE2", "PHASE3" ]
160
18
null
ALL
false
This trail will be carried out to evaluated the effect and safety of acupuncture for the anorexia in patients with gastrointestinal tract and lung cancers.
Acupuncture used for anorexia related to cancer, but there were lack of powerful evidence. The 160 eligibilities will be randomly divided into 3 groups(Acupuncture and Placebo group, Megestrol acetate and Sham Acupuncture group, Placebo and Sham Acupuncture group).The effect will be investigated baseline, the 2,5,8 and...
Inclusion Criteria: 1. Diagnosed gastrointestinal tand lung cancers; 2. Age ≥18 years; 3. Appetite score≤ 6 (0= worst appetite), and the symptom lasted 2 weeks at lest at screening; 4. Had a history of weight loss ≥5% within 6 moths; 5. Maintained oral intake; 6. Signed the informed consent. Exclusion Criteria: 1. P...
Xinqiao Hospital of Chongqing
OTHER
{ "id": "2014YLC32", "link": null, "type": null }
Unknown
{ "hasExpandedAccess": false, "nctId": null, "statusForNctId": null }
2015-11-27T00:00:00
{ "date": "2015-12-04", "type": "ESTIMATED" }
{ "date": "2015-12-02", "type": "ESTIMATED" }
[ "ADULT", "OLDER_ADULT" ]
null
null
true
{ "allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "interventionModelDescription": null, "maskingInfo": { "masking": "TRIPLE", "maskingDescription": null, "whoMasked": [ "PARTICIPANT", "INVESTIGATOR", "OUTCOMES_ASSESSOR" ] }, "observationalModel": null, "prima...
[ "Anorexia", "Cancer Cachexia" ]
["Cancer Anorexia Cachexia Syndrome", "Acupuncture", "Megestrol acetate", "Poor Appetite", "Anorexia", "Randomized Controlled Trial"]
null
[ { "city": "Jiangbei", "country": "China", "facility": "Chongqing TCM Hospital", "geoPoint": null, "state": "Chongqing" }, { "city": "Shapingba", "country": "China", "facility": "XinQiao Hosiptal", "geoPoint": { "lat": 29.16792, "lon": 109.40029 }, "state":...
[ { "class": "OTHER", "name": "Chengdu University of Traditional Chinese Medicine" } ]
null
{ "other": [ { "description": null, "measure": "Edmonton Symptom Assessment Scale", "timeFrame": "Baseline, the days 8 and 15." }, { "description": null, "measure": "The Questionnaire of Acupuncture-related Events(QAE)", "timeFrame": "Baseline and the days 7" } ],...
[ { "affiliation": "Chengdu University of Traditional Chinese Medicine", "name": "Yong Tang, PhD", "role": "STUDY_CHAIR" }, { "affiliation": "Xinqiao Hospital", "name": "Chaoting Zhao, MD", "role": "STUDY_DIRECTOR" }, { "affiliation": "Xinqiao Hospital", "name": "Haiou Luo, PhD...
[{"pmid": "23439759", "type": "BACKGROUND", "citation": "Del Fabbro E, Dev R, Hui D, Palmer L, Bruera E. Effects of melatonin on appetite and other symptoms in patients with advanced cancer and cachexia: a double-blind placebo-controlled trial. J Clin Oncol. 2013 Apr 1;31(10):1271-6. doi: 10.1200/JCO.2012.43.6766. Epub...
{"versionHolder": "2025-06-18"}
{ "ancestors": [ { "id": "D012817", "term": "Signs and Symptoms, Digestive" }, { "id": "D015431", "term": "Weight Loss" }, { "id": "D001836", "term": "Body Weight Changes" }, { "id": "D001835", "term": "Body Weight" }, { "id": "...
{ "ancestors": [ { "id": "D003278", "term": "Contraceptives, Oral, Hormonal" }, { "id": "D003276", "term": "Contraceptives, Oral" }, { "id": "D003271", "term": "Contraceptive Agents, Female" }, { "id": "D003270", "term": "Contraceptive Agents...
{ "conditions": [ { "id": "D019282", "term": "Wasting Syndrome" }, { "id": "D000855", "term": "Anorexia" }, { "id": "D002100", "term": "Cachexia" } ], "interventions": [ { "id": "D008535", "term": "Megestrol" }, { "id": "D01...
NCT04939766
null
Impact of the Use of a Closed-loop Insulin Therapy on the Burden of the Diabetes and the Quality of Life
Impact of the Use of a Closed-loop Insulin Therapy on the Burden of the Diabetes and the Quality of Life in Type 1 Diabetic Patients With Continuous Glucose Monitoring (CGM)
IMPLIQUE
INTERVENTIONAL
UNKNOWN
2021-06-16T00:00:00
null
null
null
[ "NA" ]
250
13
null
ALL
false
The use by diabetes patients of real-time Continuous Glucose Monitoring (CGM) system is becoming widespread and has changed diabetic practice. Automated closed-loop (CL) insulin therapy has come of age. This major technological advance is expected to significantly improve the quality of care for adults, adolescents and...
This cohort study will follow patients with type 1 diabetes undergoing under continuous subcutaneous insulin infusion (CSII) with Continuous Glucose Monitoring (GCM). After inclusion visit, there's a 20 days' period to assess their quality of life and perception of the burden of their diabetes and confirm their eligibi...
Inclusion Criteria: * Type 1 diabetic patients undergoing a CSII therapy for at least 6 months and using Tandem t:slim X2 for at least 4 weeks. * Patient using CGM for 6 months including Dexcon G6 for at least 4 weeks. * Eligible patient (according to French Society recommendations) for activation of the closed loop *...
VitalAire
INDUSTRY
{ "id": "2021-A00005-36", "link": null, "type": null }
Unknown
{ "hasExpandedAccess": false, "nctId": null, "statusForNctId": null }
2021-06-24T00:00:00
{ "date": "2021-06-25", "type": "ACTUAL" }
{ "date": "2021-06-25", "type": "ACTUAL" }
[ "CHILD", "ADULT", "OLDER_ADULT" ]
null
null
true
{ "allocation": "NA", "interventionModel": "SINGLE_GROUP", "interventionModelDescription": "Longitudinal cohort study with a 6 months follow-up evaluation evaluating in type 1 diabetic patients under CSII the impact of closed loop use on quality of life and burden using different validated self questionnaires.", ...
[ "Quality of Life", "Burden, Dependency" ]
["Continuous subcutaneous insulin infusion", "Diabetes type 1", "Closed loop"]
null
null
null
null
{ "other": null, "primary": [ { "description": null, "measure": "Change in Quality of life following activation of closed loop", "timeFrame": "Score comparison between Baseline and 6 months after activation of closed loop" }, { "description": null, "measure": "Change in bur...
[ { "affiliation": "University Hospital, Caen", "name": "Yves Reznik, MD PHD", "role": "STUDY_CHAIR" } ]
[{"pmid": "33152550", "type": "BACKGROUND", "citation": "Tubiana-Rufi N, Schaepelynck P, Franc S, Chaillous L, Joubert M, Renard E, Reznik Y, Abettan C, Bismuth E, Beltrand J, Bonnemaison E, Borot S, Charpentier G, Delemer B, Desserprix A, Durain D, Farret A, Filhol N, Guerci B, Guilhem I, Guillot C, Jeandidier N, Labl...
{"versionHolder": "2025-06-18"}
{ "ancestors": null, "browseBranches": [ { "abbrev": "BC18", "name": "Nutritional and Metabolic Diseases" }, { "abbrev": "BC19", "name": "Gland and Hormone Related Diseases" }, { "abbrev": "All", "name": "All Conditions" }, { "abbrev": "BC20", ...
{ "ancestors": [ { "id": "D007004", "term": "Hypoglycemic Agents" }, { "id": "D045505", "term": "Physiological Effects of Drugs" } ], "browseBranches": [ { "abbrev": "Hypo", "name": "Hypoglycemic Agents" }, { "abbrev": "All", "name": "All...
{ "conditions": [], "interventions": [ { "id": "D007328", "term": "Insulin" } ] }
NCT02029066
null
Pharmacokinetic Study of Solamargine in Patients With Actinic Keratosis
An Open-label, Single Dose, Pharmacokinetic Study of SR-T100 Gel (Containing 2.3% Solamargine in Solanum Undatum Plant Extract) in Patients With Actinic Keratosis
None
INTERVENTIONAL
COMPLETED
2013-10-31T00:00:00
null
null
null
[ "PHASE1" ]
2
20
null
ALL
false
This study is designed to evaluate the pharmacokinetics of solamargine of SR-T100 gel. As safety parameters, adverse events, and vital signs (blood pressure, heart rate, and body temperature) will be recorded.
In the study period, a single dose of 2 g topical SR-T100 gel (containing 2.3% solamargine in Solanum undatum plant extract) in 100 cm2 skin area covered by an occlusive dressing will be administered. Sampling Time Schedule: 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 16, 20, 24, 36 hours after dosing.
Inclusion Criteria: 1. Male or female is 20 years of age or above. 2. Patient has AK lesions located within a 100 cm2 contiguous or non-contiguous treatment area. 3. Patient has at least one clinical confirmed AK lesion within the selected treatment area before. Exclusion Criteria: 1. Patient had used the following ...
G&E Herbal Biotechnology Co., LTD
INDUSTRY
{ "id": "GESRTAKC", "link": null, "type": null }
Unknown
{ "hasExpandedAccess": false, "nctId": null, "statusForNctId": null }
2014-01-05T00:00:00
{ "date": "2015-08-13", "type": "ESTIMATED" }
{ "date": "2014-01-07", "type": "ESTIMATED" }
[ "ADULT", "OLDER_ADULT" ]
null
null
false
{ "allocation": "NA", "interventionModel": "SINGLE_GROUP", "interventionModelDescription": null, "maskingInfo": { "masking": "NONE", "maskingDescription": null, "whoMasked": null }, "observationalModel": null, "primaryPurpose": null, "timePerspective": null }
[ "Actinic Keratosis" ]
["actinic keratosis", "SR-T100", "pharmacokinetics"]
null
[ { "city": "Tainan", "country": "Taiwan", "facility": "National Cheng Kung University Hospital", "geoPoint": { "lat": 22.99083, "lon": 120.21333 }, "state": null } ]
null
null
{ "other": null, "primary": [ { "description": null, "measure": "To assess the delivery of SR-T100 from the topical gel by determining the plasma solamargine levels in subjects with AK within a 100 cm^2 treatment area.", "timeFrame": "33 days" } ], "secondary": [ { "descripti...
[ { "affiliation": "National Cheng-Kung University Hospital", "name": "Hamm-Ming Sheu, M.D.", "role": "PRINCIPAL_INVESTIGATOR" } ]
null
{"versionHolder": "2025-06-18"}
{ "ancestors": [ { "id": "D012871", "term": "Skin Diseases" }, { "id": "D011230", "term": "Precancerous Conditions" }, { "id": "D009369", "term": "Neoplasms" } ], "browseBranches": [ { "abbrev": "BC04", "name": "Neoplasms" }, { ...
null
{ "conditions": [ { "id": "D055623", "term": "Keratosis, Actinic" }, { "id": "D007642", "term": "Keratosis" } ], "interventions": null }
NCT03128866
null
Tranexamic Acid in Reducing Blood Loss in Patients With Pelvic Tumors Undergoing Hemipelvectomy Surgery
Reducing Blood Loss in Hemipelvectomy Surgery With the Use Tranexamic Acid (TXA)
None
INTERVENTIONAL
RECRUITING
2017-04-21T00:00:00
null
2026-05-31T00:00:00
2026-05-31T00:00:00
[ "EARLY_PHASE1" ]
80
null
null
ALL
false
This early phase I trial studies how well tranexamic acid works in reducing the loss of blood in patients with pelvic tumors undergoing hemipelvectomy surgery. Tranexamic acid decreases blood loss by stabilizing clots and preventing clot lysis in patients undergoing surgery.
PRIMARY OBJECTIVES: I. To determine if the use of tranexamic acid results in a significant reduction in intraoperative and perioperative blood loss. SECONDARY OBJECTIVES: I. To determine if use of tranexamic acid lowers the amount of blood products transfused in hemipelvectomy surgeries and during first postoperativ...
Inclusion Criteria: * Both pediatric and adult patients can be eligible to participate * Cognitively impaired and non-English speakers can be eligible to participate. * Both male and female patients must have a pelvic tumor and are scheduled to have surgery at University of Texas (UT) Monroe Dunaway (MD) Anderson Canc...
M.D. Anderson Cancer Center
OTHER
{ "id": "2016-0650", "link": null, "type": null }
Unknown
{ "hasExpandedAccess": false, "nctId": null, "statusForNctId": null }
2017-04-24T00:00:00
{ "date": "2025-04-02", "type": "ACTUAL" }
{ "date": "2017-04-25", "type": "ACTUAL" }
[ "CHILD", "ADULT", "OLDER_ADULT" ]
null
null
true
{ "allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "interventionModelDescription": null, "maskingInfo": { "masking": "NONE", "maskingDescription": null, "whoMasked": null }, "observationalModel": null, "primaryPurpose": "SUPPORTIVE_CARE", "timePerspective": null }
[ "Pelvic Mass" ]
null
null
[ { "city": "Houston", "country": "United States", "facility": "M D Anderson Cancer Center", "geoPoint": { "lat": 29.76328, "lon": -95.36327 }, "state": "Texas" } ]
[ { "class": "NIH", "name": "National Cancer Institute (NCI)" } ]
null
{ "other": null, "primary": [ { "description": null, "measure": "Total perioperative blood loss defined as the total intraoperative estimation of blood (EBL) loss", "timeFrame": "During first post-operative week" } ], "secondary": [ { "description": null, "measure": "To...
[ { "affiliation": "M.D. Anderson Cancer Center", "name": "Valerae O Lewis", "role": "PRINCIPAL_INVESTIGATOR" } ]
null
{"versionHolder": "2025-06-18"}
{ "ancestors": [ { "id": "D010335", "term": "Pathologic Processes" } ], "browseBranches": [ { "abbrev": "BC23", "name": "Symptoms and General Pathology" }, { "abbrev": "All", "name": "All Conditions" }, { "abbrev": "BC04", "name": "Neopla...
{ "ancestors": [ { "id": "D000933", "term": "Antifibrinolytic Agents" }, { "id": "D050299", "term": "Fibrin Modulating Agents" }, { "id": "D045504", "term": "Molecular Mechanisms of Pharmacological Action" }, { "id": "D006490", "term": "Hemos...
{ "conditions": [ { "id": "D006470", "term": "Hemorrhage" } ], "interventions": [ { "id": "D014148", "term": "Tranexamic Acid" } ] }
NCT05740566
null
Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer
A Randomized, Open-label, Phase 3 Study of Tarlatamab Compared With Standard of Care in Subjects With Relapsed Small Cell Lung Cancer After Platinum-based First-line Chemotherapy
DeLLphi-304
INTERVENTIONAL
ACTIVE_NOT_RECRUITING
2023-02-07T00:00:00
null
2025-01-29T00:00:00
2027-07-29T00:00:00
[ "PHASE3" ]
509
18
null
ALL
false
The main objective is to compare the efficacy of tarlatamab with standard of care (SOC) on prolonging overall survival (OS).
null
Inclusion Criteria: * Participant has provided informed consent prior to initiation of any study specific activities/procedures. * Age ≥ 18 years (or legal adult age within country, whichever is older) at the time of signing the informed consent. * Histologically or cytologically confirmed SCLC with demonstrated progr...
Amgen
INDUSTRY
{ "id": "20210004", "link": null, "type": null }
Unknown
{ "hasExpandedAccess": true, "nctId": "NCT06064500", "statusForNctId": "APPROVED_FOR_MARKETING" }
2023-02-21T00:00:00
{ "date": "2025-05-18", "type": "ACTUAL" }
{ "date": "2023-02-23", "type": "ACTUAL" }
[ "ADULT", "OLDER_ADULT" ]
null
null
true
{ "allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "interventionModelDescription": null, "maskingInfo": { "masking": "NONE", "maskingDescription": null, "whoMasked": null }, "observationalModel": null, "primaryPurpose": "TREATMENT", "timePerspective": null }
[ "Small Cell Lung Cancer (SCLC)" ]
["Small Cell Lung Cancer", "SCLC", "AMG 757", "Tarlatamab"]
null
[ { "city": "Mobile", "country": "United States", "facility": "University of South Alabama Mitchell Cancer Institute", "geoPoint": { "lat": 30.69436, "lon": -88.04305 }, "state": "Alabama" }, { "city": "Anchorage", "country": "United States", "facility": "Alaska Onc...
null
null
{ "other": null, "primary": [ { "description": null, "measure": "Overall Survival (OS)", "timeFrame": "Up to approximately 4 years" } ], "secondary": [ { "description": null, "measure": "Progression Free Survival (PFS)", "timeFrame": "Up to approximately 4 years" ...
[ { "affiliation": "Amgen", "name": "MD", "role": "STUDY_DIRECTOR" } ]
null
{"versionHolder": "2025-06-18"}
{ "ancestors": [ { "id": "D012142", "term": "Respiratory Tract Neoplasms" }, { "id": "D013899", "term": "Thoracic Neoplasms" }, { "id": "D009371", "term": "Neoplasms by Site" }, { "id": "D009369", "term": "Neoplasms" }, { "id": ...
{ "ancestors": [ { "id": "D059004", "term": "Topoisomerase I Inhibitors" }, { "id": "D059003", "term": "Topoisomerase Inhibitors" }, { "id": "D004791", "term": "Enzyme Inhibitors" }, { "id": "D045504", "term": "Molecular Mechanisms of Pharmac...
{ "conditions": [ { "id": "D008175", "term": "Lung Neoplasms" }, { "id": "D055752", "term": "Small Cell Lung Carcinoma" } ], "interventions": [ { "id": "D019772", "term": "Topotecan" }, { "id": "C055866", "term": "Amrubicin" }, { ...
NCT03095066
null
Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Neurobehavioral Disinhibition Including Aggression, Agitation, and Irritability in Participants With Traumatic Brain Injury
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deudextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Neurobehavioral Disinhibition Including Aggression, Agitation, and Irritability in Patients With Tr...
None
INTERVENTIONAL
COMPLETED
2017-03-23T00:00:00
null
2022-08-22T00:00:00
2022-08-31T00:00:00
[ "PHASE2" ]
168
18
75
ALL
false
This is a multicenter, randomized, placebo-controlled study to evaluate AVP-786 for the treatment of neurobehavioral disinhibition including aggression, agitation, and irritability in participants with traumatic brain injury (TBI).
Eligible participants for this study must have a diagnosis of neurobehavioral disinhibition including aggression, agitation, and irritability that persists after brain injury. This is a multicenter, randomized, placebo-controlled study, consisting of up to 12 weeks of treatment.
Inclusion Criteria: * Participants with TBI * Participants with neurobehavioral disinhibition symptoms that are present after trauma or after recovery of consciousness * Score of ≥4 on the mCGI-S scale and the Agitation/Aggression or Irritability/Lability subscales of the Neuropsychiatric Inventory (NPI) scale at scre...
Otsuka Pharmaceutical Development & Commercialization, Inc.
INDUSTRY
{ "id": "17-AVP-786-205", "link": null, "type": null }
Unknown
{ "hasExpandedAccess": false, "nctId": null, "statusForNctId": null }
2017-03-23T00:00:00
{ "date": "2023-09-29", "type": "ACTUAL" }
{ "date": "2017-03-29", "type": "ACTUAL" }
[ "ADULT", "OLDER_ADULT" ]
null
null
false
{ "allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "interventionModelDescription": null, "maskingInfo": { "masking": "QUADRUPLE", "maskingDescription": null, "whoMasked": [ "PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR" ] }, "observati...
[ "Neurobehavioral Disinhibition" ]
["aggression", "agitation", "irritability", "non-penetrating brain injury", "traumatic brain injury", "TBI", "AVP-786"]
null
[ { "city": "Tuscaloosa", "country": "United States", "facility": "Tuscaloosa Veterans Affairs Medical Center", "geoPoint": { "lat": 33.20984, "lon": -87.56917 }, "state": "Alabama" }, { "city": "Phoenix", "country": "United States", "facility": "Absolute Clinical R...
null
null
{ "other": null, "primary": [ { "description": null, "measure": "Change from Baseline to Week 12 in the Composite of the Clinical Impression Severity Scores on the Neuropsychiatric Inventory Clinician Rating Scale (NPI-C) Subscales of Aggression, Agitation, and Irritability/Lability (NPI-C-3)", ...
null
null
{"versionHolder": "2025-06-18"}
{ "ancestors": [ { "id": "D014947", "term": "Wounds and Injuries" }, { "id": "D001927", "term": "Brain Diseases" }, { "id": "D002493", "term": "Central Nervous System Diseases" }, { "id": "D009422", "term": "Nervous System Diseases" }, ...
{ "ancestors": null, "browseBranches": [ { "abbrev": "Infe", "name": "Anti-Infective Agents" }, { "abbrev": "AnArAg", "name": "Anti-Arrhythmia Agents" }, { "abbrev": "ChanBlk", "name": "Channel Blockers" }, { "abbrev": "All", "name": "All D...
{ "conditions": [ { "id": "D001930", "term": "Brain Injuries" }, { "id": "D000070642", "term": "Brain Injuries, Traumatic" }, { "id": "D011595", "term": "Psychomotor Agitation" }, { "id": "D000374", "term": "Aggression" } ], "interven...
NCT06009666
null
Elastographic and Ultrasonographic Evaluation of Patients With Breast Cancer Related Lymphedema
Elastographic and Ultrasonographic Evaluation of Patients With Breast Cancer Related Lymphedema and Investigation of the Relationship of These Parameters With Clinical Data
None
OBSERVATIONAL
COMPLETED
2023-02-03T00:00:00
null
2022-04-01T00:00:00
2022-11-01T00:00:00
null
72
18
75
FEMALE
true
The aim of this study is to evaluate the feasibility of shear-wave elastography for the diagnosis and staging of breast cancer related lymphedema by assessing the skin and subcutaneous tissues of the arm and forearm, which could serve as a reference standard and be more easily applicable in daily life; and to investiga...
Both upper extremities of 72 patients with lymphedema and 72 healthy upper extremities were included in the study. The patients' demographic and clinical data were recorded. The thickness and echogenicity of the skin and subcutaneous tissues of all extremities were evaluated with B-mode ultrasonography, and the stiffne...
Inclusion Criteria: For the patient group * between the ages of 18-75 * diagnosed with breast cancer-associated lymphedema by lymphoscintigraphy * being stage 0-1-2 lymphedema according to ISL staging For the control group * between the ages of 18-75 * no history of breast cancer Exclusion Criteria: * History of su...
Marmara University
OTHER
{ "id": "07.01.2022.145", "link": null, "type": null }
Unknown
{ "hasExpandedAccess": false, "nctId": null, "statusForNctId": null }
2023-08-20T00:00:00
{ "date": "2023-08-24", "type": "ACTUAL" }
{ "date": "2023-08-24", "type": "ACTUAL" }
[ "ADULT", "OLDER_ADULT" ]
In our study, individuals with breast cancer-related lymphedema diagnosis followed by Marmara University Pendik Training and Research Hospital Physical Medicine and Rehabilitation Department were included in the patient group, while upper extremity data of healthy volunteers without a known lymphedema history were cont...
NON_PROBABILITY_SAMPLE
false
{ "allocation": null, "interventionModel": null, "interventionModelDescription": null, "maskingInfo": null, "observationalModel": "CASE_CONTROL", "primaryPurpose": null, "timePerspective": "CROSS_SECTIONAL" }
[ "Lymphedema of Upper Arm", "Stiffness of Hand, Not Elsewhere Classified", "Evaluations, Diagnostic Self" ]
null
null
[ { "city": "İstanbul", "country": "Turkey", "facility": "Canan Şanal-Toprak", "geoPoint": { "lat": 41.01384, "lon": 28.94966 }, "state": null }, { "city": "Istanbul", "country": "Turkey", "facility": "Marmara University School of Medicine, Pendik Education and Rese...
null
null
{ "other": null, "primary": [ { "description": null, "measure": "B Mode Ultrasonography Measurements", "timeFrame": "Day 0" }, { "description": null, "measure": "Shear Wave Elastography Measurements", "timeFrame": "Day 0" }, { "description": null, ...
[ { "affiliation": "Marmara University", "name": "CANAN ŞANAL TOPRAK", "role": "STUDY_CHAIR" } ]
null
{"versionHolder": "2025-06-18"}
{ "ancestors": [ { "id": "D008206", "term": "Lymphatic Diseases" }, { "id": "D011183", "term": "Postoperative Complications" }, { "id": "D010335", "term": "Pathologic Processes" } ], "browseBranches": [ { "abbrev": "BC04", "name": "Neopla...
null
{ "conditions": [ { "id": "D008209", "term": "Lymphedema" }, { "id": "D000072656", "term": "Breast Cancer Lymphedema" } ], "interventions": null }
NCT01394666
null
Non-interventional Treatment Patterns Study in Chronic Phase Chronic Myelogenous Leukemia (CP-CML)
Treatment Patterns and Associated Outcomes in Chronic Phase (CP) Chronic Myelogenous Leukemia (CML) Patients Who Fail Imatinib 400 mg Daily
None
OBSERVATIONAL
COMPLETED
2011-07-08T00:00:00
null
null
null
null
150
18
null
ALL
false
The purpose of this study is to evaluate treatment patterns and associated outcomes for CP-CML patients who fail Imatinib 400 mg daily in a real-world setting.
Time Perspective: Retrospective and Prospective
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com. Inclusion Criteria: * Adult patients (18 years or older) in Chronic phase CML patients who have been treated with Imatinib 400 mg and have failed.
Bristol-Myers Squibb
INDUSTRY
{ "id": "CA180-240", "link": null, "type": null }
Unknown
{ "hasExpandedAccess": false, "nctId": null, "statusForNctId": null }
2011-07-13T00:00:00
{ "date": "2016-07-11", "type": "ESTIMATED" }
{ "date": "2011-07-14", "type": "ESTIMATED" }
[ "ADULT", "OLDER_ADULT" ]
Primary care clinic, academic and community oncology centers
PROBABILITY_SAMPLE
false
{ "allocation": null, "interventionModel": null, "interventionModelDescription": null, "maskingInfo": null, "observationalModel": "COHORT", "primaryPurpose": null, "timePerspective": "RETROSPECTIVE" }
[ "Chronic Myeloid Leukemia" ]
null
null
null
null
null
{ "other": null, "primary": [ { "description": null, "measure": "Complete Cytogenic Response (CCyR) for CP-CML patients who failed Imatinib 400 mg daily", "timeFrame": "At 3 months post treatment change" }, { "description": null, "measure": "Complete Cytogenic Response (CCy...
[ { "affiliation": "Bristol-Myers Squibb", "name": "Bristol-Myers Squibb", "role": "STUDY_DIRECTOR" } ]
null
{"versionHolder": "2025-06-18"}
{ "ancestors": [ { "id": "D009370", "term": "Neoplasms by Histologic Type" }, { "id": "D009369", "term": "Neoplasms" }, { "id": "D006402", "term": "Hematologic Diseases" }, { "id": "D009196", "term": "Myeloproliferative Disorders" }, ...
{ "ancestors": null, "browseBranches": [ { "abbrev": "ANeo", "name": "Antineoplastic Agents" }, { "abbrev": "All", "name": "All Drugs and Chemicals" } ], "browseLeaves": [ { "asFound": null, "id": "M324", "name": "Imatinib Mesylate", "relevance...
{ "conditions": [ { "id": "D007938", "term": "Leukemia" }, { "id": "D007951", "term": "Leukemia, Myeloid" }, { "id": "D015464", "term": "Leukemia, Myelogenous, Chronic, BCR-ABL Positive" } ], "interventions": [] }
NCT02763566
null
A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Compare NSAI (Anastrozole or Letrozole) Plus Abemaciclib, a CDK4 and CDK6 Inhibitor, or Plus Placebo, and to Compare Fulvestrant Plus Abemaciclib or Plus Placebo in Postmenopausal Women With Hormone Receptor-Positive, HER2-Negative Locoregionally Recurren...
MONARCH plus
INTERVENTIONAL
ACTIVE_NOT_RECRUITING
2016-05-04T00:00:00
null
2019-03-29T00:00:00
null
[ "PHASE3" ]
463
18
null
FEMALE
false
The main purpose of this study is to evaluate the efficacy of the study drug abemaciclib in postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) locoregionally recurrent or metastatic breast cancer.
null
Inclusion Criteria: * Have a diagnosis of HR+, HER2- breast cancer. Although not required as a protocol procedure, metastatic disease should be considered for biopsy whenever possible to reassess hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2) status if clinically indicated. * To fulfill t...
Eli Lilly and Company
INDUSTRY
{ "id": "15530", "link": null, "type": null }
Unknown
{ "hasExpandedAccess": false, "nctId": null, "statusForNctId": null }
2016-05-04T00:00:00
{ "date": "2025-04-20", "type": "ACTUAL" }
{ "date": "2016-05-05", "type": "ESTIMATED" }
[ "ADULT", "OLDER_ADULT" ]
null
null
true
{ "allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "interventionModelDescription": null, "maskingInfo": { "masking": "DOUBLE", "maskingDescription": null, "whoMasked": [ "PARTICIPANT", "INVESTIGATOR" ] }, "observationalModel": null, "primaryPurpose": "TREATMENT", ...
[ "Breast Cancer" ]
["Hormone Receptor-Positive", "HER2-Negative", "CDK4", "CDK6"]
null
[ { "city": "Ijui", "country": "Brazil", "facility": "ONCOSITE - Centro de Pesquisa Clinica em Oncologia", "geoPoint": { "lat": -28.38778, "lon": -53.91472 }, "state": "Rio Grande Do Sul" }, { "city": "Porto Alegre", "country": "Brazil", "facility": "Centro Gaucho I...
null
null
{ "other": null, "primary": [ { "description": null, "measure": "Progression Free Survival (PFS) (Abemaciclib + NSAI & Placebo NSAI)", "timeFrame": "Randomization to Measured Progressive Disease or Death (up to 26 Months)" } ], "secondary": [ { "description": null, "mea...
[ { "affiliation": "Eli Lilly and Company", "name": "Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)", "role": "STUDY_DIRECTOR" } ]
[{"pmid": "33149768", "type": "DERIVED", "citation": "Zhang QY, Sun T, Yin YM, Li HP, Yan M, Tong ZS, Oppermann CP, Liu YP, Costa R, Li M, Cheng Y, Ouyang QC, Chen X, Liao N, Wu XH, Wang XJ, Feng JF, Hegg R, Kanakasetty GB, Coccia-Portugal MA, Han RB, Lu Y, Chi HD, Jiang ZF, Hu XC. MONARCH plus: abemaciclib plus endocr...
{"versionHolder": "2025-06-18"}
{ "ancestors": [ { "id": "D009371", "term": "Neoplasms by Site" }, { "id": "D009369", "term": "Neoplasms" }, { "id": "D001941", "term": "Breast Diseases" }, { "id": "D012871", "term": "Skin Diseases" } ], "browseBranches": [ { ...
{ "ancestors": [ { "id": "D000970", "term": "Antineoplastic Agents" }, { "id": "D047072", "term": "Aromatase Inhibitors" }, { "id": "D065088", "term": "Steroid Synthesis Inhibitors" }, { "id": "D004791", "term": "Enzyme Inhibitors" }, ...
{ "conditions": [ { "id": "D001943", "term": "Breast Neoplasms" } ], "interventions": [ { "id": "D000077289", "term": "Letrozole" }, { "id": "D000077267", "term": "Fulvestrant" }, { "id": "D000077384", "term": "Anastrozole" } ] }
NCT04892966
null
TXI for the Recognition of Adenomas in Colonoscopy
Texture and Color Enhancement Imaging (TXI) Versus Standard White-light (WLI) Colonoscopy for Colorectal Adenoma Detection: a Multicenter, Randomized, Trial
TRACK
INTERVENTIONAL
COMPLETED
2021-05-03T00:00:00
null
2022-04-30T00:00:00
2022-09-30T00:00:00
[ "NA" ]
747
40
null
ALL
true
This two parallel arms, randomized, multicenter trial is aimed at evaluating whether TXI is superior to WLI endoscopy in terms of adenoma detection. Secondary aims will be advanced adenoma detection rate, serrated polyp/adenoma detection rate, as well as procedure variables such as withdrawal time.
null
Inclusion criteria: - All \>40 years-old patients undergoing a colonoscopy for primary screening, Faecal Immunochemical Test (FIT) +, post-polypectomy surveillance Exclusion criteria: * patients with personal history of colorectal cancer (CRC), or Inflammatory Bowel Disease (IBD). * Patients affected with Lynch synd...
University of Roma La Sapienza
OTHER
{ "id": "TRACK_GA", "link": null, "type": null }
Unknown
{ "hasExpandedAccess": false, "nctId": null, "statusForNctId": null }
2021-05-18T00:00:00
{ "date": "2022-11-03", "type": "ACTUAL" }
{ "date": "2021-05-19", "type": "ACTUAL" }
[ "ADULT", "OLDER_ADULT" ]
null
null
false
{ "allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "interventionModelDescription": null, "maskingInfo": { "masking": "DOUBLE", "maskingDescription": null, "whoMasked": [ "PARTICIPANT", "OUTCOMES_ASSESSOR" ] }, "observationalModel": null, "primaryPurpose": "PREVENTIO...
[ "Colorectal Polyp" ]
null
null
[ { "city": "Ariccia", "country": "Italy", "facility": "Ospedale Dei Castelli", "geoPoint": { "lat": 41.72063, "lon": 12.6723 }, "state": "Rome" } ]
null
null
{ "other": null, "primary": [ { "description": null, "measure": "Adenoma Detection Rate (ADR)", "timeFrame": "1 year" } ], "secondary": [ { "description": null, "measure": "Advanced ADR", "timeFrame": "1 year" }, { "description": null, "measure...
null
null
{"versionHolder": "2025-06-18"}
{ "ancestors": [ { "id": "D009375", "term": "Neoplasms, Glandular and Epithelial" }, { "id": "D009370", "term": "Neoplasms by Histologic Type" }, { "id": "D009369", "term": "Neoplasms" } ], "browseBranches": [ { "abbrev": "BC04", "name": ...
null
{ "conditions": [ { "id": "D000236", "term": "Adenoma" } ], "interventions": null }